Heteroaryl compounds for the treatment of Huntington's disease
The treatment needs of Huntington's disease are addressed by developing compounds or forms containing specific substituted benzothiazole compounds, providing a potential treatment or relief of the symptoms of the disease.
Patent Information
- Application Number
- CN201980050967.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-06-27
- Filing Date
- 2019-06-25
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2039-06-25
AI Technical Summary
There are no effective small molecule therapies available for the treatment or mitigation of Huntington's disease (HD), resulting in an unmet need for drugs that can be used to treat or mitigate the disease.
A compound or form thereof comprising a specific substituted benzothiazole compound is developed for the treatment or amelioration of Huntington's disease by administering to a subject an effective amount of the compound or composition thereof.
A potential treatment or relief of Huntington's disease is provided, which may effectively alleviate the symptoms of the disease by using a specific compound or composition thereof.
Smart Images

Figure CN112805280B_ABST
Abstract
Description
Technical Field
[0001] One aspect of the present invention relates to compounds, forms thereof, and pharmaceutical compositions, and methods of using such compounds, forms thereof, or compositions for treating or alleviating Huntington's disease. Specifically, another aspect of the present invention relates to substituted benzothiazole compounds, forms thereof, and pharmaceutical compositions, and methods of using such compounds, forms thereof, or compositions for treating or alleviating Huntington's disease. Background Art
[0002] Huntington's disease (HD) is a progressive, autosomal dominant neurodegenerative disease of the brain, characterized by involuntary movements, cognitive impairment and mental decline. Death, usually caused by pneumonia or coronary artery disease, often occurs 13 to 15 years after the onset of symptoms. In the population of Western European descent, the prevalence of HD is 3 to 7 individuals per 100,000 people. In North America, an estimated 30,000 people suffer from HD, while another 200,000 are at risk of inheriting the disease from an affected parent. The disease is caused by an uninterrupted trinucleotide CAG repeat expansion in the "mutated" Huntington (Htt) gene, which leads to the production of HTT (Htt protein) with an expanded polyglutamine (polyQ) segment (also known as a "CAG repeat" sequence). There are currently no small molecule therapies targeting the underlying cause of the disease, which leaves a high demand for drugs that can be used to treat or alleviate HD unmet. Therefore, there is still a need to identify and provide small molecule compounds for treating or alleviating HD.
[0003] All other documents mentioned herein are incorporated by reference into this application as if fully set forth herein. Summary of the invention
[0004] One aspect herein includes compounds comprising a compound of Formula (I) or Formula (II), or a form thereof:
[0005]
[0006] wherein R1, R2, X, W1, W2 and W3 are as defined herein.
[0007] One aspect herein includes a method for treating or alleviating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form thereof.
[0008] One aspect herein includes a method of using a compound of Formula (I) or Formula (II), or a form or composition thereof, to treat or alleviate HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form or composition thereof.
[0009] One aspect herein includes the use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or a form thereof.
[0010] One aspect herein includes the use of a compound of formula (I) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of the medicament.
[0011] One aspect herein includes the use of a combination product of a compound of Formula (I) or a form thereof and one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or a form thereof in combination with an effective amount of one or more agents. DETAILED DESCRIPTION
[0012] One aspect herein relates to compounds comprising a compound of formula (I) or formula (II) or a form thereof:
[0013]
[0014] in:
[0015] W1, W2 and W3 are independently CR a or N;
[0016] In each instance, R a are independently selected from hydrogen, cyano, halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkyl-carbonyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkyl, C 1-6 Alkoxy-carbonyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl and hydroxy-C 1-6 alkyl;
[0017] X is selected from NR b , O or key;
[0018] R b Selected from hydrogen and C 1-6 alkyl;
[0019] R1 is selected from C 3-10 Cycloalkyl and heterocyclic groups,
[0020] wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2 or 3 heteroatom ring members independently selected from N, O or S, and
[0021] In each instance, C 3-10 Cycloalkyl and heterocyclyl are optionally substituted with one, two, three or four R3 substituents and optionally substituted with one additional R4 substituent, or
[0022] Where, alternatively, in each instance, C 3-10 Cycloalkyl and heterocyclyl are optionally substituted with one, two, three, four or five R3 substituents;
[0023] In each instance, R3 is independently selected from cyano, halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkyl-carbonyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkyl, C 1-6 Alkoxy-carbonyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl and hydroxy-C 1-6 alkyl;
[0024] R4 is selected from C 3-10 Cycloalkyl, phenyl, heterocyclyl, and heteroaryl;
[0025] wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2 or 3 heteroatom ring members independently selected from N, O or S,
[0026] wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3 or 4 heteroatom ring members independently selected from N, O or S, and
[0027] where, in each instance, C 3-10 Cycloalkyl, phenyl, heterocyclyl and heteroaryl are optionally substituted with one, two or three R7 substituents;
[0028] R2 is selected from phenyl and heteroaryl,
[0029] wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3 or 4 heteroatom ring members independently selected from N, O or S,
[0030] wherein, in each instance, phenyl and heteroaryl are optionally substituted with one, two or three R5 substituents and optionally substituted with one additional R6 substituent, or
[0031] wherein, alternatively, in each instance, phenyl and heteroaryl are optionally substituted with one, two, three or four R5 substituents;
[0032] In each instance, R5 is independently selected from cyano, halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkyl-carbonyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkyl, C 1-6 Alkoxy-carbonyl, C 1-6 Alkoxy-carbonyl-C 1-6 Alkyl, carboxyl, C 1-6 Alkyl-carboxyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl, amino-carbonyl and hydroxy-C 1-6 alkyl;
[0033] R6 is selected from C 3-10 Cycloalkyl, phenyl, phenyl-C 1-6 Alkoxy, phenoxy (phenyl-oxy), heterocyclyl, and heteroaryl;
[0034] wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2 or 3 heteroatom ring members independently selected from N, O or S,
[0035] wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3 or 4 heteroatom ring members independently selected from N, O or S, and
[0036] where, in each instance, C 3-10 Cycloalkyl, phenyl, heterocyclyl and heteroaryl are optionally substituted with one, two or three R7 substituents; and
[0037] In each instance, R7 is independently selected from cyano, halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkyl-carbonyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy, C1-6 Alkoxy-C 1-6 Alkyl, C 1-6 Alkoxy-carbonyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl and hydroxy-C 1-6 alkyl;
[0038] Wherein, the form of the compound is selected from the group consisting of salts, hydrates, solvates, racemates, enantiomers, diastereomers, stereoisomers and tautomer forms of the compound.
[0039] Aspects of this article
[0040] Another aspect herein includes compounds of formula (I) or formula (II):
[0041]
[0042] or a form thereof in which:
[0043] W1, W2 and W3 are independently CR a or N;
[0044] In each instance, R a are independently selected from hydrogen, cyano, halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkyl-carbonyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkyl, C 1-6 Alkoxy-carbonyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl and hydroxy-C 1-6 alkyl;
[0045] X is selected from NR b , O or key;
[0046] R b Selected from hydrogen and C 1-6 alkyl;
[0047] R1 is selected from C 3-10 Cycloalkyl and heterocyclic groups,
[0048] wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2 or 3 heteroatom ring members independently selected from N, O or S, and
[0049] where, in each instance, C 3-10 Cycloalkyl and heterocyclyl are optionally substituted with one, two, three or four R3 substituents and optionally substituted with one additional R4 substituent, or
[0050] Where, alternatively, in each instance, C 3-10 Cycloalkyl and heterocyclyl are optionally substituted with one, two, three, four or five R3 substituents;
[0051] In each instance, R3 is independently selected from cyano, halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkyl-carbonyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkyl, C 1-6 Alkoxy-carbonyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl and hydroxy-C 1-6 alkyl;
[0052] R4 is selected from C 3-10 Cycloalkyl, phenyl, heterocyclyl, and heteroaryl;
[0053] wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2 or 3 heteroatom ring members independently selected from N, O or S,
[0054] wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3 or 4 heteroatom ring members independently selected from N, O or S, and
[0055] where, in each instance, C 3-10 Cycloalkyl, phenyl, heterocyclyl and heteroaryl are optionally substituted with one, two or three R7 substituents;
[0056] R2 is selected from phenyl and heteroaryl,
[0057] wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3 or 4 heteroatom ring members independently selected from N, O or S,
[0058] wherein, in each instance, phenyl and heteroaryl are optionally substituted with one, two or three R5 substituents and optionally substituted with one additional R6 substituent, or
[0059] wherein, alternatively, in each instance, phenyl and heteroaryl are optionally substituted with one, two, three or four R5 substituents;
[0060] In each instance, R5 is independently selected from cyano, halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkyl-carbonyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkyl, C 1-6 Alkoxy-carbonyl, C 1-6 Alkoxy-carbonyl-C 1-6 Alkyl, carboxyl, C 1-6 Alkyl-carboxyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl, amino-carbonyl and hydroxy-C 1-6 alkyl;
[0061] R6 is selected from C 3-10 Cycloalkyl, phenyl, phenyl-C 1-6 Alkoxy, phenoxy, heterocyclyl, and heteroaryl;
[0062] wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2 or 3 heteroatom ring members independently selected from N, O or S,
[0063] wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3 or 4 heteroatom ring members independently selected from N, O or S, and
[0064] where, in each instance, C 3-10 Cycloalkyl, phenyl, heterocyclyl and heteroaryl are optionally substituted with one, two or three R7 substituents; and
[0065] In each instance, R7 is independently selected from cyano, halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkyl-carbonyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy, C 1-6 Alkoxy-C1-6 Alkyl, C 1-6 Alkoxy-carbonyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl and hydroxy-C 1-6 alkyl.
[0066] One aspect includes compounds of formula (I) or formula (II), wherein W1, W2 and W3 are CR a .
[0067] One aspect includes compounds of Formula (I) or Formula (II), wherein W1 is N.
[0068] Another aspect includes compounds of formula (I) or formula (II) wherein W1 is N, and W2 and W3 are CR a .
[0069] One aspect includes compounds of Formula (I) or Formula (II), wherein W2 is N.
[0070] Another aspect includes compounds of formula (I) or formula (II) wherein W2 is N, and W1 and W3 are CR a .
[0071] One aspect includes compounds of Formula (I) or Formula (II), wherein W3 is N.
[0072] Another aspect includes compounds of formula (I) or formula (II) wherein W3 is N, and W1 and W2 are CR a .
[0073] One aspect includes compounds of Formula (I) or Formula (II), wherein W1 and W2 are N.
[0074] Another aspect includes compounds of formula (I) or formula (II) wherein W1 and W2 are N and W3 is CR a .
[0075] One aspect includes compounds of Formula (I) or Formula (II), wherein W1 and W3 are N.
[0076] Another aspect includes compounds of formula (I) or formula (II) wherein W1 and W3 are N and W2 is CR a .
[0077] One aspect includes compounds of Formula (I) or Formula (II), wherein W2 and W3 are N.
[0078] Another aspect includes compounds of formula (I) or formula (II) wherein W2 and W3 are N and W2 is CR a .
[0079] One aspect includes compounds of Formula (I) or Formula (II), wherein W1, W2 and W3 are N.
[0080] One aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R a are independently selected from hydrogen, cyano, halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkyl-carbonyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkyl, C 1-6 Alkoxy-carbonyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl and hydroxy-C 1-6 alkyl.
[0081] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R a are independently selected from hydrogen, cyano, halogen, hydroxyl and C 1-6 Alkoxy.
[0082] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R a For hydrogen.
[0083] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R a It is cyano.
[0084] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R a is a halogen selected from bromine, chlorine, fluorine and iodine.
[0085] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R a is a halogen selected from chlorine and fluorine.
[0086] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R a It is hydroxyl.
[0087] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R a C is selected from the following 1-6 Alkoxy: methoxy, ethoxy, propoxy, isopropoxy and tert-butoxy.
[0088] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R a It is a methoxy group.
[0089] One aspect includes compounds of formula (I) or formula (II), wherein X is selected from NR b , O or key.
[0090] Another aspect includes compounds of formula (I) or formula (II) wherein X is NR b .
[0091] Another aspect includes compounds of Formula (I) or Formula (II) wherein X is O.
[0092] Another aspect includes compounds of Formula (I) or Formula (II) wherein X is a bond.
[0093] One aspect includes compounds of formula (I) or formula (II), wherein R b Selected from hydrogen and C 1-6 alkyl.
[0094] Another aspect includes compounds of formula (I) or formula (II) wherein R b It's hydrogen.
[0095] Another aspect includes compounds of formula (I) or formula (II) wherein R b Is selected from the following C 1-6 Alkyl: methyl, ethyl, propyl, isopropyl and tert-butyl.
[0096] Another aspect includes compounds of formula (I) or formula (II) wherein R b It is C 1-6 The alkyl group is selected from the group consisting of methyl and ethyl.
[0097] One aspect includes compounds of formula (I) or formula (II), wherein R1 is selected from C 3-10 Cycloalkyl and heterocyclic groups,
[0098] wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2 or 3 heteroatom ring members independently selected from N, O or S, and
[0099] where, in each instance, C 3-10 Cycloalkyl and heterocyclyl are optionally substituted with one, two, three or four R3 substituents and optionally substituted with one additional R4 substituent, or
[0100] Where, alternatively, in each instance, C 3-10Cycloalkyl and heterocyclyl are optionally substituted with one, two, three, four or five R3 substituents.
[0101] Another aspect includes compounds of formula (I) or formula (II), wherein R1 is a C selected from the following 3-10 Cycloalkyl: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexyl and adamantyl, optionally substituted with one, two, three or four R3 substituents and optionally substituted with one additional R4 substituent, or alternatively, optionally substituted with one, two, three, four or five R3 substituents.
[0102] Another aspect includes compounds of formula (I) or formula (II), wherein R1 is a C selected from the following 3-10 Cycloalkyl: cyclobutyl and cyclohexyl, optionally substituted with one, two, three or four R3 substituents and optionally substituted with one additional R4 substituent, or alternatively, optionally substituted with one, two, three, four or five R3 substituents.
[0103] Another aspect includes compounds of formula (I) or formula (II) wherein R1 is a heterocyclyl selected from the group consisting of azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, 1H-azepinyl, 2,3,6,7-tetrahydro-1H-azepinyl, azepanyl, 1,4-diazepanyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, octahydroindolizinyl, octahydro-1H-pyrrolo[3,2-c]pyridinyl, (3aS,7aR)-octahydro-1H-pyrrolo[3,2-c]pyridinyl, 1-azabicyclo[2.2 .2]octyl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 3-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-en-yl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-en-yl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 1,4-diazabicyclo[3.3.1] heterobicyclo[3.1.1]heptyl, 3,6-diazabicyclo[3.2.0]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 1,4-diazabicyclo[3.2.1]octyl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, 3,8-diazabicyclo[4.2.0]octyl, (1S,6R)-3,8-diazabicyclo[4.2.0]octyl, (1R,6S)-3,8-diazabicyclo[4.2.0]octyl, 2-azaspiro[3.3]heptyl, 4,7-diazaspiro[2.5]octyl, 2,6-diazabicyclo[3.1.1]heptyl, 3,6-diazabicyclo[3.2.0]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 1,4-diazabicyclo[3.2.1]octyl, 3,8-diazabicyclo[3.2.1]octyl, 4-diazaspiro[4.5]decyl and 6,9-diazaspiro[4.5]decyl, optionally substituted with one, two, three or four R3 substituents and optionally substituted with one additional R4 substituent, or alternatively, optionally substituted with one, two, three, four or five R3 substituents.
[0104] Another aspect includes compounds of formula (I) or formula (II) wherein R1 is a heterocyclyl selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, 2,3,6,7-tetrahydro-1H-azacycloheptatrienyl, azepanyl, 1,4-diazepanyl, 1,2,3,6-tetrahydropyridinyl, octahydroindolizinyl, octahydro-1H-pyrrolo[3,2-c]pyridinyl, (3aS,7aR)-octahydro-1H-pyrrolo[3,2-c]pyridinyl, 1-azabicyclo[2.2.2]octyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 9-azabicyclo[3.3.1]nonyl, 3,8-diazabicyclo[3,3,6] cyclo[4.2.0]octyl, (1S,6R)-3,8-diazabicyclo[4.2.0]octyl, (1R,6S)-3,8-diazabicyclo[4.2.0]octyl, 2-azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 1,6-diazaspiro[3.5]nonyl, 1,7-diazaspiro[3.5]nonyl, 2,6-diazaspiro[3.5]nonyl, 2,7-diazaspiro[3.5]nonyl and 2,7-diazaspiro[4.4]nonyl, which are optionally substituted with one, two, three or four R3 substituents and optionally substituted with one additional R4 substituent, or alternatively, optionally substituted with one, two, three, four or five R3 substituents.
[0105] Another aspect includes compounds of formula (I) or formula (II) wherein R1 is a heterocyclyl selected from the group consisting of azetidin-2-yl, azetidin-3-yl, tetrahydrofuran-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, piperazin-2-yl, 1H-azepin-2-yl, 1H-azepin-3-yl, 1H-azepin-4-yl, 2,3,6,7-tetrahydro-1H-azepin-4-yl, azepan-2-yl, azepan-3-yl, azepan-4-yl, 1,4-diazepan-1-yl, 1,4-diazepan- 2-yl, 1,4-diazepan-3-yl, 1,2,5,6-tetrahydropyridin-5-yl, 1,2,3,6-tetrahydropyridin-4-yl, octahydroindolizine-7-yl, octahydro-1H-pyrrolo[3,2-c]pyridin-1-yl, (3aS,7aR)-octahydro-1H-pyrrolo[3,2-c]pyridin-1-yl, 1-azacycloheptan-3-yl, 1,2,5,6-tetrahydropyridin-5-yl, 1,2,3,6-tetrahydropyridin-4-yl, octahydroindolizine-7-yl, octahydro-1H-pyrrolo[3,2-c]pyridin-1-yl, cyclo[2.2.2]oct-4-yl, 3-azabicyclo[3.1.0]hex-3-yl, 3-azabicyclo[3.2.1]oct-8-yl, 8-azabicyclo[3.2.1]oct-3-yl, (1R,5S)-8-azabicyclo[3.2.1]oct-3-yl, 8-azabicyclo[3.2.1]oct-2-en-3-yl, (1 R,5S)-8-azabicyclo[3.2.1]oct-2-en-3-yl, 9-azabicyclo[3.3.1]non-3-yl, (1R,5S)-9-azabicyclo[3.3.1]non-3-yl, 2,5-diazabicyclo[2.2.1]hept-2-yl, (1S,4S)-2,5-diazabicyclo[2.2.1]hept- 2-yl, 1,4-diazabicyclo[3.1.1]hept-4-yl, 3,6-diazabicyclo[3.2.0]hept-3-yl, 3,6-diazabicyclo[3.2.0]hept-6-yl, 2,5-diazabicyclo[2.2.2]oct-2-yl, 1,4-diazabicyclo[3.2.1]oct-4-yl, 3,8-diazabicyclo [3.2.1]oct-3-yl, (1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl, 1,4-diazabicyclo[3.2.2]non-4-yl, 3,8-diazabicyclo[4.2.0]oct-8-yl, (1S,6R)-3,8-diazabicyclo[4.2.0]oct-8-yl, (1R,6S )-3,8-diazabicyclo[4.2.0]oct-8-yl, 2-azaspiro[3.3]hept-2-yl, 2-azaspiro[3.3]hept-6-yl, 4,7-diazaspiro[2.5]oct-4-yl, 4,7-diazaspiro[2.5]oct-7-yl, 2,6-diazaspiro[3.3]hept-2-yl, 2,6-diazaspiro[3.4]octan-2-yl, 2,6-diazaspiro[3.4]octan-6-yl, 1,6-diazaspiro[3.5]non-1-yl, 1,7-diazaspiro[3.5]non-1-yl, 1,7-diazaspiro[4.4]non-1-yl, 1,7-diazaspiro[4.4]non-7-yl, 2,6-diazaspiro[3.5]non-2-yl, 2,6-diazaspiro[3.5]non-6-yl, 2,7-diazaspiro[3.5]non-7-yl, 5,8- Diazaspiro[3.5]non-8-yl, 2,7-diazaspiro[4.4]non-2-yl, 2,7-diazaspiro[4.5]dec-2-yl, 2,7-diazaspiro[4.5]dec-7-yl and 6,9-diazaspiro[4.5]dec-9-yl, optionally substituted with one, two, three or four R3 substituents and optionally substituted with one additional R4 substituent, or alternatively, optionally substituted with one, two, three, four or five R3 substituents. .
[0106] Another aspect includes compounds of formula (I) or formula (II), wherein R1 is a heterocyclic group selected from the group consisting of azetidin-3-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, 2,3,6,7-tetrahydro-1H-azepan-4-yl, azepan-4-yl, 1,4-diazepan-1-yl, 1,2,3,6-tetrahydropyridine-4 -yl, octahydroindolizine-7-yl, octahydro-1H-pyrrolo[3,2-c]pyridin-1-yl, (3aS,7aR)-octahydro-1H-pyrrolo[3,2-c]pyridin-1-yl, 1-azabicyclo[2.2.2]oct-4-yl, 3-azabicyclo[3.2.1]oct-8-yl, 8-azabicyclo[3.2.1]oct-3-yl, 9-azabicyclo[3.3.1]non-3-yl, 3, 8-diazabicyclo[4.2.0]oct-8-yl, (1S,6R)-3,8-diazabicyclo[4.2.0]oct-8-yl, (1R,6S)-3,8-diazabicyclo[4.2.0]oct-8-yl, 2-azaspiro[3.3]hept-6-yl, 2,6-diazaspiro[3.3]hept-2-yl, 1,6-diazaspiro[3.5]non-1-yl, 1,7-diazaspiro[3.5 ]non-1-yl, 2,6-diazaspiro[3.5]non-2-yl, 2,7-diazaspiro[3.5]non-7-yl and 2,7-diazaspiro[4.4]non-2-yl, which are optionally substituted with one, two, three or four R3 substituents and optionally substituted with one additional R4 substituent, or, alternatively, each instance of heterocyclyl is optionally substituted with one, two, three, four or five R3 substituents.
[0107] One aspect includes compounds of formula (I) or formula (II), wherein in each instance, R3 is independently selected from cyano, halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkyl-carbonyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkyl, C 1-6 Alkoxy-carbonyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl and hydroxy-C 1-6 alkyl.
[0108] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R3 is independently selected from halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino and hydroxy-C 1-6 alkyl.
[0109] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R3 is halogen selected from bromine, chlorine, fluorine and iodine.
[0110] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R3 is fluoro.
[0111] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R3 is hydroxy.
[0112] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R3 is a C selected from the following 1-6 Alkyl: methyl, ethyl, propyl, isopropyl and tert-butyl.
[0113] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R3 is C 1-6 The alkyl group is selected from the group consisting of methyl and ethyl.
[0114] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R3 is halo-C 1-6 Alkyl, where C 1-6 The alkyl group is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, which are partially or fully substituted, as permitted by the available valences, with one or more halogens selected from bromine, chlorine, fluorine and iodine.
[0115] Another aspect includes compounds of formula (I), wherein in each instance, R3 is halo-C 1-6 The alkyl group is selected from fluoroethyl.
[0116] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R3 is amino.
[0117] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R3 is C 1-6 Alkyl-amino, where C 1-6 The alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.
[0118] Another aspect includes compounds of formula (I) wherein in each instance, R3 is methylamino.
[0119] Another aspect includes compounds of formula (I), wherein in each instance, R3 is (C 1-6 Alkyl) 2-amino, wherein C 1-6 The alkyl groups are independently selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.
[0120] Another aspect includes compounds of formula (I) wherein in each instance, R3 is dimethylamino.
[0121] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R3 is hydroxy-C 1-6 Alkyl, where C 1-6 The alkyl group is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, which are partially or fully substituted with one or more hydroxyl groups as permitted by available valences.
[0122] Another aspect includes compounds of formula (I), wherein in each instance, R3 is hydroxy-C 1-6 The alkyl group is selected from hydroxymethyl and hydroxyethyl.
[0123] One aspect includes compounds of formula (I) or formula (II), wherein R4 is selected from C 3-10 Cycloalkyl, phenyl, heterocyclyl, and heteroaryl;
[0124] wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2 or 3 heteroatom ring members independently selected from N, O or S,
[0125] wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3 or 4 heteroatom ring members independently selected from N, O or S, and
[0126] where, in each instance, C 3-10 Cycloalkyl, phenyl, heterocyclyl and heteroaryl are optionally substituted with one, two or three R7 substituents.
[0127] One aspect includes compounds of formula (I) or formula (II), wherein R4 is a C selected from the following 3-10 Cycloalkyl: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexyl and adamantyl, which are optionally substituted with one, two or three R7 substituents.
[0128] Another aspect includes compounds of formula (I) or formula (II) wherein R4 is cyclopropyl, which is optionally substituted with one, two or three R7 substituents.
[0129] One aspect includes compounds of formula (I) or formula (II), wherein R2 is selected from phenyl and heteroaryl,
[0130] wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3 or 4 heteroatom ring members independently selected from N, O or S,
[0131] wherein, in each instance, phenyl and heteroaryl are optionally substituted with one, two or three R5 substituents and optionally substituted with one additional R6 substituent, or
[0132] Wherein, alternatively, in each instance, phenyl and heteroaryl are optionally substituted with one, two, three or four R5 substituents.
[0133] Another aspect includes compounds of formula (I) or formula (II) wherein R2 is phenyl, which is optionally substituted with one, two or three R5 substituents and optionally substituted with an additional R6 substituent, or, alternatively, optionally substituted with one, two, three or four R5 substituents.
[0134] Another aspect includes compounds of formula (I) or formula (II), wherein R2 is a heteroaryl selected from the group consisting of furanyl, 1H-pyrazolyl, 1H-imidazolyl, 1H-1,2,3-triazolyl, 4H-1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1H-indolyl, 2H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuran ... 1H-pyrrolo[2,3-b]pyridyl, 1H-pyrrolo[2,3-c]pyridyl, 1,3-benzoxazolyl, 1,5-pyridyl, 1H-pyrrolo[1,5-a]pyridyl, 1H-pyrrolo[1,5-b]pyridyl, 1H-pyrrolo[2,3-c]pyridyl, 1,2-a]pyrimidinyl, 1,2-a]pyrazinyl, 1,2-b]pyridinyl, 1,2-b]pyridinyl, 1,2-c]pyridinyl, 1,3-benzoxazolyl, 1,3-fluoro[2,3-b]pyridyl, 1,2-b]pyridyl, 1,2-c]pyridinyl, 1,2-a]pyrimidinyl, 1,2-a]pyrazinyl, 1,2-b]pyridinyl, 1,2-b]pyridinyl, 1,2-b]pyridinyl, 1,2-c ...b]pyridinyl, 1,2-b]pyridinyl, [4,3-b]pyridinyl, 2H-pyrazolo[4,3-b]pyridinyl, 2H-pyrazolo[4,3-c]pyridinyl, pyrazolo[1,5-a]pyrazinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-a]pyrazinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,5-a]pyridinyl, imidazo[2,1-b]pyridinyl [1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[1,5-b]pyridazinyl and quinolinyl, optionally substituted with one, two or three R5 substituents and optionally substituted with one additional R6 substituent, or, alternatively, optionally substituted with one, two, three or four R5 substituents.
[0135] Another aspect includes compounds of formula (I) or formula (II), wherein R2 is a heteroaryl group selected from the group consisting of 1H-indazolyl, 2H-indazolyl, 1H-benzimidazolyl, 1,3-benzoxazolyl, fluoro[3,2-b]pyridinyl, pyrrolo[1,2-a]pyrazinyl, 1H-pyrazolo[4,3-b]pyridinyl, 2H-pyrazolo[4,3-b]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-b]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridinyl, pyrazolo[1,2-a]pyrimidinyl, imidazo[1,2-b]pyridinyl, pyrazolo[1,2-a]pyrimidinyl, imidazo[1,2-b]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridinyl, pyrazolo[1,2-a]pyrimidinyl, pyrazolo[1,2-b]pyrid ...5-a]pyrimidinyl, pyrazolo[1,2-b]pyridinyl, pyrazolo[1,2-b]pyridinyl, pyrazolo[1,2-a]pyrimidinyl, [1,2-a]pyrazinyl, imidazo[1,2-b]pyridazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,2,4]triazolo[1,5-a]pyridinyl and [1,2,4]triazolo[1,5-b]pyridazinyl, optionally substituted with one, two or three R5 substituents and optionally substituted with one additional R6 substituent, or, alternatively, optionally substituted with one, two, three or four R5 substituents.
[0136] Another aspect includes compounds of formula (I) or formula (II) wherein R2 is a heteroaryl group selected from the group consisting of furan-2-yl, furan-3-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-imidazol-1-yl, 1H-imidazol-4-yl, 1H-1,2,3-triazol-1-yl, 4H-1,2,4-triazol-4-yl, 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyridazin-5-yl, pyrimidin-4-yl, pyrazin-1-yl, 1H-indol-3-yl, 1H-indol-4-yl, 1H-indol-5-yl, 1H-indol- Indole-6-yl, 1H-indazol-5-yl, 1H-indazol-6-yl, 2H-indazol-5-yl, 2H-indazol-6-yl, indolizine-2-yl, benzofuran-2-yl, benzofuran-5-yl, 1H-benzimidazol-2-yl, 1H-benzimidazol-5-yl, 1H-benzimidazol-6-yl, 1,3-benzooxazol-2-yl, 1,3-benzene oxazol-5-yl, 1,3-benzooxazol-6-yl, fluoro[2,3-b]pyridin-6-yl, fluoro[2,3-c]pyridin-2-yl, fluoro[3,2-b]pyridin-2-yl, fluoro[3,2-c]pyridin-2-yl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1H-pyrrolo[2,3-c]pyridin-4-yl, pyrrolo[ 1,2-a]pyrimidin-7-yl, pyrrolo[1,2-a]pyrazin-7-yl, pyrrolo[1,2-b]pyridazin-2-yl, pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyridin-5-yl, 1H-pyrazolo[4,3-b]pyridin-5-yl, 2H-pyrazolo[4,3-b]pyridin-5-yl, 2H-pyrazolo[4,3-b]pyridin-5-yl, oxazolo[4,3-c]pyridin-5-yl, pyrazolo[1,5-a]pyrazin-2-yl, pyrazolo[1,5-a]pyrimidin-5-yl, imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyridin-6-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[1,2-a]pyrimidin-6-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[1,2-a]pyrimidin-6-yl, imidazo[1,2 -a]pyrazin-2-yl, imidazo[1,2-a]pyrazin-3-yl, imidazo[1,2-a]pyrazin-6-yl, imidazo[1,2-b]pyridazin-2-yl, imidazo[1,2-b]pyridazin-6-yl, imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,5-a]pyridin-6-yl, imidazo[1,5-a]pyridin- 7-yl, imidazo[2,1-b][1,3]thiazol-6-yl, imidazo[2,1-b][1,3,4]thiadiazol-6-yl, [1,3]oxazolo[4,5-b]pyridin-2-yl, [1,2,4]triazolo[1,5-a]pyridin-5-yl, [1,2,4]triazolo[1,5-a]pyridin-6-yl, [1,2,4]triazolo[1,5-b]pyridin-6-yl, [1,2,4]triazolo[1,5-b]pyridin-5-yl, [1,2,4]triazolo[1,5-b]pyridazin-6-yl, quinolin-6-yl, quinolin-7-yl and quinolin-8-yl, optionally substituted with one, two or three R5 substituents and optionally substituted with one additional R6 substituent, or, alternatively, optionally substituted with one, two, three or four R5 substituents. ,
[0137] Another aspect includes compounds of formula (I) or formula (II), wherein R2 is a heteroaryl group selected from the group consisting of 1H-indazol-5-yl, 2H-indazol-5-yl, 1H-benzimidazol-6-yl, 1,3-benzoxazol-6-yl, fluoro[2,3-b]pyridin-6-yl, pyrrolo[1,2-a]pyrazin-7-yl, 1H-pyrazolo[4,3-b]pyridin-5-yl, 2H-pyrazolo[4,3-b]pyridin-5-yl, pyrazolo[1,5-a]pyrimidin-5-yl, imidazo[1,2-a]pyridin-6-yl, imidazo[1,2-a]pyrimidin-6-yl, imidazo[1 ,2-a]pyrazin-2-yl, imidazo[1,2-a]pyrazin-6-yl, imidazo[1,2-b]pyridazin-6-yl, imidazo[2,1-b][1,3]thiazol-6-yl, imidazo[2,1-b][1,3,4]thiadiazol-6-yl, [1,2,4]triazolo[1,5-a]pyridin-6-yl and [1,2,4]triazolo[1,5-b]pyridazin-6-yl, which are optionally substituted with one, two or three R5 substituents and optionally substituted with one additional R6 substituent, or, alternatively, optionally substituted with one, two, three or four R5 substituents.
[0138] One aspect includes compounds of formula (I) or formula (II), wherein in each instance, R5 is independently selected from cyano, halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkyl-carbonyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkyl, C 1-6 Alkoxy-carbonyl, C 1-6 Alkoxy-carbonyl-C 1-6 Alkyl, carboxyl, C 1-6 Alkyl-carboxyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl, amino-carbonyl and hydroxy-C 1-6 alkyl.
[0139] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R5 is independently selected from cyano, halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkoxy-carbonyl-C 1-6 Alkyl, carboxyl, C 1-6 Alkyl-carboxyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl and amino-carbonyl.
[0140] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R5 is cyano.
[0141] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R5 is halogen selected from bromine, chlorine, fluorine and iodine.
[0142] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R5 is fluoro.
[0143] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R5 is hydroxy.
[0144] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R5 is a C selected from the following 1-6 Alkyl: methyl, ethyl, propyl, isopropyl and tert-butyl.
[0145] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R5 is C 1-6 The alkyl group is selected from the group consisting of methyl and ethyl.
[0146] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R5 is halo-C 1-6 Alkyl, where C 1-6 The alkyl group is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, which are partially or fully substituted, as permitted by the available valences, with one or more halogens selected from bromine, chlorine, fluorine and iodine.
[0147] Another aspect includes compounds of formula (I), wherein in each instance, R5 is halo-C 1-6 The alkyl group is selected from trifluoromethyl.
[0148] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R5 is a C selected from the following1-6 Alkoxy: methoxy, ethoxy, propoxy, isopropoxy and tert-butoxy.
[0149] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R a It is a methoxy group.
[0150] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R5 is C 1-6 Alkoxy-carbonyl-C 1-6 Alkyl, where C 1-6 The alkoxy group is selected from methoxy, ethoxy, propoxy, isopropoxy and tert-butoxy, and wherein C 1-6 The alkyl group is selected from methyl, ethyl, propyl, isopropyl and tert-butyl.
[0151] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R5 is -CH2CO2CH3.
[0152] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R5 is carboxyl.
[0153] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R5 is C 1-6 Alkyl-carboxyl, where C 1-6 The alkyl group is selected from methyl, ethyl, propyl, isopropyl and tert-butyl.
[0154] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R5 is -CH2CO2H.
[0155] Another aspect includes compounds of Formula (I) or Formula (II), wherein in each instance, R5 is amino.
[0156] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R5 is C 1-6 Alkyl-amino, where C 1-6 The alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.
[0157] Another aspect includes compounds of formula (I) wherein in each instance, R5 is methylamino.
[0158] Another aspect includes compounds of formula (I), wherein in each instance, R5 is (C 1-6 Alkyl) 2-amino, wherein C 1-6 The alkyl groups are independently selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.
[0159] Another aspect includes compounds of formula (I) wherein in each instance, R5 is dimethylamino.
[0160] Another aspect includes compounds of formula (I), wherein in each instance, R5 is amino-C 1-6 Alkyl, where C 1-6 The alkyl groups are independently selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.
[0161] Another aspect includes compounds of formula (I), wherein in each instance, R5 is methylamine.
[0162] Another aspect includes compounds of formula (I), wherein in each instance, R5 is amino-carbonyl.
[0163] Another aspect includes compounds of formula (I) or formula (II), wherein R6 is selected from C 3-10 Cycloalkyl, phenyl, phenyl-C 1-6 Alkoxy, phenoxy, heterocyclyl, and heteroaryl;
[0164] wherein heterocyclyl is a saturated or partially unsaturated 3-7 membered monocyclic, 6-10 membered bicyclic or 13-16 membered polycyclic ring system having 1, 2 or 3 heteroatom ring members independently selected from N, O or S,
[0165] wherein heteroaryl is a 3-7 membered monocyclic or 6-10 membered bicyclic ring system having 1, 2, 3 or 4 heteroatom ring members independently selected from N, O or S, and
[0166] where, in each instance, C 3-10 Cycloalkyl, phenyl, heterocyclyl and heteroaryl are optionally substituted with one, two or three R7 substituents.
[0167] Another aspect includes compounds of formula (I) or formula (II), wherein R6 is selected from the group consisting of 3-10 Cycloalkyl: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]hexyl and adamantyl, which are optionally substituted with one, two or three R7 substituents.
[0168] Another aspect includes compounds of formula (I) or formula (II), wherein R6 is cyclopropyl, which is optionally substituted with one, two or three R7 substituents.
[0169] Another aspect includes compounds of formula (I) or formula (II), wherein R6 is phenyl-C 1-6 Alkoxy, where C 1-6 The alkoxy group is selected from methoxy, ethoxy, propoxy, isopropoxy and tert-butoxy, and wherein C 1-6The alkyl group is selected from methyl, ethyl, propyl, isopropyl and tert-butyl, and wherein the phenyl group is optionally substituted with one, two or three R7 substituents.
[0170] Another aspect includes compounds of formula (I) or formula (II) wherein R6 is benzyloxy.
[0171] Another aspect includes compounds of formula (I) or formula (II) wherein R6 is phenoxy, wherein the phenyl group is optionally substituted with one, two or three R7 substituents.
[0172] Another aspect includes compounds of formula (I) or formula (II) wherein R6 is benzyloxy.
[0173] Another aspect includes compounds of formula (I) or formula (II), wherein R6 is a heteroaryl selected from the group consisting of furanyl, 1H-pyrazolyl, 1H-imidazolyl, 1H-1,2,3-triazolyl, 4H-1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, optionally substituted with one, two or three R7 substituents.
[0174] Another aspect includes compounds of formula (I) or formula (II), wherein R6 is heteroaryl selected from 1H-pyrazolyl and 1H-imidazolyl, which is optionally substituted with one, two or three R7 substituents.
[0175] On the other hand, compounds of formula (I) or formula (II) are included, wherein R6 is a heteroaryl group selected from the group consisting of furan-2-yl, furan-3-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-imidazol-1-yl, 1H-imidazol-4-yl, 1H-1,2,3-triazol-1-yl, 4H-1,2,4-triazol-4-yl, 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazine-3-yl, pyridazine-4-yl, pyridazine-5-yl, pyrimidin-4-yl, pyrazine-1-yl, optionally substituted with one, two or three R7 substituents.
[0176] Another aspect includes compounds of formula (I) or formula (II), wherein R6 is heteroaryl selected from 1H-pyrazol-4-yl and 1H-imidazol-1-yl, which is optionally substituted with one, two or three R7 substituents.
[0177] One aspect includes compounds of formula (I) or formula (II), wherein in each instance, R7 is independently selected from cyano, halogen, hydroxyl, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkyl-carbonyl, C 1-6Alkoxy, halo-C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkyl, C 1-6 Alkoxy-carbonyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl and hydroxy-C 1-6 alkyl.
[0178] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R7 is halogen, hydroxy, C 1-6 Alkyl, halo-C 1-6 Alkyl, C 1-6 Alkyl-carbonyl, C 1-6 Alkoxy, halo-C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkyl, C 1-6 Alkoxy-carbonyl, amino, C 1-6 Alkyl-amino, (C 1-6 alkyl)2-amino, amino-C 1-6 Alkyl and hydroxy-C 1-6 alkyl.
[0179] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R7 is halogen selected from bromine, chlorine, fluorine and iodine.
[0180] Another aspect includes compounds of formula (I) or formula (II), wherein in each instance, R7 is fluoro.
[0181] One aspect of the compounds of formula (I) includes compounds selected from formula (Ia), formula (Ib), formula (Ic), formula (Id), formula (Ie), formula (If), formula (Ig), or formula (Ih):
[0182]
[0183] or its form.
[0184] Another aspect of compounds of formula (I) includes compounds selected from formula (Ia), formula (Ib), formula (Ic), formula (Id), formula (Ie), formula (If), or formula (Ig):
[0185]
[0186] or its form.
[0187] One aspect of the compound of formula (II) includes a compound selected from formula (IIa), formula (IIb), formula (IIc), formula (IId), formula (IIe), formula (IIf), formula (IIg) or formula (IIh):
[0188]
[0189] or its form.
[0190] Another aspect of compounds of formula (II) includes compounds selected from formula (IIa) or formula (IIb):
[0191]
[0192] or its form.
[0193] One aspect of the compound of Formula (Ia)-(Ib)-(Ic)-(Id)-(Ie)-(If)-(Ig)-(Ih) includes a compound selected from Formula (Ia1), (Ib1), (Ic1), (Id1), (Ie1), (If1), (Ig1) or (Ih1):
[0194]
[0195]
[0196] or its form.
[0197] Another aspect of the compounds of Formula (Ia)-(Ib)-(Ic)-(Id)-(Ie)-(If) or (Ig)-(Ig) includes compounds selected from Formula (Ia1)-(Ib1)-(Ic1)-(Id1)-(Ie1)-(If1) or (Ig1)-(Ig2):
[0198]
[0199] or its form.
[0200] One aspect of the compound of Formula (IIa)-75, Formula (IIb)-75, Formula (IIc)-75, Formula (IId)-75, Formula (IIe), Formula (IIIf), Formula (IIg)-75 or Formula (IIh)-75 includes a compound selected from Formula (IIa1), Formula (IIb1), Formula (Ic1), Formula (IId1), Formula (IIe1), Formula (IIf1), Formula (IIg1) or Formula (IIh1):
[0201]
[0202] or its form.
[0203] Another aspect of the compounds of formula (IIa) or formula (IIb) includes compounds selected from formula (IIa1) or formula (IIb1):
[0204]
[0205] or its form.
[0206] Another aspect of compounds of formula (I) includes compounds of formula (Ia1):
[0207]
[0208] or its form.
[0209] Another aspect of compounds of formula (I) includes compounds of formula (Ib1):
[0210]
[0211] or its form.
[0212] Another aspect of compounds of formula (I) includes compounds of formula (Ic1):
[0213]
[0214] or its form.
[0215] Another aspect of compounds of formula (I) includes compounds of formula (Id1):
[0216]
[0217] or its form.
[0218] Another aspect of compounds of formula (I) includes compounds of formula (Ie1):
[0219]
[0220] or its form.
[0221] Another aspect of compounds of formula (I) includes compounds of formula (If1):
[0222]
[0223] or its form.
[0224] Another aspect of compounds of formula (I) includes compounds of formula (Ig1):
[0225]
[0226] or its form.
[0227] Another aspect of compounds of formula (II) includes compounds of formula (IIa1):
[0228]
[0229] or its form.
[0230] Another aspect of compounds of formula (II) includes compounds of formula (IIb1):
[0231]
[0232] or its form.
[0233] One aspect of the compound of formula (I) or formula (II) or a form thereof includes a compound selected from the group consisting of:
[0234]
[0235]
[0236]
[0237]
[0238]
[0239]
[0240]
[0241]
[0242]
[0243]
[0244]
[0245]
[0246]
[0247]
[0248]
[0249]
[0250]
[0251]
[0252]
[0253]
[0254]
[0255]
[0256]
[0257]
[0258]
[0259]
[0260]
[0261]
[0262]
[0263]
[0264]
[0265]
[0266]
[0267]
[0268]
[0269]
[0270]
[0271] wherein the form of the compound is selected from the group consisting of salts, hydrates, solvates, racemates, enantiomers, diastereomers, stereoisomers and tautomeric forms of the compound.
[0272] A compound of formula (I) or formula (II) or a form thereof (wherein compound number (# 1 ) indicates that the salt form is isolated) includes a compound selected from the group consisting of:
[0273]
[0274]
[0275]
[0276]
[0277]
[0278]
[0279]
[0280]
[0281]
[0282]
[0283]
[0284]
[0285]
[0286]
[0287]
[0288]
[0289]
[0290]
[0291]
[0292]
[0293]
[0294]
[0295]
[0296]
[0297] wherein the form of the compound is selected from the group consisting of salts, hydrates, solvates, racemates, enantiomers, diastereomers, stereoisomers and tautomeric forms of the compound.
[0298] Another aspect of the compound of formula (I) or formula (II) or a form thereof is a salt of the compound selected from the group consisting of:
[0299]
[0300]
[0301]
[0302]
[0303]
[0304]
[0305]
[0306]
[0307]
[0308]
[0309]
[0310]
[0311]
[0312]
[0313]
[0314]
[0315] The salt form of the compound is selected from the group consisting of hydrates, solvates, racemates, enantiomers, diastereomers, stereoisomers and tautomers of the salt of the compound.
[0316] One aspect herein includes a method for preventing, treating, or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form thereof.
[0317] One aspect herein includes a method for treating or alleviating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form thereof.
[0318] Another aspect herein includes a method for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a salt of a compound of Formula (I) or Formula (II), or a form thereof.
[0319] One aspect herein includes a method of using a compound of Formula (I) or Formula (II), or a form or composition thereof, for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form or composition thereof.
[0320] Another aspect herein includes a method of using a salt of a compound of Formula (I) or Formula (II) or a form thereof or a composition thereof for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a salt of a compound of Formula (I) or Formula (II) or a form thereof.
[0321] One aspect herein includes the use of a compound of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
[0322] Another aspect herein includes the use of a salt of a compound of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a salt of a compound of Formula (I) or Formula (II) or a form thereof.
[0323] One aspect herein includes the use of a compound of Formula (I) or Formula (II), or a form thereof, in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of the medicament.
[0324] Another aspect herein includes the use of a compound of Formula (I) or Formula (II) salt or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of the medicament.
[0325] One aspect herein includes the use of a combination product of a compound of Formula (I) or Formula (II), or a form thereof, and one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form thereof, in combination with an effective amount of one or more agents.
[0326] Another aspect herein includes the use of a combination product of a compound salt of Formula (I) or Formula (II) or a form thereof and one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound salt of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of one or more agents.
[0327] Chemical Definition
[0328] Unless expressly defined otherwise, one of ordinary skill in the art will understand that the chemical terms used above and throughout this document have the meanings indicated below.
[0329] As used herein, the term “C 1-6 "Alkyl" generally refers to a saturated hydrocarbon group having 1 to 8 carbon atoms in a straight or branched configuration, including but not limited to methyl, ethyl, n-propyl (also known as propyl or propanyl), isopropyl, n-butyl (also known as butyl or butanyl), isobutyl, sec-butyl, tert-butyl, n-pentyl (also known as pentyl or pentyl), n-hexyl (also known as hexyl or hexyl), etc. In certain aspects, C 1-6 Alkyl groups include but are not limited to C 1-4 Alkyl, C 1-2 Alkyl, etc. Where available valences permit, C 1-6 Alkyl groups are optionally substituted with substituent species as described herein.
[0330] As used herein, the term “C 2-8 "Alkenyl" generally refers to partially unsaturated hydrocarbon groups having 2 to 8 carbon atoms in a straight or branched configuration and having one or more carbon-carbon double bonds therein, including but not limited to ethenyl (also known as vinyl), allyl, propenyl, and the like. In certain aspects, C 2-8 Alkenyl includes but is not limited to C 2-6 Alkenyl, C 2-4 Where available valences permit, C 2-8 Alkenyl groups are optionally substituted with substituent species as described herein.
[0331] As used herein, the term “C 2-8 "Alkynyl" generally refers to partially unsaturated hydrocarbon groups having 2 to 8 carbon atoms in a straight or branched configuration and having one or more carbon-carbon triple bonds therein, including but not limited to ethynyl, propynyl, butynyl, and the like. In certain aspects, C 2-8 Alkynyl groups include, but are not limited to, C 2-6 Alkynyl, C 2-4 Alkynyl, etc. Where available valence permits, C 2-8 Alkynyl groups are optionally substituted with substituent species as described herein.
[0332] As used herein, the term “C 1-6 "Alkoxy" generally refers to the formula -OC 168Alkyl, a saturated hydrocarbon group having 1 to 8 carbon atoms in a straight or branched configuration, including but not limited to methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy, etc. In certain aspects, C 1-6 Alkoxy includes but is not limited to C 1-4 Alkoxy, C 1-2 Alkoxy, etc. Where available valence permits, C 1-6 Alkoxy groups are optionally substituted with substituent species as described herein.
[0333] As used herein, the term “C 3-10 "Cycloalkyl" generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic hydrocarbon group, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, 1H-indanyl, indenyl, tetrahydro-naphthyl, etc. In certain aspects, C 3-10 Cycloalkyl includes but is not limited to C 3-8 Cycloalkyl, C 5-8 Cycloalkyl, etc. Where available valence permits, C 3-10 Cycloalkyl groups are optionally substituted with substituent species as described herein.
[0334] As used herein, the term "aryl" generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure group, including but not limited to phenyl, naphthyl, anthracenyl, fluorenyl, azulenyl, phenanthrenyl, etc. Aryl groups are optionally substituted with substituent species as described herein, where available valences permit.
[0335] The term "heteroaryl" as used herein generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure group, in which one or more carbon atom ring members have been replaced with one or more heteroatoms, such as O, S or N atoms, where structural stability permits, including but not limited to furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, 1,3-thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, indazolyl, indolizinyl, isoindolyl, benzofuranyl, benzothiophenyl, benzimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, purinyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, 1,3-diazinyl, 1,2-diazinyl, 1,2-diazolyl, 1,4-naphthyridinyl, acridinyl, furano[3,2-b]pyridinyl, furano[3,2-c]pyridinyl, furano[2,3- c]pyridinyl, 6H-thieno[2,3-b]pyrrolyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1, [1,2-a]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, and the like. Heteroaryl groups are optionally substituted on carbon or nitrogen atom ring members with substituent species as described herein, as permitted by available valence chemistry.
[0336] In certain aspects, the nomenclature of the heteroaryl groups may differ, such as in the non-limiting example where furanyl may also be referred to as furyl, thienyl may also be referred to as thiophenyl, pyridinyl may also be referred to as pyridyl, benzothienyl may also be referred to as benzothiophenyl and 1,3-benzoxazolyl may also be referred to as 1,3-benzooxazolyl.
[0337] In certain other aspects, the term for heteroaryl may also include other positional isomers, such as in a non-limiting example, wherein the term pyrrolyl may also include 2H-pyrrolyl, 3H-pyrrolyl, etc., the term pyrazolyl may also include 1H-pyrazolyl, etc., the term imidazolyl may also include 1H-imidazolyl, etc., the term triazolyl may also include 1H-1,2,3-triazolyl, etc., the term oxadiazolyl may also include 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, etc., the term tetrazolyl may also include 1H-tetrazolyl, 2H-tetrazolyl, etc., the term indolyl may also include 1H-indolyl, etc., the term indazolyl may also include 1H-indazolyl, 2H-indazolyl, etc., the term benzimidazolyl may also include 1H-benzimidazolyl, and the term purinyl may also include 9H-purinyl, etc.
[0338] As used herein, the term "heterocyclyl" generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic carbon atom ring structure group in which one or more carbon atom ring members have been replaced with heteroatoms such as O, S or N atoms where structural stability permits, including but not limited to oxirane, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, isoxazolinyl, isoxazolidinyl, isothiazolinyl, isothiazolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, triazolinyl, triazolidinyl, oxadiazolinyl, oxadiazolidinyl, thiadiazolinyl, thiadiazolidinyl, tetrazolinyl, tetrazolidinyl, pyranyl, dihydro- 2H-pyranyl, thiopyranyl, 1,3-dioxanyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,4-diazepanyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, 2,3-dihydro-1,4-benzodioxinyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, 6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl Pyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, [1,2-a]pyrazine-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazine-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazine-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazine-(1H)-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazine- (1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, octahydro-2H-pyrido[1,2-a]pyrazinyl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, Azabicyclo[2.2.2]octyl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl, 6,9-diazaspiro[4.5]decyl, and the like. Heterocyclyl groups are optionally substituted on carbon or nitrogen atom ring members with substituent species as described herein, as permitted by available valences. .
[0339] In certain aspects, the nomenclature of the heterocyclyl group may differ, such as in the non-limiting example where 1,3-benzodioxolyl may also be referred to as benzo[d][1,3]dioxolyl; and 2,3-dihydro-1,4-benzodioxinyl may also be referred to as 2,3-dihydrobenzo[b][1,4]dioxinyl.
[0340] As used herein, the term “C 1-6 Alkoxy-C 1-6 "Alkyl" refers to a group of the formula -C 1-6 Alkyl-OC 1-6 Alkyl group.
[0341] As used herein, the term “C 1-6 "Alkoxy-carbonyl" refers to a group of the formula -C(O)-OC 1-6 Alkyl group.
[0342] As used herein, the term “C 1-6 Alkoxy-carbonyl-C 1-6 "Alkyl" refers to a group of the formula -C 1-6 Alkyl-C(O)-OC 1-6 Alkyl group.
[0343] As used herein, the term “C 1-6 "Alkoxy-carbonyl-amino" refers to a group of the formula -NH-C(O)-OC 1-6 Alkyl group.
[0344] As used herein, the term “C 1-6"Alkyl-amino" refers to a group of the formula -NH-C 1-6 Alkyl group.
[0345] As used herein, the term “(C 1-6 "alkyl)2-amino" refers to a group of the formula -N(C 1-6 alkyl)2 group.
[0346] As used herein, the term “C 1-6 "Alkyl-carbonyl" refers to a group of the formula -C(O)-C 1-6 Alkyl group.
[0347] As used herein, the term “C 1-6 "Alkyl-carbonyl-amino" refers to a group of the formula -NH-C(O)-C 1-6 Alkyl group.
[0348] As used herein, the term "amino-C 1-6 "Alkyl" refers to a group of the formula -C 1-6 Alkyl-NH2 group.
[0349] As used herein, the term "amino-carbonyl" refers to a group of formula -C(O)-NH2.
[0350] As used herein, the term "aryl-C 1-6 "Alkoxy" refers to a group of the formula -OC 1-6 Alkyl-aryl groups.
[0351] As used herein, the term "aryl-oxy" refers to a group of formula -O-aryl.
[0352] As used herein, the term "aryl-C 1-6 "Alkyl" refers to a group of the formula -C 1-6 Alkyl-aryl groups.
[0353] As used herein, the term "benzyloxy-carbonyl" refers to a radical of the formula -C(O)-O-CH2-phenyl.
[0354] As used herein, the term "halo" or "halogen" generally refers to a halogen atom radical, including fluorine, chlorine, bromine, and iodine.
[0355] As used herein, the term "halo-C 1-6 "Alkoxy" refers to a group of the formula -OC 1-6 Alkyl-halogenated groups in which, where available valence permits, C 1-6 The alkyl group is partially or fully substituted by one or more halogen atoms.
[0356] As used herein, the term "halo-C 1-6 "Alkyl" refers to a group of the formula -C 1-6Alkyl-halogenated groups in which, where available valence permits, C 1-6 The alkyl group is partially or fully substituted by one or more halogen atoms.
[0357] As used herein, the term "carboxyl" refers to a group of formula -COOH, -C(O)OH, or -CO2H.
[0358] As used herein, the term “C 1-6 "Alkyl-carboxyl" refers to a group of the formula -C 1-6 Alkyl-COOH, -C 1-6 Alkyl-C(O)OH or -C 1-6 Alkyl-CO2H group.
[0359] As used herein, the term "hydroxy" refers to a group of formula -OH.
[0360] As used herein, the term "hydroxy-C 1-6 Alkoxy-C 1-6 "Alkyl" refers to a group of the formula -C 1-6 Alkyl-OC 1-6 Alkyl-OH group.
[0361] As used herein, the term "hydroxy-C 1-6 "Alkyl" refers to a group of the formula -C 1-6 An alkyl-OH group in which, where available valences permit, C 1-6 The alkyl group is partially or fully substituted with one or more hydroxyl groups.
[0362] As used herein, the term "substituent" means a position variable on a core molecule atom that is substituted at a designated atomic position, replacing one or more hydrogens on the designated atom, provided that the normal valence of the designated atom is not exceeded, and the substitution produces a stable compound. Such combinations are allowed only when the combination of substituents and / or variables produces a stable compound. It should be noted by those of ordinary skill in the art that any carbon and heteroatom with a valence that does not appear to be satisfied as described or shown herein is assumed to have a sufficient number of hydrogen atoms to satisfy the valence described or shown. In some cases, in this article, one or more substituents with double bonds (e.g., "oxo" or "=O") as a point of attachment may be described, displayed, or listed in the substituent, wherein the structure may only show single bonds as a point of attachment to the core structure of formula (I) or formula (II). It should be understood by those of ordinary skill in the art that, although only single bonds are shown, double bonds are also intended to be used for those substituents.
[0363] With respect to the definitions of chemical terms provided herein, the term "and the like" as used herein means variations in chemical structures that would be expected by one skilled in the art, including but not limited to isomers (including chain, branched or positional structural isomers), hydration of ring systems (including saturated or partially unsaturated monocyclic, bicyclic or polycyclic structures), and all other variations that result in stable compounds as permitted by available chemical valences.
[0364] For purposes herein, when one or more substituent variables of a compound of Formula (I) or Formula (II), or a form thereof, encompass a functional group incorporated into the compound of Formula (I) or Formula (II), each functional group occurring at any position within the disclosed compound may be independently selected and, where appropriate, independently and / or optionally substituted.
[0365] As used herein, the term "independently selected" or "individually selected" refers to a functional variable in a substituent list that can appear more than once in a structure of Formula (I) or Formula (II), and the substitution pattern at each occurrence is independent of the pattern at any other occurrence. In addition, in any formula or structure of the compounds described herein, the use of general substituent variables should be understood to include replacement of general substituents with species substituents encompassed within a particular generic, for example, aryl can be replaced with phenyl or naphthyl, etc., and the resulting compounds will be included within the scope of the compounds described herein.
[0366] When in a sentence such as "...C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, Aryl, Aryl-C 1-4 Alkyl, Heteroaryl, Heteroaryl-C 1-4 Alkyl, heterocyclyl and heterocyclyl-C 1-4 As used herein, the term "each instance" or "when present, in each instance" is intended to refer to each C 3-10 Cycloalkyl, aryl, heteroaryl and heterocyclyl ring systems.
[0367] As used herein, the term "optionally substituted" means optional substitution with the specified substituent variable, group, radical, or moiety.
[0368] Compound form
[0369] As used herein, the term "form" means a compound of formula (I) or formula (II) having a form selected from the group consisting of its free acid, free base, prodrug, salt, hydrate, solvate, inclusion compound, isotopomer, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomeric form.
[0370] In certain aspects described herein, the compound of Formula (I) or Formula (II) is in the form of a free acid, a free base, or a salt thereof.
[0371] In certain aspects described herein, the compound of Formula (I) or Formula (II) is in the form of a salt thereof.
[0372] In certain aspects described herein, the compound of Formula (I) or Formula (II) is in the form of an isotopologue thereof.
[0373] In certain aspects described herein, the compound of Formula (I) or Formula (II) is in the form of a stereoisomer, racemate, enantiomer or diastereomer thereof.
[0374] In certain aspects described herein, the compound of Formula (I) or Formula (II) is in the form of a tautomer thereof.
[0375] In certain aspects described herein, the form of the compound of Formula (I) or Formula (II) is in a pharmaceutically acceptable form.
[0376] In certain aspects described herein, a compound of Formula (I) or Formula (II), or a form thereof, is isolated for use.
[0377] The term "isolated" as used herein means the physical state of a compound of Formula (I) or Formula (II) or a form thereof, after separation and / or purification from a synthetic process (e.g., from a reaction mixture) or a natural source, or a combination thereof, with sufficient purity as characterized by standard analytical techniques described herein or known to those skilled in the art (e.g., chromatography, recrystallization, etc.), according to one or more separation or purification methods described herein or known to those skilled in the art.
[0378] As used herein, the term "protected" means that the functional group in the compound of formula (I) or formula (II) or its form is in a form that is modified to prevent undesirable side reactions at the protected site when the compound is reacted. Suitable protecting groups will be known to those of ordinary skill in the art, and reference can also be made to standard textbooks, such as TW Greene et al., Protective Groups in organic Synthesis (1991), Wiley, New York. Such functional groups include hydroxyl, phenol, amino and carboxylic acid. Suitable protecting groups for hydroxyl or phenol include trialkylsilyl or diarylalkylsilyl (e.g., tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, substituted benzyl, methyl, methoxymethanol, etc. Suitable protecting groups for amino, amidino and guanidino include tert-butyloxycarbonyl, benzyloxycarbonyl, etc. Suitable protecting groups for carboxylic acids include alkyl, aryl or arylalkyl esters. In some instances, the protecting group may also be a polymer resin, such as Wang resin or 2-chlorotrityl chloride resin. Protecting groups may be added or removed according to standard techniques known to those skilled in the art and as described herein. It will also be appreciated by those skilled in the art that, although such protected derivatives of the compounds described herein may not themselves be pharmacologically active, they may be administered to a subject and subsequently metabolized in vivo to form pharmacologically active compounds described herein. Such derivatives may therefore be described as "prodrugs". All prodrugs of the compounds described herein are included within the scope of the uses described herein.
[0379] As used herein, the term "prodrug" means a form of a compound of the invention (e.g., a drug precursor) that is transformed in vivo to produce an active compound of formula (I) or formula (II) or a form thereof. The transformation can occur by various mechanisms (e.g., by metabolic and / or non-metabolic chemical processes), such as hydrolysis and / or metabolism in the blood, liver, and / or other organs and tissues. The following literature provides a discussion of the use of prodrugs: T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems", ACSSymposium Series, Vol. 14; and, Bioreversible Carriers in Drug Design, Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, 1987.
[0380] In one example, when the compound of formula (I) or formula (II) or a form thereof contains a carboxylic acid functional group, the prodrug may include an ester formed by replacing the hydrogen atom of the acidic group with a functional group such as an alkyl group. In another example, when the compound of formula (I) or formula (II) or a form thereof contains a hydroxyl functional group, the prodrug form can be prepared by replacing the hydrogen atom of the hydroxyl group with another functional group such as an alkyl, alkylcarbonyl or phosphonate. In another example, when the compound of formula (I) or formula (II) or a form thereof contains an amine functional group, the prodrug form can be prepared by replacing one or more amine hydrogen atoms with a functional group such as an alkyl or substituted carbonyl. Pharmaceutically acceptable prodrugs of the compound of formula (I) or formula (II) or a form thereof include, where appropriate, those compounds substituted with one or more of the following groups: carboxylate, sulfonate, amino acid ester, phosphonate, and monophosphate, diphosphate or triphosphate, or alkyl substituent. As described herein, one of ordinary skill in the art appreciates that one or more such substituents may be used to provide a compound of Formula (I) or Formula (II), or a form thereof, as a prodrug.
[0381] One or more compounds described herein may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and the description herein is intended to encompass both solvated and unsolvated forms.
[0382] As used herein, the term "solvate" means a physical association of a compound described herein with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In some cases, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid, the solvate will be able to separate. As used herein, "solvate" encompasses both solution phase and separable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.
[0383] As used herein, the term "hydrate" means a solvate in which the solvent molecule is water.
[0384] Compounds of formula (I) or formula (II) can form salts, which are intended to be included in the scope of this article. Unless otherwise indicated, reference to compounds of formula (I) or formula (II) or their forms herein should be understood to include reference to their salt forms. As used herein, the term "salt" means an acidic salt formed with an inorganic acid and / or organic acid, and a basic salt formed with an inorganic base and / or organic base. In addition, when a compound of formula (I) or formula (II) or its form contains both a basic moiety (such as, but not limited to, an amine moiety) and an acidic moiety (such as, but not limited to, a carboxylic acid), a zwitterion ("inner salt") can be formed and is included in the term "salt" as used herein.
[0385] As used herein, the term "pharmaceutically acceptable salt" means those salts of the compounds described herein that are safe and effective (i.e., non-toxic, physiologically acceptable) for use in mammals, and that have biological activity, although other salts may also be used. Salts of compounds of Formula (I) or (II) can be formed, for example, by reacting a compound of Formula (I) or (II) or a form thereof with an amount, such as an equivalent amount, of an acid or base in a medium (such as a medium in which the salt is precipitated) or in an aqueous medium, followed by lyophilization.
[0386] Pharmaceutically acceptable salts include one or more salts of acidic or basic groups present in the compounds described herein. Specific aspects of acid addition salts include, but are not limited to, acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, bitartrate, borate, bromide, butyrate, chloride, citrate, camphorate, camphorsulfonate, ethanesulfonate, formate, fumarate, gentisinate, gluconate, glucuronate, glutamate, iodide, isonicotinate, lactate, maleate, methanesulfonate, naphthenate, nitrate, oxalate, pamoate, pantothenate, phosphate, propionate, saccharate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate (also known as toluenesulfonate), trifluoroacetate, etc. Certain specific aspects of acid addition salts include chloride or dichloride.
[0387] In addition, acids generally considered suitable for forming pharmaceutically useful salts from basic drug compounds are discussed, for example, in P. Stahl et al., Camille G. (ed.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al., Journal of Pharmaceutical Sciences (1977) 66 (1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33, 201-217; Anderson et al., The Practice of Medicinal Chemistry (1996), Academic Press, New York; and The Orange Book (Food & Drug Administration, Washington, DC). See its webpage). The disclosures of these are incorporated herein by reference.
[0388] Suitable basic salts include, but are not limited to, aluminum, ammonium, calcium, lithium, magnesium, potassium, sodium, and zinc salts.
[0389] All such acid salts and base salts are intended to be included within the scope of pharmaceutically acceptable salts as described herein. Additionally, for purposes herein, all such acid salts and base salts are considered equivalent to the free forms of the corresponding compounds.
[0390] The compounds of Formula (I) or Formula (II) and forms thereof may further exist as tautomers. All such tautomeric forms are contemplated and intended to be included within the scope of the compounds of Formula (I) or Formula (II) or forms thereof as described herein.
[0391] The compounds of formula (I) or formula (II) or forms thereof may contain asymmetric centers or chiral centers and therefore exist in different stereoisomeric forms. It is intended herein to include all stereoisomeric forms of the compounds of formula (I) or formula (II) and mixtures thereof, including racemic mixtures.
[0392] The compounds described herein may include one or more chiral centers and may therefore exist as racemic mixtures (R / S) or as substantially pure enantiomers and diastereomers. The compounds (when there is one chiral center) may also exist as substantially pure (R) or (S) enantiomers. In one particular aspect, the compounds described herein are (S) isomers and may exist as enantiomerically pure compositions substantially comprising only (S) isomers. In another particular aspect, the compounds described herein are (R) isomers and may exist as enantiomerically pure compositions substantially comprising only (R) isomers. As will be appreciated by those skilled in the art, when there is more than one chiral center, the compounds described herein may also exist as (R,R), (R,S), (S,R) or (S,S) isomers as defined by the IUPAC Nomenclature Recommendations.
[0393] The term "substantially pure" as used herein refers to a compound consisting essentially of a single isomer in an amount greater than or equal to 90%, an amount greater than or equal to 92%, an amount greater than or equal to 95%, an amount greater than or equal to 98%, an amount greater than or equal to 99%, or an amount equal to 100% of the single isomer.
[0394] In one aspect herein, a compound of Formula (I) or Formula (II) or a form thereof is in substantially pure (S) enantiomeric form, which is present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%.
[0395] In one aspect herein, a compound of Formula (I) or Formula (II) or a form thereof is in substantially pure (R) enantiomeric form, which is present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%.
[0396] As used herein, a "racemate" is any mixture of isometric forms that is not "enantiomerically pure," including mixtures such as, but not limited to, in ratios of about 50 / 50, about 60 / 40, about 70 / 30, or about 80 / 20.
[0397] In addition, all geometric isomers and positional isomers are encompassed herein. For example, if a compound of formula (I) or formula (II) or a form thereof is incorporated into a double bond or a fused ring, the cis form and the trans form, as well as mixtures, are encompassed within the scope of this article. A diastereomeric mixture can be separated into its single diastereomer based on its physicochemical differences by methods well known to those skilled in the art, such as by chromatography and / or fractional crystallization. Enantiomers can be separated by using chiral HPLC columns or other chromatographic methods known to those skilled in the art. Enantiomers can also be separated in the following manner: reacting with an appropriate optically active compound (e.g., a chiral auxiliary, such as a chiral alcohol or Mosher's acid chloride), converting an enantiomeric mixture into a diastereomeric mixture; separating diastereomers; and converting each diastereomer (e.g., hydrolyzing) into the corresponding pure enantiomer. Additionally, some of the compounds of Formula (I) or Formula (II) may be atropisomers (eg, substituted biaryls) and are considered as part of this document.
[0398] All stereoisomers (e.g., geometric isomers, optical isomers, etc.) of the compounds of the present invention (including salts, solvates, esters and prodrugs of the compounds, and those of salts, solvates and esters of the prodrugs), such as those that may exist due to asymmetric carbons on various substituents, including enantiomeric forms (even in the absence of asymmetric carbons), rotational isomers, atropisomers and diastereomeric forms are included within the scope of this article, such as positional isomers (e.g., 4-pyridyl and 3-pyridyl). As described above, each stereoisomer of the compounds described herein may, for example, be substantially free of other isomers, or exist in the form of a racemic mixture.
[0399] The use of the terms "salt," "solvate," "ester," "prodrug," and the like are intended to apply equally to the salts, solvates, esters, and prodrugs of enantiomers, stereoisomers, rotational isomers, tautomers, positional isomers, racemates, or isotopomers of the compounds of the invention.
[0400] The term "isotopologue" refers to an isotopically enriched compound described herein, which is identical to a compound described herein except for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17O. 31 P. 32 P. 35 S. 18 F. 35 Cl and 36 Cl, each of which is also within the scope of this invention.
[0401] Certain isotopically enriched compounds described herein (e.g., 3 H and 14 C-labeled) can be used in compound and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred due to their ease of preparation and detectability. 2 Substitution with heavier isotopes may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and thus may be preferred in some circumstances.
[0402] Crystalline polymorphs and amorphous forms of the compounds of Formula (I) or (II), as well as salts, solvates, hydrates, esters and prodrugs of the compounds of Formula (I) or (II) are further intended to be included herein.
[0403] Compound Uses
[0404] According to the intended scope herein, various aspects herein include compounds that have been identified and demonstrated to be useful for selectively preventing, treating or ameliorating HD and have been provided for use in preventing, treating or ameliorating HD.
[0405] One aspect herein includes a method for preventing, treating, or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form thereof.
[0406] One aspect herein includes a method for treating or alleviating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form thereof.
[0407] One aspect herein includes a method for preventing HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form thereof.
[0408] One aspect herein includes a method for treating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form thereof.
[0409] One aspect herein includes a method for alleviating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form thereof.
[0410] Another aspect herein includes a method for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a salt of a compound of Formula (I) or Formula (II), or a form thereof.
[0411] One aspect herein includes a method of using a compound of Formula (I) or Formula (II), or a form or composition thereof, for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form or composition thereof.
[0412] Another aspect herein includes a method of using a salt of a compound of Formula (I) or Formula (II) or a form thereof or a composition thereof for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a salt of a compound of Formula (I) or Formula (II) or a form thereof.
[0413] One aspect herein includes the use of a compound of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II) or a form thereof.
[0414] Another aspect herein includes the use of a salt of a compound of Formula (I) or Formula (II) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a salt of a compound of Formula (I) or Formula (II) or a form thereof.
[0415] One aspect herein includes the use of a compound of Formula (I) or Formula (II), or a form thereof, in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of the medicament.
[0416] Another aspect herein includes the use of a compound of Formula (I) or Formula (II) salt or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of the medicament.
[0417] One aspect herein includes the in vitro or in vivo use of a compound of Formula (I) or Formula (II), or a form thereof, that is active against HD.
[0418] One aspect herein includes the use of a compound of Formula (I) or Formula (II), or a form thereof, in combination therapy to provide additive or synergistic activity, thereby enabling the development of a combination product for the treatment or alleviation of HD.
[0419] Another aspect herein includes combination therapies comprising a compound described herein in combination with one or more known drugs or one or more known therapies, which combination therapies can be used to treat HD, regardless of whether HD is responsive to the known drugs.
[0420] One aspect herein includes the use of a combination product of a compound of Formula (I) or Formula (II), or a form thereof, and one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form thereof, in combination with an effective amount of one or more agents.
[0421] Another aspect herein includes the use of a combination product of a compound salt of Formula (I) or Formula (II) or a form thereof and one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound salt of Formula (I) or Formula (II) or a form thereof in combination with an effective amount of one or more agents.
[0422] In one aspect of the uses or methods provided herein, a compound of formula (I) or formula (II) or a form thereof used in combination with one or more additional agents may be administered to the subject or contacted with the cells of the subject or patient before, simultaneously with, or after the additional agent is administered to the subject or patient, or contacted with the cells of the subject or patient. The compound of formula (I) or formula (II) or a form thereof and the additional agent may be administered to the subject or contacted with the cells in a single composition or in different compositions. In a specific aspect, a compound of formula (I) or formula (II) or a form thereof is used in combination with gene therapy to inhibit HTT expression (using, for example, a viral delivery vector), or in combination with the administration of another small molecule HTT inhibitor. In another specific aspect, a compound of formula (I) or formula (II) or a form thereof is used in combination with cell replacement, wherein the cell replacement uses differentiated non-mutated HTT stem cells. In another specific aspect, a compound of formula (I) or formula (II) or a form thereof is used in combination with cell replacement, wherein the cell replacement uses differentiated HTT stem cells.
[0423] In one aspect, provided herein is the use of a compound of Formula (I) or Formula (II), or a form thereof, in combination with supportive standard of care therapy, including palliative care.
[0424] One aspect herein includes the use of a compound of Formula (I) or Formula (II), or a form thereof, in the preparation of a kit for treating or alleviating HD in a subject in need thereof, the kit comprising a compound of Formula (I) or Formula (II), or a form thereof, and instructions for administering an effective amount of the compound of Formula (I) or Formula (II), or a form thereof.
[0425] One aspect herein includes the use of a compound of Formula (I) or Formula (II), or a form thereof, in the preparation of a kit for treating or alleviating HD in a subject in need thereof, the kit comprising a compound of Formula (I) or Formula (II), or a form thereof, and instructions for administering an effective amount of a compound of Formula (I) or Formula (II), or a form thereof; and optionally, instructions for administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form thereof, in combination with an effective amount of one or more therapeutic agents.
[0426] One aspect herein includes the use of a compound of Formula (I) or Formula (II), or a form thereof, in the preparation of a kit for treating or alleviating HD in a subject in need thereof, the kit comprising a compound of Formula (I) or Formula (II), or a form thereof, and instructions for administering an effective amount of a compound of Formula (I) or Formula (II), or a form thereof; and optionally, instructions for administering to the subject an effective amount of a combination of a compound of Formula (I) or Formula (II), or a form thereof, and an effective amount of one or more therapeutic agents; and optionally, instructions for administering to the subject an effective amount of a combination of a compound of Formula (I) or Formula (II), or a form thereof, and an effective amount of one or more therapeutic agents in combination with standard of care supportive therapy, wherein the standard of care supportive therapy is palliative care.
[0427] In one aspect, for each such aspect, the subject is treatment naive. In another aspect, for each such aspect, the subject is not treatment naive.
[0428] As used herein, the term "preventing" refers to preventing a disease, disorder or condition from occurring in a subject who may be susceptible to the disease, disorder and / or condition but has not yet been diagnosed as having the disease, disorder and / or condition.
[0429] As used herein, the term "treating" refers to inhibiting the progression of a disease, disorder and / or condition in a subject already displaying symptoms of the disease, disorder and / or condition, i.e., arresting the development of a disease, disorder and / or condition already affecting the subject.
[0430] As used herein, the term "alleviate" refers to a relief of the symptoms of a disease, disorder and / or condition in a subject already displaying symptoms of the disease, disorder and / or condition, even if the disease, disorder and / or condition that has affected the subject has resolved.
[0431] As used herein, the term "subject" refers to an animal or any living organism that has sensory and voluntary motor abilities and requires oxygen and organic food. Non-limiting examples include members of human, primate, horse, pig, cow, mouse, rat, dog, and cat species. In some aspects, the subject is a mammal or a warm-blooded vertebrate. In other aspects, the subject is a human. As used herein, the term "patient" can be used interchangeably with "subject" and "human".
[0432] As used herein, the term "effective amount" or "therapeutically effective amount" means an amount of a compound of Formula (I) or Formula (II) or a form thereof, composition or medicament that achieves an effective target plasma concentration in treating or alleviating HD as described above and thus produces the desired therapeutic, alleviating, inhibitory or preventive effect in a subject in need thereof. In one aspect, an effective amount may be the amount required to treat HD in a subject or patient or human (more specifically).
[0433] On the other hand, the concentration-biological effect relationship observed for the compounds of Formula (I) or Formula (II) or forms thereof indicates a target plasma concentration in the range of about 0.001 μg / mL to about 50 μg / mL, about 0.01 μg / mL to about 20 μg / mL, about 0.05 μg / mL to about 10 μg / mL, or about 0.1 μg / mL to about 5 μg / mL. To achieve such plasma concentrations, the compounds described herein can be administered at varying doses such as, for example, but not limited to, 1.0 ng to 10,000 mg.
[0434] In one aspect, the dose administered to achieve an effective target plasma concentration can be administered based on subject or patient specific factors, wherein the dose administered based on weight can be in the range of about 0.001 mg / kg / day to about 3500 mg / kg / day, or about 0.001 mg / kg / day to about 3000 mg / kg / day, or about 0.001 mg / kg / day to about 2500 mg / kg / day, or about 0.001 mg / kg / day to about 2000 mg / kg / day, or about 0.001 mg / kg / day to about 1500 mg / kg / day, or about 0.001 mg / kg / day to about 1000 mg / kg / day, or about 0.001 mg / kg / day to about 500 mg / kg / day. g / kg / day, or about 0.001 mg / kg / day to about 250 mg / kg / day, or about 0.001 mg / kg / day to about 200 mg / kg / day, or about 0.001 mg / kg / day to about 150 mg / kg / day, or about 0.001 mg / kg / day to about 100 mg / kg / day, or about 0.001 mg / kg / day to about 75 mg / kg / day, or about 0.001 mg / kg / day to about 50 mg / kg / day, or about 0.001 mg / kg / day to about 25 mg / kg / day, or about 0.001 mg / kg / day to about 10 mg / kg / day, or about 0.001 mg / kg / day to about 5 mg / kg / day, or about 0. 0.01 mg / kg / day to about 1 mg / kg / day, or about 0.001 mg / kg / day to about 0.5 mg / kg / day, or about 0.001 mg / kg / day to about 0.1 mg / kg / day, or about 0.01 mg / kg / day to about 3500 mg / kg / day, or about 0.01 mg / kg / day to about 3000 mg / kg / day, or about 0.01 mg / kg / day to about 2500 mg / kg / day, or about 0.01 mg / kg / day to about 2000 mg / kg / day, or about 0.01 mg / kg / day to about 1500 mg / kg / day, or about 0.01 mg / kg / day to about 1000 mg / kg / day, or about 0.01 mg / kg / day to about g / day to about 500 mg / kg / day, or about 0.01 mg / kg / day to about 250 mg / kg / day, or about 0.01 mg / kg / day to about 200 mg / kg / day, or about 0.01 mg / kg / day to about 150 mg / kg / day, or about 0.01 mg / kg / day to about 100 mg / kg / day, or about 0.01 mg / kg / day to about 75 mg / kg / day, or about 0.01 mg / kg / day to about 50 mg / kg / day, or about 0.01 mg / kg / day to about 25 mg / kg / day, or about 0.01 mg / kg / day to about 10 mg / kg / day, or about 0.01 mg / kg / day to about 5 mg / kg / day, or about 0.01 mg / kg / day to about 0.The dosage form may be from about 0.01 mg / kg / day to about 1 mg / kg / day, or from about 0.01 mg / kg / day to about 0.5 mg / kg / day, or from about 0.01 mg / kg / day to about 0.1 mg / kg / day, or from about 0.1 mg / kg / day to about 3500 mg / kg / day, or from about 0.1 mg / kg / day to about 3000 mg / kg / day, or from about 0.1 mg / kg / day to about 2500 mg / kg / day, or from about 0.1 mg / kg / day to about 2000 mg / kg / day, or from about 0.1 mg / kg / day to about 1500 mg / kg / day, or from about 0.1 mg / kg / day to about 1000 mg / kg / day, or from about 0.1 mg / kg / day to about 500 mg / kg / day, or from about 0.1 mg / kg / day to about g / kg / day to about 250mg / kg / day, or about 0.1mg / kg / day to about 200mg / kg / day, or about 0.1mg / kg / day to about 150mg / kg / day, or about 0.1mg / kg / day to about 100mg / kg / day, or about 0.1mg / kg / day to about 75mg / kg / day, or about 0.1mg / kg / day to about 50mg / kg / day, or about 0.1mg / kg / day to about 25mg / kg / day, or about 0.1mg / kg / day to about 10mg / kg / day, or about 0.1mg / kg / day to about 5mg / kg / day, or about 0.1mg / kg / day to about 1mg / kg / day or about 0.1mg / kg / day to about 0.5mg / kg / day. .
[0435] The effective amount for a given subject can be determined by routine experimentation, based on factors relevant to the subject, which is within the skill and judgment of a clinician or technician in the field. Dosage and administration can be adjusted to provide sufficient levels of active agent or to maintain the desired effect. Factors that may be considered include genetic screening, severity of the disease state, disease progression status, general health of the subject, race, age, weight, sex, diet, time of day and frequency of administration, drug combinations, reaction sensitivities, experience with other therapies, and tolerance / response to therapy.
[0436] The dose administered to achieve an effective target plasma concentration can be orally administered once (once within an approximately 24-hour period; i.e., "once a day (qd)"), twice (once within an approximately 12-hour period; i.e., "twice a day (bid)" or "once every 12 hours (q.12h)"), three times (once within an approximately 8-hour period; i.e., "three times a day (tid)" or "once every 8 hours ("q.8h)"), or four times (once within an approximately 6-hour period; i.e., "four times a day (qds)", "four times a day (qid)" or "once every 6 hours (q.6h)") per day.
[0437] In certain aspects, for patients or subjects with a weight in the range of about 40 to about 200 kg, the dosage administered to achieve an effective target plasma concentration can also be administered in a single dose, divided doses, or continuous doses (the dosage can be adjusted for patients or subjects above or below the range, particularly children below 40 kg). It is expected that the median weight of a typical adult subject is in the range of about 70 kg. Depending on the half-life and clearance rate of a particular formulation, a long-acting pharmaceutical composition can be administered every 2 days, 3 days, or 4 days, once a week, or once every two weeks.
[0438] The compounds and compositions described herein can be administered to a subject by any drug delivery route known in the art. Non-limiting examples include oral, ocular, rectal, buccal, topical, nasal, sublingual, transdermal, subcutaneous, intramuscular, intravenous (bolus and infusion), intracerebral and pulmonary administration routes.
[0439] In another aspect, the dose administered can be adjusted based on the dosage forms described herein, formulated for administration at about 0.02 mg / day, 0.025 mg / day, 0.03 mg / day, 0.05 mg / day, 0.06 mg / day, 0.075 mg / day, 0.08 mg / day, 0.09 mg / day, 0.10 mg / day, 0.20 mg / day, 0.25 mg / day, 0.30 mg / day, 0.50 mg / day, 0.60 mg / day, 0.75 mg / day, 0.80 mg / day, 0.90 mg / day, 1.0 mg / day, 1.10 mg / day, 1.20 mg / day, 1.30 mg / day, 1.40 mg / day, 1.50 mg / day, 1.60 mg / day, 1.70 mg / day, 1.80 mg / day, 1.90 mg / day, 2.15 mg / day, 2.20 mg / day, 2.30 mg / day, 2.40 mg / day, 2.50 mg / day, 2.60 mg / day, 2.70 mg / day, 2.80 mg / day, 2.90 mg / day In some embodiments, the present invention provides an amount of 20 mg / day, 1.25 mg / day, 1.50 mg / day, 1.75 mg / day, 2.0 mg / day, 3.0 mg / day, 5.0 mg / day, 10 mg / day, 20 mg / day, 30 mg / day, 40 mg / day, 50 mg / day, 100 mg / day, 150 mg / day, 200 mg / day, 250 mg / day, 300 mg / day, 400 mg / day, 500 mg / day, 1000 mg / day, 1500 mg / day, 2000 mg / day, 2500 mg / day, 3000 mg / day or 4000 mg / day.
[0440] For any compound, the effective amount can be estimated initially in cell culture assays or in relevant animal models (such as mice, guinea pigs, chimpanzees, marmosets or tamarins). The relevant animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes of administration in humans. Therapeutic efficacy and toxicity can be assessed by standard pharmaceutical procedures in cell cultures or experimental animals, such as ED 50 (the amount therapeutically effective in 50% of the population) and LD 50The dose ratio between therapeutic and toxic effects is the therapeutic index and can be expressed as the ratio LD 50 / ED 50 In certain aspects, the effective amount is such that a large therapeutic index can be achieved. In other specific aspects, the dosage is within a range of circulating concentrations that include the ED with little or no toxicity. 50 The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
[0441] In one aspect, provided herein is a method for regulating the amount of HTT (Hentin protein), the method comprising contacting a human cell with a compound of formula (I) or formula (II) or a form thereof. In a specific aspect, provided herein is a method for regulating the amount of HTT, the method comprising contacting a human cell with a compound of formula (I) or formula (II) or a form thereof that regulates HTT expression. Human cells can be contacted with a compound of formula (I) or formula (II) or a form thereof in vitro or in vivo (e.g., in a non-human animal or in a human). In a specific aspect, the human cell is from a human or in a human. In another specific aspect, the human cell is from a human with HD or in a human with HD. In another specific aspect, the human cell is from a human with HD or in a human with HD, wherein HD is caused by CAG repeats in the Htt gene, resulting in loss of HTT expression and / or function. In another aspect, the human cell is from a human with HD. In another aspect, the human cell is in a human with HD. In one aspect, the compound is in the form of a compound of formula (I) or formula (II).
[0442] In one specific aspect, provided herein is a method for enhancing the inhibition of mutant HTT transcribed from the Htt gene, the method comprising contacting a human cell with a compound of formula (I) or formula (II) or a form thereof. The human cell may be contacted with a compound of formula (I) or formula (II) or a form thereof in vitro or in vivo (e.g., in a non-human animal or in a human). In one specific aspect, the human cell is from a human or in a human. In another specific aspect, the human cell is from a human with HD or in a human with HD. In another specific aspect, the human cell is from a human with HD or in a human with HD, wherein HD is caused by CAG repeats in the Htt gene, resulting in loss of wild-type "normal" HTT expression and / or function. In another aspect, the human cell is from a human with HD. In another aspect, the human cell is in a human with HD. In one aspect, the compound is in the form of a compound of formula (I) or formula (II).
[0443] In another aspect, provided herein is a method for regulating the inhibition of mutant HTT transcribed from the Htt gene, the method comprising administering a compound of formula (I) or formula (II) or a form thereof to a non-human animal model of HD. In a specific aspect, provided herein is a method for regulating the inhibition of mutant HTT transcribed from the Htt gene, the method comprising administering a compound of formula (I) or formula (II) or a form thereof to a non-human animal model of HD. In a specific aspect, the compound is in the form of a compound of formula (I) or formula (II).
[0444] On the other hand, provided herein is a method for reducing the amount of mutant HTT, the method comprising contacting a human cell with a compound of formula (I) or formula (II) or a form thereof. In a specific aspect, provided herein is a method for reducing the amount of mutant HTT, the method comprising contacting a human cell with a compound of formula (I) or formula (II), the compound of formula (I) or formula (II) inhibiting transcription of mutant HTT (Hentengton mRNA) from the Htt gene. In another specific aspect, provided herein is a method for reducing the amount of HTT, the method comprising contacting a human cell with a compound of formula (I) or formula (II), the compound of formula (I) or formula (II) inhibiting expression of mutant HTT transcribed from the Htt gene. Human cells may be contacted with a compound of formula (I) or formula (II) or a form thereof in vitro or in vivo (e.g., in a non-human animal or in a human). In a specific aspect, the human cell is from a human or in a human body. In another specific aspect, the human cell is from a human with HD or in a human with HD. In another specific aspect, the human cell is from or is in a human with HD caused by CAG repeats in the Htt gene, resulting in loss of HTT expression and / or function. In another aspect, the human cell is from a human with HD. In another aspect, the human cell is in a human with HD. In one aspect, the compound is in the form of a compound of formula (I) or formula (II).
[0445] In certain aspects, treating or alleviating HD with a compound of Formula (I) or Formula (II) or a form thereof (alone or in combination with an additional agent) has a therapeutic effect and / or a beneficial effect. In a specific aspect, treating HD with a compound of Formula (I) or Formula (II) or a form thereof (alone or in combination with an additional agent) produces one, two or more of the following effects: (i) reducing or alleviating the severity of HD; (ii) delaying the onset of HD; (iii) inhibiting the progression of HD; (iv) reducing the subject's hospitalization; (v) reducing the subject's length of hospital stay; (vi) increasing the subject's survival; (vii) improving the subject's quality of life; (viii) reducing the number of symptoms associated with HD; (ix) reducing or alleviating the severity of symptoms associated with HD; (x) reducing the duration of symptoms associated with HD; (xi) preventing the recurrence of symptoms associated with HD; (xii) inhibiting the development or onset of HD symptoms; and / or (xiii) inhibiting the progression of symptoms associated with HD.
[0446] Metabolites
[0447] On the other hand, also included within the scope of this invention are the use of metabolites of the compounds described herein in vivo. Such products may be produced, for example, by oxidation, reduction, hydrolysis, amidation, esterification, etc. of the administered compound, primarily due to enzymatic processes. Thus, included herein are the use of compounds produced by a process comprising contacting a compound described herein with a mammalian tissue or mammal for a period of time sufficient to produce a metabolite thereof.
[0448] Such products are typically identified by preparing radiolabeled isotopologues of the compounds described herein (e.g., 14 C or 3 H), administering a radiolabeled compound to a mammal such as a rat, mouse, guinea pig, dog, monkey or human at a detectable dose (e.g., greater than about 0.5 mg / kg), allowing sufficient time for metabolism to occur (generally about 30 seconds to about 30 hours), and identifying metabolic conversion products from urine, bile, blood or other biological samples. Conversion products are easily isolated because they are "radiolabeled" due to isotopic enrichment (other products are isolated by using antibodies that can bind to epitopes remaining in the metabolites). Metabolite structures are determined in conventional manner, for example, by MS or NMR analysis. In general, analysis of metabolites can be performed in the same manner as conventional drug metabolism studies well known to those skilled in the art. Conversion products, as long as they are not otherwise found in vivo, can be used in diagnostic assays for therapeutic administration of the compounds described herein, even if they do not have their own biological activity.
[0449] Pharmaceutical composition
[0450] According to the intended scope herein, aspects herein include compounds that have been identified and demonstrated to be useful for selectively preventing, treating or ameliorating HD and that have been provided for use as one or more pharmaceutical compositions for preventing, treating or ameliorating HD.
[0451] One aspect herein includes the use of a compound of Formula (I) or Formula (II), or a form thereof, in the preparation of a pharmaceutical composition for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or Formula (II), or a form thereof, mixed with one or more pharmaceutically acceptable excipients.
[0452] One aspect herein includes the use of a compound of Formula (I) or Formula (II), or a pharmaceutical composition in a form thereof, in the preparation of a kit for treating or ameliorating HD in a subject in need thereof, the kit comprising a compound of Formula (I) or Formula (II), or a pharmaceutical composition in a form thereof, and instructions for administering the pharmaceutical composition.
[0453] The term "composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
[0454] The pharmaceutical composition can be formulated to achieve a physiologically compatible pH ranging from about pH 3 to about pH 11. In certain aspects, the pharmaceutical composition is formulated to achieve a pH of about pH 3 to about pH 7. In other aspects, the pharmaceutical composition is formulated to achieve a pH of about pH 5 to about pH 8.
[0455] The term "pharmaceutically acceptable excipient" refers to an excipient used to administer a medicament, such as a compound described herein. The term refers to any pharmaceutical excipient that can be administered without undue toxicity. A pharmaceutically acceptable excipient can be determined, in part, by the particular composition being administered and by the particular mode of administration and / or dosage form. Non-limiting examples of pharmaceutically acceptable excipients include carriers, solvents, stabilizers, adjuvants, diluents, and the like. Thus, there are a wide variety of suitable pharmaceutical composition formulations for the compounds of the invention described herein (see, e.g., Remington's Pharmaceutical Sciences).
[0456] Suitable excipients can be carrier molecules, which include large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acid, polyglycolic acid, polymeric amino acids, amino acid copolymers, and inactive antibodies. Other exemplary excipients include antioxidants such as ascorbic acid; chelating agents such as EDTA; carbohydrates such as dextrins, hydroxyalkylcelluloses, hydroxyalkylmethylcelluloses (e.g., hydroxypropylmethylcellulose, also known as HPMC), stearic acid; liquids such as oils, water, saline, glycerol, and ethanol; wetting agents or emulsifiers; pH buffer substances; and the like. Liposomes are also encompassed within the definition of pharmaceutically acceptable excipients.
[0457] The pharmaceutical compositions described herein can be formulated in any form suitable for the intended use described herein. Suitable formulations for oral administration include solids, liquid solutions, emulsions, and suspensions, while suitable inhalable formulations for pulmonary administration include liquids and powders. Alternative formulations include syrups, creams, ointments, tablets, and lyophilized solids, wherein the lyophilized solids can be reconstituted with a physiologically compatible solvent prior to administration.
[0458] When intended for oral use, for example, tablets, buccal tablets, lozenges, aqueous or oily suspensions, non-aqueous solutions, dispersible powders or granules (including micronized particles or nanoparticles), emulsions, hard or soft capsules, syrups or elixirs can be prepared. Compositions intended for oral use can be prepared according to any method known in the art of pharmaceutical composition manufacture, and such compositions may contain one or more agents, including sweeteners, flavoring agents, coloring agents and preservatives, in order to provide a palatable preparation.
[0459] Pharmaceutically acceptable excipients suitable for use in conjunction with tablets include, for example, inert diluents such as cellulose, calcium or sodium carbonate, lactose, calcium or sodium phosphate; disintegrants such as cross-linked sodium carboxymethylcellulose, cross-linked povidone, corn starch or alginic acid; binders such as povidone, starch, gelatin or acacia; and lubricants such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract, thereby providing a sustained action over a longer period of time. For example, time-delay materials such as glyceryl monostearate or glyceryl distearate may be used alone or with a wax.
[0460] Formulations for oral use may also be presented as hard gelatin capsules, in which the active ingredient is mixed with an inert solid diluent such as cellulose, lactose, calcium phosphate or kaolin, or as soft gelatin capsules, in which the active ingredient is mixed with a non-aqueous or oily medium such as glycerol, propylene glycol, polyethylene glycol, peanut oil, liquid paraffin or olive oil.
[0461] In other aspects, the pharmaceutical compositions described herein can be formulated as suspensions comprising a compound of formula (I) or formula (II) or a form thereof mixed with one or more pharmaceutically acceptable excipients suitable for making suspensions. In other aspects, the pharmaceutical compositions described herein can be formulated as dispersible powders and granules suitable for preparing suspensions by adding one or more excipients.
[0462] Excipients suitable for use in conjunction with the suspension include suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, tragacanth gum, gum arabic, dispersants or wetting agents such as naturally occurring phospholipids (e.g., lecithin), condensation products of alkylene oxides with fatty acids (e.g., polyoxyethylene stearate), condensation products of ethylene oxides with long-chain aliphatic alcohols (e.g., heptadecaethyleneoxyethanol), condensation products of ethylene oxides with partial esters derived from fatty acids and hexitol anhydrides (e.g., polyoxyethylene sorbitan monooleate); and thickeners such as carbomer, beeswax, hard paraffin or cetyl alcohol. The suspension may also contain one or more preservatives such as acetic acid, methyl paraben and / or n-propyl paraben; one or more coloring agents; one or more flavoring agents; and one or more sweeteners such as sucrose or saccharin.
[0463] The pharmaceutical compositions described herein may also be in the form of an oil-in-water emulsion. The oil phase may be a vegetable oil (such as olive oil or peanut oil), a mineral oil (such as liquid paraffin) or a mixture thereof. Suitable emulsifiers include naturally occurring gums such as gum arabic and gum tragacanth; naturally occurring phospholipids such as soy lecithin, esters or partial esters derived from fatty acids; hexitol anhydrides such as sorbitan monooleate; and condensation products of these partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. Emulsions may also contain sweeteners and flavorings. Syrups and elixirs may be formulated with sweeteners such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
[0464] In addition, the pharmaceutical compositions described herein may be in the form of sterile injectable preparations (such as sterile injectable aqueous emulsions or oily suspensions). Such emulsions or suspensions may be prepared according to known techniques using those suitable dispersants or wetting agents mentioned above, and suspending agents. Sterile injectable preparations may also be sterile injectable solutions or suspensions in nontoxic parenteral acceptable diluents or solvents, such as solutions in 1,2-propylene glycol. Sterile injectable preparations may also be prepared as lyophilized powders. Acceptable vehicles and solvents that may be used include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils may be used as solvents or suspension media. For this purpose, any mild fixed oil may be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids, such as oleic acid, may also be used to prepare injections.
[0465] The compounds described herein may be substantially insoluble in water and slightly soluble in most pharmaceutically acceptable protic solvents and vegetable oils, but are generally soluble in medium chain fatty acids (e.g., caprylic acid and capric acid) or triglycerides, and soluble in propylene glycol esters of medium chain fatty acids. Thus, compounds that have been modified by substitution or addition of chemical or biochemical moieties, such as by esterification, glycosylation, PEGylation, etc., are contemplated herein to make the compound more suitable for delivery (e.g., to increase solubility, biological activity, palatability, reduce adverse reactions, etc.).
[0466] In certain aspects, the compounds described herein are formulated for oral administration in lipid-based compositions suitable for low solubility compounds. Lipid-based formulations generally enhance the oral bioavailability of such compounds. Thus, the pharmaceutical compositions described herein may comprise an effective amount of a compound of Formula (I) or Formula (II) or a form thereof, together with at least one pharmaceutically acceptable excipient selected from medium-chain fatty acids or propylene glycol esters thereof (e.g., edible fatty acids, such as propylene glycol esters of caprylic acid and capric acid), and a pharmaceutically acceptable surfactant, such as polysorbate 20 or 80 (also known as polysorbate 80, respectively). 20 or 80) or polyoxyethylene 40 hydrogenated castor oil.
[0467] In other aspects, the bioavailability of low solubility compounds can be enhanced using particle size optimization techniques, including preparing nanoparticles or nanosuspensions using techniques known to those skilled in the art. The compound forms present in such formulations include amorphous forms, partially amorphous forms, partially crystalline forms, or crystalline forms.
[0468] In alternative aspects, the pharmaceutical composition may further include one or more aqueous solubility enhancers, such as cyclodextrins. Non-limiting examples of cyclodextrins include hydroxypropyl derivatives, hydroxyethyl derivatives, glucosyl derivatives, maltosyl derivatives and maltotriosyl derivatives of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, and hydroxypropyl-β-cyclodextrin (HPBC). In certain aspects, the pharmaceutical composition further includes HPBC in the range of about 0.1% to about 20%, about 1% to about 15% or about 2.5% to about 10%. The amount of the solubility enhancer used may depend on the amount of the compound in the composition.
[0469] Preparation of compounds
[0470] General Synthesis Methods
[0471] As disclosed herein, the general method for preparing a compound of formula (I) or formula (II) as described herein or its form can be obtained via standard, well-known synthetic methods. Many starting materials are commercially available, or when unavailable, can be prepared using techniques known to those skilled in the art using the following approaches. The synthetic scheme provided herein includes multiple reaction steps, each of which is intended to be carried out independently and can be carried out with or without any preceding or following steps. In other words, each single reaction step of the synthetic scheme provided separately herein is encompassed.
[0472] Option A:
[0473] The compounds of formula (I) or formula (II) can be prepared as described in Scheme A below, wherein R1 and R2 are independently selected from C 3-10 Cycloalkyl, heterocyclyl, phenyl or heteroaryl ring systems.
[0474]
[0475] Compound A1 (wherein X1 and X3 are independently bromine, chlorine, fluorine, etc.; W1, W2 and W3 are independently CR) is reacted with potassium ethyl xanthate in a suitable solvent (such as DMF, etc.) at an elevated temperature (such as 130°C). a or N, where R aCompound A2 (X2 = Cl, Br) is converted to Compound A2, which is further reacted with sulfonyl chloride to obtain Compound A3 (X2 = Cl). Alternatively, Compound A1 is reacted with Fmoc-NCS to obtain Compound A4, which is deprotected by an amine (such as piperidine) to obtain Compound A5. Alternatively, Compound A1 is reacted with KNCS in a suitable solvent (such as MeOH) in the presence of CuSO4 to obtain Compound A5. Compound A5 is then converted to A3 (X2 = Cl, Br) by a Sandmeyer reaction using an alkyl nitrite (such as tert-butyl nitrite) and a copper (II) halide in a suitable solvent (such as acetonitrile). Compound A3 is converted to A6 by nucleophilic substitution with a primary or secondary amine or an alcohol in the presence of a suitable base (such as NaH, K2CO3, etc.) in a suitable solvent (such as DMF, etc.). Alternatively, compound A2 can be reacted with iodomethane to give compound A9, which can be oxidized by an oxidant (such as mCPBA) to give compound A10. Compound A10 is converted to A6 by nucleophilic substitution with a primary or secondary amine or alcohol in a suitable solvent (such as DMF, etc.) in the presence of a suitable base (such as NaH, K2CO3, etc.). Compound A6 is converted to compound A7 by Suzuki coupling with an aryl boronic acid or heteroaryl boronic acid (or pinacol boronate) in the presence of a catalyst (such as Pd(dppf)Cl2, etc.) and a base (such as aqueous K2CO3, etc.) in a suitable solvent (such as 1,4-dioxane, etc.). Alternatively, compound A6 is converted to compound A8 by coupling with B2Pin2 in the presence of a catalyst (such as Pd(dppf)Cl2, etc.) and a base (such as KOAc, etc.) in a suitable solvent (such as 1,4-dioxane, etc.). Compound A8 is further coupled with an aryl halide or heteroaryl halide in the presence of a catalyst (such as Pd(dppf)Cl2, etc.) and a base (such as aqueous K2CO3, etc.) in a suitable solvent (such as 1,4-dioxane, etc.) to give Compound A7.
[0476] Option B:
[0477] The compounds of formula (II) can be prepared as described in Scheme B below, wherein R1 and R2 are independently selected from C 3-10 Cycloalkyl, heterocyclyl, phenyl or heteroaryl ring systems.
[0478]
[0479] Compound B1 (wherein X1 and X2 are independently bromine, chlorine, etc.; W1, W2 and W3 are independently CR) is reacted by Suzuki coupling with aryl boronic acid or heteroaryl boronic acid (or pinacol borate) in the presence of a catalyst (such as Pd(dppf)Cl2, etc.) and a base (such as aqueous K2CO3, etc.) in a suitable solvent (such as 1,4-dioxane, etc.). a or N, where R a The functional substituents may be further derivatized using techniques known to those skilled in the art) are converted to B2. Compound B2 is converted to compound B3 by nucleophilic substitution with a primary or secondary amine in the presence of a suitable base (such as K2CO3, etc.) in a suitable solvent (such as DMF, etc.); or compound B2 is converted to compound B3 by Buchwald-Hartwig coupling in the presence of a catalyst (such as Pd2(dba)3 / RuPhos, etc.) and a base (such as t-BuONa, etc.) in a suitable solvent (such as 1,4-dioxane, etc.).
[0480] Option C:
[0481] The compounds of formula (I) or formula (II) can be prepared as described in Scheme C below, wherein R1 and R2 are independently selected from C 3-10 Cycloalkyl, heterocyclyl, phenyl or heteroaryl ring systems.
[0482]
[0483] Compound C1 (wherein X1 and X2 are independently bromine, chlorine, etc.; W1, W2 and W3 are independently CR) is reacted by Suzuki coupling with an optionally substituted and appropriately protected amino-containing cycloalkyl / cycloalkenyl pinacol borate (wherein Y is hydrogen or an optionally substituted alkyl group, and P is a protecting group such as Boc, etc.) in the presence of a catalyst (such as Pd(dppf)Cl2, etc.) and a base (such as aqueous K2CO3, etc.) in a suitable solvent (such as 1,4-dioxane, etc.). a or N, where R aThe functional substituents may be further derivatized using techniques known to those of ordinary skill in the art) are converted to compound C2. Alternatively, compound C1 is converted to compound C2 by Negishi coupling with an optionally substituted and appropriately protected amino-containing cycloalkyl zinc halide in the presence of a catalyst such as Pd(dppf)Cl2 in a suitable solvent such as 1,4-dioxane. Compound C2 is converted to compound C3 by Suzuki coupling with an aryl or heteroaryl boronic acid (or pinacol boronate) in the presence of a catalyst such as Pd(dppf)Cl2 and a base such as aqueous K2CO3 in a suitable solvent such as 1,4-dioxane. Compound C3 is converted to compound C4 after treatment with a deprotecting agent suitable for the protecting group such as HCl in dioxane for the Boc protecting group. Compound C4 is converted to compound C5 by reductive amination with a suitable aldehyde and a reducing agent (such as NaBH(OAc)3, etc.) in a suitable solvent (such as 1,2-dichloroethane, etc.). Alternatively, compound C4 is converted to compound C5 by alkylation with an alkyl halide (such as 2-iodopropane, etc.) in the presence of a suitable base (such as K2CO3, etc.). In the case of unsaturation in the ring containing the basic amino group, the compound can be converted to a fully saturated analog under H2 atmosphere in a suitable solvent (such as methanol, etc.) and in the presence of a catalyst (such as 10% Pd / C, etc.).
[0484] Plan D:
[0485] The compounds of formula (II) can be prepared as described in Scheme D below, wherein R1 and R2 are independently selected from C 3-10 Cycloalkyl, heterocyclyl, phenyl or heteroaryl ring systems.
[0486]
[0487] Compound D1 can be converted to compounds D4 and D5 using the conditions described in Scheme C where steps 1 and 2 are reversed.
[0488] Plan E:
[0489] Compounds of formula (I) or formula (II) can be prepared as described in Scheme E below, wherein R1 and R2 are independently selected from C 3-10 Cycloalkyl, heterocyclyl, phenyl or heteroaryl ring systems.
[0490]
[0491] Compound E1 (wherein X1 and X3 are independently bromine, chlorine, fluorine, etc.; W1, W2 and W3 are independently CR) is prepared by reacting with an optionally substituted and appropriately protected amino-containing cycloalkyl / cycloalkenyl carboxylic acid (wherein Y is hydrogen or an optionally substituted alkyl group, P is a protecting group such as Boc, etc., and R is H, halogen or an optionally substituted alkyl group) in the presence of an activating agent (such as oxalyl chloride, etc.) and a base (such as aqueous pyridine, etc.) in a suitable solvent (such as dichloromethane, etc.). a or N, where R a Compound E3 is converted to compound E4 by coupling with B2Pin2 in the presence of a catalyst (such as Pd(dppf)Cl2, etc.) and a base (such as KOAc, etc.) in a suitable solvent (such as 1,4-dioxane, etc.). Compound E4 is further coupled with an aryl halide or heteroaryl halide in the presence of a catalyst (such as Pd(dppf)Cl2, etc.) and a base (such as aqueous K2CO3, etc.) in a suitable solvent (such as 1,4-dioxane, etc.) to obtain compound E5. Alternatively, compound E3 is converted to compound E5 by Suzuki coupling with aryl or heteroaryl boronic acid (or pinacol boronate) in the presence of a catalyst (such as Pd(dppf)Cl2, etc.) and a base (such as aqueous K2CO3, etc.) in a suitable solvent (such as 1,4-dioxane, etc.). Compound E5 is converted to compound E6 after treatment with a deprotecting agent suitable for the protecting group (such as HCl in dioxane for the Boc protecting group). Compound E6 is converted to compound E7 by reductive amination with a suitable aldehyde and a reducing agent (such as NaBH(OAc)3, etc.) in a suitable solvent (such as 1,2-dichloroethane, etc.).
[0492] Plan F:
[0493] Compounds of formula (I) or formula (II) can be prepared as described in Scheme F below, wherein R1 and R2 are independently selected from C 3-10 Cycloalkyl, heterocyclyl, phenyl or heteroaryl ring systems.
[0494]
[0495] Compound F1 (wherein X1 and X3 are independently bromine, chlorine, fluorine, etc.; W1, W2 and W3 are independently CR) is reacted by coupling with B2Pin2 in the presence of a catalyst (such as Pd(dppf)Cl2, etc.) and a base (such as KOAc, etc.) in a suitable solvent (such as 1,4-dioxane, etc.). a or N, where R a The functional substituents (which may be further derivatized using techniques known to those of ordinary skill in the art) are converted to compound F2, which is further coupled with an aryl halide or heteroaryl halide in the presence of a catalyst (such as Pd(dppf)Cl2, etc.) and a base (such as aqueous K2CO3, etc.) in a suitable solvent (such as 1,4-dioxane, etc.) to obtain compound F3. Compound F3 is converted to compound F4 by reacting with potassium ethyl xanthate in a suitable solvent (such as DMF, etc.) at an elevated temperature (such as 130° C.), and compound F4 is further reacted with iodomethane to obtain compound F5. Compound F5 is oxidized with potassium persulfate (Oxone) to obtain compound F6. Compound F6 is converted to compound F7 by nucleophilic substitution with a primary or secondary amine in the presence of a suitable base (such as K2CO3, etc.) in a suitable solvent (such as DMF, etc.).
[0496] Specific Synthesis Example
[0497] In order to describe in more detail and to facilitate understanding, the following non-limiting examples are provided to more fully illustrate the scope of the compounds described herein, and should not be interpreted as explicitly limiting their scope. Such variations of compounds described herein that may be known or developed later (which will be within the scope determined by those skilled in the art) are considered to fall within the scope of the compounds as described herein and claimed below. These examples illustrate the preparation of certain compounds. It will be appreciated by those skilled in the art that the techniques described in these embodiments represent techniques that work well in synthetic practice as described by those of ordinary skill in the art, and therefore constitute a preferred mode for its practice. However, it should be understood that those skilled in the art should understand that many changes can be made to the disclosed specific method without departing from the spirit and scope of this article according to the present invention, and still obtain the same or similar results.
[0498] Except in the following examples of the embodied compounds, unless otherwise indicated, all numbers used in the specification and claims to represent the amount of ingredients, reaction conditions, experimental data, etc. should be understood to be modified by the term "about". Therefore, all such numbers represent approximate values, which may vary according to the desired properties sought to be obtained by reaction or as a result of variable experimental conditions. Therefore, within the expected range of experimental reproducibility, the term "about" refers to the data range provided that can vary according to the standard deviation from the mean value in the context of the obtained data. Similarly, for the experimental results provided, the obtained data can be rounded up or down to present the data consistently without losing significant figures. At least, and without attempting to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be interpreted according to the number of significant figures and the rounding techniques used by those skilled in the art.
[0499] Although the numerical ranges and parameters setting forth the broad scope of this document are approximations, the numerical values set forth in the examples described below are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0500] Compound Examples
[0501] As used above and herein, unless otherwise indicated, the following abbreviations shall be understood to have the following meanings:
[0502]
[0503]
[0504]
[0505]
[0506]
[0507] Intermediate 1
[0508] (1R,5S,8S)-8-(Methylamino)-3-azabicyclo[3.2.1]octane-3-carboxylic acid benzyl ester
[0509]
[0510] Step 1:At 0 ° C, (1R, 5S, 8S) -3- azabicyclo [3.2.1] octane -8- yl) tert-butyl carbamate (500mg, 2.21mmol) was dissolved in CH2Cl2 (2.5mL) and Et3N (0.36mL, 2.58mmol). Benzyl chloroformate (0.36mL, 2.44mmol) was added dropwise. The reaction mixture was then stirred at room temperature for 30min. The precipitated triethylammonium hydrochloride was filtered out. The filtrate was purified by silica gel chromatography (10-20% EtOAc in CH2Cl2) to obtain (1R, 5S, 8S) -8- ((tert-butoxycarbonyl) amino) -3- azabicyclo [3.2.1] octane -3- carboxylic acid benzyl ester (718mg, 90%) as a white solid.
[0511] 1 H NMR(acetone-d6)δ:7.30-7.45(m,5H),5.86(br s,1H),5.08-5.18(m,2H),3.90-3.96(m,2H),3.61(m,1H),3.09(d,J=12Hz,1H),2.97( d,J=12Hz,1H),2.22-2.27(m,2H),1.86-1.89(m,2H),1.43-1.49(m,2H),1.41(s,9H).
[0512] Step 2: (1R, 5S, 8S)-8-((tert-butoxycarbonyl)amino)-3-azabicyclo[3.2.1]octane-3-carboxylic acid benzyl ester (716 mg, 1.99 mmol), THF (12 mL) and NaH (60% oily suspension, 160 mg, 4 mmol) were stirred at room temperature for 30 min. MeI (375 μL, 6 mmol) was added. The mixture was heated at 60 ° C for 6 h. The mixture was partitioned between EtOAc and H2O. The organic layer was dried over MgSO4, filtered and concentrated under vacuum. Purification by silica gel chromatography (10-20% EtOAc in CH2Cl2) gave (1R, 5S, 8S)-8-((tert-butoxycarbonyl)(methyl)amino)-3-azabicyclo[3.2.1]octane-3-carboxylic acid benzyl ester (546 mg, 73%) as a clear oil.
[0513] 1H NMR (acetone-d6) δ: 7.30-7.45 (m, 5H), 5.10-5.16 (m, 2H), 3.92-3.97 (m, 2H), 3.78 (s, 1H), 3.13 (d, J = 12 Hz, 1H), 3.02 (d, J = 12 Hz, 1H), 2.84 (s, 3H), 2.42-2.46 (m, 2H), 1.78-1.83 (m, 2H), 1.53-1.59 (m, 2H), 1.47 (s, 9H).
[0514] Step 3: Benzyl (1R,5S,8S)-8-((tert-butoxycarbonyl)(methyl)amino)-3-azabicyclo[3.2.1]octane-3-carboxylate (510 mg, 1.36 mmol) was stirred in 4N HCl (2 mL, 8 mmol) in dioxane at room temperature for 16 h. The reaction mixture was diluted with ether and filtered to give benzyl (1R,5S,8s)-8-(methylamino)-3-azabicyclo[3.2.1]octane-3-carboxylate hydrochloride (374 mg, 88%) as a white solid.
[0515] 1 H NMR(methanol-d4)δ:7.31-7.41(m,5H),5.11-5.20(m,2H),4.04(dd,J=13Hz,3Hz,2H),3.37(s,1H),3.11(d,J =13Hz,1H),3.01(d,J=13Hz,1H),2.75(s,3H),2.46-2.54(m,2H),1.82-1.86(m,2H),1.61-1.69(m,2H).
[0516] Intermediate 2
[0517] N-Ethyl-2,2,6,6-tetramethylpiperidin-4-amine dihydrochloride
[0518]
[0519] Step 1:2,2,6,6-Tetramethylpiperidin-4-amine (1 g, 6.4 mmol), (2,5-dioxopyrrolidin-1-yl)benzyl carbonate (1.82 g, 7.3 mmol), NaHCO3 (1 M in H2O, 14 mL, 14 mmol) and acetone (20 mL) were stirred at room temperature for 15 h. The product, which was very soluble in water, was extracted from the reaction mixture with ethyl acetate. The organic layer was dried over MgSO4, filtered and concentrated under vacuum. The concentrate was treated with HCl in ether and filtered to give (2,2,6,6-tetramethylpiperidin-4-yl)benzyl carbamate hydrochloride (1.93 g, 92%) as a white solid.
[0520] 1 H NMR (methanol-d4) δ: 7.30-7.42 (m, 5H), 5.11 (s, 2H), 4.0-4.06 (m, 1H), 2.08 (dd, J = 14Hz, 3.5Hz, 2H), 1.54 (br s, 6H), 1.47 (m, 2H), 1.41 (s, 6H).
[0521] Step 2: Benzyl (2,2,6,6-tetramethylpiperidin-4-yl)carbamate hydrochloride (1.9 g, 5.8 mmol), THF (19 mL) and 60% NaH suspension (1.9 g, 48 mmol) were stirred at room temperature for 30 min. EtI (1.5 mL, 19 mmol) was added thereafter. The reaction mixture was stirred at room temperature for 2 days. The mixture was distributed between EtOAc and H2O. The organic layer was dried over MgSO4, filtered and concentrated under vacuum. Purification was performed by silica gel chromatography (5-10% MeOH in CH2Cl2 with 0.1% NH4OH modifier). The product was dissolved in ether and filtered to remove particulate impurities. The filtrate was concentrated to give ethyl (2,2,6,6-tetramethylpiperidin-4-yl)carbamate (701 mg, 38%) as a transparent oil.
[0522] 1 H NMR (acetone-d6) δ: 7.30-7.50 (m, 5H), 5.15 (s, 2H), 4.48 (m, 1H), 3.25 (q, J = 7 Hz, 2H), 1.53-1.59 (m, 2H), 1.38 (t, J = 12 Hz, 2H), 1.21 (br 2, 6H), 1.13 (t, J = 7 Hz, 3H), 1.10 (s, 6H).
[0523] Step 3:Benzyl ethyl(2,2,6,6-tetramethylpiperidin-4-yl)carbamate (700 mg, 2.2 mmol), ethanol (12 mL), 20% Pd(OH)2 on carbon (100 mg) and 10% Pd / C (100 mg) were hydrogenated at 50 psi for 2 days. The reaction mixture was passed through Filter. The filtrate was concentrated and then treated with ethereal HCl. The formed precipitate was filtered and washed with ether to give N-ethyl-2,2,6,6-tetramethylpiperidin-4-amine dihydrochloride (525 mg, 93%) as a white solid.
[0524] 1 H NMR (methanol-d4) δ: 8.48 (s, 1H), 3.69 (m, 1H), 3.12 (q, J = 7 Hz, 2H), 2.26 (dd, J = 14 Hz, 3.5 Hz, 2H), 1.67 (t, J = 13 Hz, 2H), 1.51 (s, 12H), 1.35 (t, J = 7 Hz, 3H).
[0525] Intermediate 3
[0526] (1R,3S,5S)-N,1,5-Trimethyl-8-azabicyclo[3.2.1]octan-3-amine dihydrochloride
[0527]
[0528] Step 1:Hexane-2,5-dione (10.8 mL, 92.1 mmol) and 3-oxoglutaric acid (26 g, 178 mmol) were dissolved in H2O (75 mL) at 0°C. A solution of KOH (23.2 g, 414 mmol) in H2O (15 mL) was added dropwise, followed by a solution of NaOAc (9 g, 109.7 mmol) and NH4Cl (15 g, 280.4 mmol) in H2O (135 mL). Aqueous 50% w / w KOH (8 mL) was added to adjust the pH to 9. More H2O (60 mL) was added. It was stirred at room temperature for 5 days. The reaction mixture was then cooled to 0°C again. 50% w / w H2SO4 (120 mL) was slowly added until the pH was 2, resulting in CO2 evolution. The mixture was then washed with CH2Cl2 (2×300 mL). The aqueous layer was made basic with solid KOH. It was extracted into EtOAc (5×300 mL). The EtOAc layer was backwashed with brine, dried over MgSO4, filtered, and concentrated under vacuum to give the crude amine. It was treated with a solution of oxalic acid dihydrate (5.4 g) in 600 mL of ether. The solid was filtered out, washed with ether, then with EtOH, and then washed with ether again to give (1R, 5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-one hemioxalate (6.085 g, 27.2%) as an off-white solid.
[0529] 1 H NMR (D2O) δ: 2.79 (d, J = 12.5Hz, 2H), 2.59 (d, J = 12.5Hz, 2H), 1.98-2.06 (m, 4H), 1.50 (s, 6H).
[0530] Step 2:(1R,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-one hemioxalate (500 mg) was distributed between diluted aqueous NaOH and CH2Cl2. The organic layer was dried over MgSO4, filtered, and concentrated under vacuum to give the free base (1R,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-one (330 mg, 2.15 mmol) as a clear light orange liquid. It was dissolved in titanium isopropoxide (2.15 mL, 7.25 mmol) and benzylmethylamine (0.42 mL, 3.3 mmol) and stirred at room temperature for 15 h. The mixture was cooled to 0 °C. MeOH (8.4 mL) was added followed by NaBH4 (195 mg, 5.15 mmol) in one portion. It was stirred at 0 °C for 1 h. 50% (w / w) KOH solution (0.8 mL) was added, and the mixture was then diluted in CH2Cl2 and filtered through diatomaceous earth. The product was washed off from the diatomaceous earth pad using CH2Cl2 / MeOH. The filtrate was concentrated under vacuum. Purification by silica gel chromatography (9 / 1 / 0.1CH2Cl2 / MeOH / NH4OH) gave (1R, 3S, 5S)-N-benzyl-N, 1, 5-trimethyl-8-azabicyclo [3.2.1] octane-3-amine (413 mg, 74%).
[0531] 1 H NMR (methanol-d4) δ: 7.25-7.40 (m, 5H), 3.61 (s, 2H), 2.92 (m, 1H), 2.23 (s, 3H), 1.72-1.77 (m, 2H), 1.55-1.70 (m, 4H), 1.48 (t, J=12 Hz, 2H), 1.29 (s, 6H).
[0532] Step 3: (1R, 3S, 5S) -N- benzyl -N, 1, 5- trimethyl -8- azabicyclo [3.2.1] octane -3- amine (395mg, 1.53mmol) was dissolved in EtOH (10mL). Pd / C (10%, 100mg) and Pd (OH) 2 (20%, supported on carbon, 100mg) were added, and the mixture was hydrogenated at 50psi for 1h. The reaction mixture was then filtered through diatomaceous earth. The filtrate was concentrated under vacuum. The concentrate was ground with ethereal HCl, the resulting solid was filtered and washed with ether to obtain (1R, 3s, 5S) -N, 1, 5- trimethyl -8- azabicyclo [3.2.1] octane -3- amine dihydrochloride (281mg, 76%) as a white solid.
[0533] 1H NMR (methanol-d4) δ: 3.66 (m, 1H), 2.77 (s, 3H), 2.31 (dd, J = 14 Hz, 5.5 Hz, 2H), 2.10-2.20 (m, 2H), 1.97-2.07 (m, 2H), 1.94 (t, J = 13 Hz, 2H), 1.58 (s, 6H).
[0534] Intermediate 3a
[0535] (1R,3r,5S)-1,5-Diethyl-N-methyl-8-azabicyclo[3.2.1]octan-3-amine
[0536] Intermediate 3a was prepared in a similar manner to Intermediate 3.
[0537] 1 H NMR (methanol-d4) δ: 3.64 (m, 1H), 2.80 (s, 3H), 2.36 (dd, J = 13.5, 4.5 Hz, 2H), 2.14 (m, 2H), 1.85-2.0 (m, 8H), 1.09 (t, J = 7.5 Hz, 6H).
[0538] Intermediate 4
[0539] 8-(Benzyloxy)-6-chloro-2-methylimidazo[1,2-b]pyridazine
[0540]
[0541] A mixture of 8-bromo-6-chloro-2-methyl-imidazo[1,2-b]pyridazine (100 mg, 0.41 mmol, 1.0 eq.), benzyl alcohol (89 mg, 0.085 mL, 0.81 mmol, 2.0 eq.) and Cs2CO3 (400 mg, 1.2 mmol, 3.0 eq.) in acetonitrile (1.0 mL) was stirred at 88° C. overnight, then cooled, diluted with ethyl acetate and filtered through celite. The filtrate was concentrated and purified on silica with ethyl acetate in CH2Cl2 (0 to 10% gradient) to give 8-benzyloxy-6-chloro-2-methyl-imidazo[1,2-b]pyridazine (81 mg, 73%).
[0542] 1 H NMR (CDCl3) δ: 7.62 (d, J = 0.6 Hz, 1H), 7.46-7.53 (m, 2H), 7.36-7.44 (m, 3H), 6.41 (s, 1H), 5.39 (s, 2H), 2.48 (d, J = 0.6 Hz, 3H).
[0543] Using the procedures described above, additional intermediates described herein can be prepared by substituting the appropriate starting materials, suitable reagents and reaction conditions to provide compounds such as those selected from the group consisting of:
[0544]
[0545]
[0546] Intermediate 5
[0547] Methyl 2-(6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)acetate
[0548]
[0549] To a solution of 6-chloro-2,8-dimethyl-imidazo[1,2-b]pyridazine (50 mg, 0.28 mmol, 1.0 eq.) in THF (1.2 mL) cooled at -45 °C was added LDA (2.0 M) (0.17 mL, 0.33 mmol, 1.2 eq.), and the mixture was stirred at -45 °C for 30 min, then dimethyl carbonate (38 mg, 0.035 mL, 0.41 mmol, 1.5 eq.) was added. After 30 min, the temperature was raised to 0 °C and the mixture was stirred for 2 h, then quenched with saturated NH4Cl. The mixture was extracted with ethyl acetate, then dried and evaporated. The residue was purified on silica gel with methanol in dichloromethane (0 to 5% gradient) to give methyl 2-(6-chloro-2-methyl-imidazo[1,2-b]pyridazin-8-yl)acetate (48 mg, 0.20 mmol, 0.73 eq., 73%).
[0550] 1 H NMR (CDCl3) δ: 7.63 (d, J = 0.6 Hz, 1H), 6.97 (s, 1H), 4.00 (d, J = 0.6 Hz, 2H), 3.70 (s, 3H), 2.42 (s, 3H).
[0551] Intermediate 6
[0552] 6-Chloro-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile
[0553]
[0554] Step 1:A mixture of 3-amino-6-chloro-pyridazine-4-carboxylic acid ethyl ester (360 mg, 1.8 mmol, 1.0 eq.) and chloroacetone (3.0 mL) was stirred at 100°C for 48 h, then cooled, diluted with ether and filtered. The solid was dissolved in methanol and purified by a C18 column to give 6-chloro-2-methyl-imidazo[1,2-b]pyridazine-8-carboxylic acid (150 mg, 40%).
[0555] 1 H NMR (methanol-d4) δ: 8.36 (br s, 1H), 8.24 (d, J=7.6 Hz, 1H), 2.64 (s, 3H).
[0556] Step 2: To a solution of 6-chloro-2-methyl-imidazo[1,2-b]pyridazine-8-carboxylic acid (150 mg, 0.71 mmol, 1.0 eq.) in DMF (4.0 mL) was added HATU (560 mg, 1.4 mmol, 2.0 eq.). After 10 min, tert-butylamine (78 mg, 0.11 mL, 1.1 mmol, 1.5 eq.) was added followed by DIPEA (280 mg, 0.37 mL, 2.1 mmol, 3.0 eq.). The mixture was then stirred at room temperature for 5 min, at which time LC / MS showed complete reaction. After aqueous work up, purification on silica gel with ethyl acetate in hexanes (2% to 20% gradient) gave N-tert-butyl-6-chloro-2-methyl-imidazo[1,2-b]pyridazine-8-carboxamide (111 mg, 59%).
[0557] 1 H NMR (CDCl3) δ: 9.82-9.95 (br.s., 1H), 7.81 (s, 1H), 7.76 (d, J = 0.6Hz, 1H), 2.52 (d, J = 0.6Hz, 3H), 1.56 (s, 9H).
[0558] Step 3: A mixture of N-tert-butyl-6-chloro-2-methyl-imidazo[1,2-b]pyridazine-8-carboxamide (102 mg, 0.382 mmol, 0.54 eq.) and POCl3 (0.80 mL, 8.5 mmol, 12 eq.) in toluene (2.0 mL) was stirred at 110°C for 48 h, then cooled and filtered. Pure 6-chloro-2-methyl-imidazo[1,2-b]pyridazine-8-carbonitrile solid (110 mg, 81%) was collected.
[0559] 1H NMR (CDCl3) δ: 7.88 (s, 1H), 7.36 (s, 1H), 2.60 (d, J = 0.6Hz, 3H).
[0560] Intermediate 7
[0561] Racemic (3R,4R)-3-Fluoro-N,2,2,6,6-pentamethylpiperidin-4-amine
[0562]
[0563] Step 1: 2,2,6,6-tetramethylpiperidin-4-one (2.60 g, 16.78 mmol) was added to a dried vial and circulated under nitrogen. THF (10 mL) was added and the reaction was stirred and cooled to -78 ° C. LHMDS (1 mol / L) in THF (17.7 mL, 17.7 mmol) was added dropwise over 5 min. The solution was stirred at -78 ° C for 30 min. N-fluorobenzenesulfonimide (6.13 g, 19.45 mmol) was added portionwise to the stirred solution over 5 min at -78 ° C. Stirring was continued at -78 ° C for 4 h, and then the reactants were slowly warmed to 23 ° C over 16 h. Methanol (20 mL) was added and the reactants were concentrated to dryness. The residue was purified by silica gel flash column chromatography (with dichloromethane (0-10% gradient) in methanol to give a white solid (1.26 g, 43%).
[0564] MS m / z 174.3[M+H] + ; 1 H NMR (methanol-d4) δ: 4.77 (d, J = 0.9Hz, 1H), 2.60 (d, J = 12.5Hz, 1H), 2.42 (dd, J = 12. 8,4.6Hz,1H),1.32(s,3H),1.29(s,3H),1.22(s,3H),1.15(d,J=3.4Hz,3H).
[0565] Step 2:3-Fluoro-2,2,6,6-tetramethyl-piperidin-4-one (601.4 mg, 3.47 mmol) was added to a dried vial, followed by methanol (15 mL) and methylamine (33% by mass in ethanol) (6 mL, 48.2 mmol). The solution was stirred at 23 °C for 45 min. Sodium triacetoxyborohydride (3.01 g, 14.2 mmol) was added portionwise to the solution at room temperature, and the solution was stirred for 3 h. The temperature was raised to 40 °C, and another portion of sodium triacetoxyborohydride (4.0 eq., 13.8 mmol) was added portionwise, followed by stirring at 40 °C for another 3 h. While stirring at 40 °C, a third portion of sodium triacetoxyborohydride (4.0 eq., 13.8 mmol) was added portionwise, and the reaction was stirred at 40 °C for 16 h. The reactants were concentrated to dryness. The residue was partitioned between dichloromethane / methanol (9 / 1) and sodium hydroxide solution (1.0 N, aqueous). The layers were separated and the aqueous layer was extracted once with dichloromethane / methanol (9 / 1) and then twice with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered and concentrated to give a light tan solid (519.3 mg, 79%) as a brown liquid which completely solidified after standing for 2-3 weeks.
[0566] MS m / z 189.3[M+H] + ; 1 H NMR (methanol-d4) δ: 4.42 (dd, J = 50.7, 1.2 Hz, 1H), 3.01 (dddd, J = 30.2, 12.5, 4.3, 1.5 Hz, 1H), 2.48 (s, 3H), 1.70 (dd, J = 12.8, 4.3 Hz, 1H), 1.36 (t, J = 12.7 Hz, 1H), 1.24 (s, 3H), 1.23 (d, J = 1.8 Hz, 3H), 1.20 (d, J = 2.4 Hz, 3H), 1.19 (s, 3H), NH proton was not observed.
[0567] Intermediate 8
[0568] Racemic (1S,2R,3R,5R)-2-Fluoro-N,1,5-trimethyl-8-azabicyclo[3.2.1]octan-3-amine
[0569]
[0570] Step 1:1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-one 1 / 2 oxalate (491 mg, 2.87 mmol, 1.0 eq.) and THF (5 mL) were added to a dried vial and cooled to -78 °C. Lithium bis(trimethylsilyl)amide (1.0 M in THF, 11 mL, 11.0 mmol, 3.83 eq.) was added dropwise and the suspension was allowed to warm to room temperature over 1 h. The suspension was cooled to -78 °C and N-fluorobenzenesulfonimide (1.98 g, 6.27 mmol, 2.18 eq.) was then added portionwise. After complete addition, the reactants were warmed to room temperature over 16 h. The reactants were concentrated under reduced pressure and the solids were then ground with CH2Cl2 / MeOH (1:1). The suspension was filtered and the orange filtrate was concentrated. The residue was purified by column chromatography (eluting with 0-40% MeOH in CH2Cl2) to give impure racemic 4-fluoro-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-one (491.3 mg, 57 mass %). MS m / z 172.3 [M+H] + .
[0571] Step 2: To a dried vial was added impure racemic 4-fluoro-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-one (373 mg, 2.18 mmol, 1.0 eq.), followed by titanium (IV) isopropoxide (3.4 mL, 11 mmol, 5.2 eq.) and N-methyl-1-phenyl-methylamine (0.71 mL, 5.5 mmol, 2.5 eq.). The reaction was stirred at room temperature for 16 h. Methanol (10 mL) was added, followed by sodium borohydride (802 mg, 20.7 mmol, 9.53 eq.). Stirring was continued at room temperature for 2 h. The reaction was quenched with aqueous sodium hydroxide (0.2 N, 35 mL). The reaction was then diluted with CH2Cl2 / MeOH (9:1) and filtered through celite to remove the emulsion. The layers were then separated and the aqueous layer was extracted twice with CH2Cl2 / MeOH (9:1). The combined organic phases were dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (eluting with 0-15% MeOH in CH2Cl2) to give racemic (1S,3S,4S,5R)-N-benzyl-4-fluoro-N,1,5-trimethyl-8-azabicyclo[3.2.1]octan-3-amine (40.5 mg, 7%).
[0572] MS m / z 277.4[M+H] + ; 1H NMR (methanol-d4) δ: 7.23-7.42 (m, 5H), 4.60 (dd, J = 50.7, 2.4 Hz, 1H), 3.78 (d, J = 13.1 Hz, 1H), 3.70 (d, J = 13.4 Hz, 1H), 2.85 (dddd, J = 36.0, 10.1, 8.2, 2.4 Hz, 1H), 2.34 (s, 3H), 1.77 (br d, J = 9.2 Hz, 2H), 1.65-1.71 (m, 2H), 1.56-1.64 (m, 2H), 1.33 (d, J = 2.4 Hz, 6H); 1NH not observed.
[0573] Step 3: Racemic (1S, 3S, 4S, 5R) -N- benzyl -4- fluoro -N, 1, 5- trimethyl -8- azabicyclo [3.2.1] octane -3- amine (40.5 mg, 0.147 mmol, 1.0 eq.), palladium hydroxide (20% w / w, supported on carbon) (19.4 mg, 0.0276 mmol, 0.19 eq.) and ethanol (5 mL) were combined and shaken at 4.5 atm for 72 h under a hydrogen atmosphere. The reaction was filtered through celite and rinsed with EtOH. The filtrate was concentrated to give racemic (1S, 3S, 4S, 5R) -4- fluoro -N, 1, 5- trimethyl -8- azabicyclo [3.2.1] octane -3- amine (23.3 mg, 85%).
[0574] MS m / z 187.3[M+H] + ; 1 H NMR (methanol-d4) δ: 4.40 (dd, J = 50.7, 3.1 Hz, 1H), 2.93 (dddd, J = 30.5, 12.2, 6.1, 3.1 Hz, 1H), 2.41 (s, 3H), 1.77 (dd, J = 13.0, 6.0 Hz, 1H), 1.62-1.71 (m, 2H), 1.53-1.61 (m, 2H), 1.27-1.32 (m, 1H), 1.24 (s, 3H), 1.19 (s, 3H); 2NHs was not observed.
[0575] Intermediate 9
[0576] (±) tert-Butyl 2,4-trans-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-(methylamino)piperidine-1-carboxylate
[0577]
[0578] Step 1:(±)(R)-4-oxopiperidin-1,2-dicarboxylic acid 1-(tert-butyl) 2-methyl ester (10 g, 38.9 mmol) was dissolved in MeOH (50 mL). N-methylbenzylamine (8 mL, 62 mmol) was added followed by acetic acid (1 mL, 17.4 mmol). The reaction was stirred at room temperature for 1 h. After the mixture was cooled to 0 °C, NaBH3CN (3.7 g, 59 mmol) was added in one portion. The reaction was warmed to room temperature and stirred for 15 h. The mixture was partitioned between EtOAc and H2O. The organic layer was dried over MgSO4, filtered, and then concentrated under vacuum. Purification by silica chromatography (20-50% EtOAc in hexanes) gave (±)(cis)-4-(benzyl(methyl)amino)piperidine-1,2-dicarboxylic acid 1-(tert-butyl) 2-methyl ester (A) (3.96 g, 28%) as the second most major component on TLC (when visualized with iodine stain) and (±)(trans)-4-(benzyl(methyl)amino)piperidine-1,2-dicarboxylic acid 1-(tert-butyl) 2-methyl ester (B) (2.49 g, 18%) as the lowest major non-baseline TLC component.
[0579] A: 1 H NMR (methanol-d4) δ: 7.20-7.40 (m, 5H), 4.49 (m, 1H), 3.70-3.85 (m, 2H), 3.67 (s, 3H), 3.35-3.50 (m, 1H), 3.30 (m, 1H), 2.45-2.60 (m, 2H), 2.10 (m, 1H), 2.07 (s, 3H), 1.93-2.00 (m, 1H), 1.70-1.78 (m, 1H), 1.47 (s, 9H).
[0580] B: 1 H NMR (methanol-d4) 1:1 mixture of rotamers δ: 7.33 (d, J = 4.3 Hz, 4H), 7.23-7.29 (m, 1H), 4.89-4.99 (m, 1H), 4.03-4.09 (m, 1H), 3.67-3.72 (m, 3H), 3.63 (s, 2H), 2.84-3.05 (m, 1H), 2.39-2.50 (m, 2H), 2.23 (s, 3H), 1.70-1.92 (m, 2H), 1.51-1.57 (m, 1H), 1.46 (br d, 9H)
[0581] Step 2: In a 100 mL round-bottom flask, add (±) 2,4-trans-4-[benzyl(methyl)amino]piperidine-1,2-dicarboxylic acid O 1 -tert-Butyl Ester O 2-Methyl ester (2.49 g, 6.87 mmol) was dissolved in anhydrous THF (45 mL). A dried Teflon-coated stirring rod was added. The tube was fitted with a septum cap and the headspace was purged with dry N2. The flask was then immersed in an ice bath and the reaction mixture was cooled to 0 ° C. Under N2, 1.0M LiAlH4 solution (6.3 mL, 6.3 mmol, 0.92 eq.) in THF was added dropwise at room temperature, and the reaction mixture (clear solution) was stirred at 0 ° C for 1 h. The reaction mixture was then diluted with anhydrous Et2O (20 mL) and quenched by the Fieser method at 0 ° C, under N2 purge, with vigorous stirring. The reaction mixture was then stirred at room temperature for 1 h. The reaction mixture was then filtered through diatomaceous earth (45×15 mm bed) and the diatomaceous earth was washed with 1:1Et2O / EtOAc (150 mL). The clear, colorless filtrate was concentrated on a rotovap and then concentrated under high vacuum (0.3 mm Hg, room temperature) to give crude (±) tert-butyl 2,4-trans 4-[benzyl(methyl)amino]-2-(hydroxymethyl)piperidine-1-carboxylate (2.22 g, 97% yield) as a clear, light amber mobile oil.
[0582] 1 H NMR (CDCl3) δ: 7.34–7.27 (m, 4H), 7.26–7.21 (m, 1H), 4.49 (d, J = 50.4 Hz, 1H), 4.13 (d, J = 56.5 Hz, 1H), 3.73 (t, J = 10.0 Hz, 1H), 3.63–3.48 (m, 3H), 2.95–2.77 (m, 1H), 2.71 (t, J = 11.8 Hz, 1H), 2.18 (s, 3H), 1.89 (d, J = 13.1 Hz, 1H), 1.81 (d, J = 10.5 Hz, 1H), 1.65 (td, J = 12.8, 6.2 Hz, 1H), 1.52–1.40 (m, 10H); OH proton was not observed.
[0583] Step 3:A 100-mL round-bottom flask was charged with a solution of (±) tert-butyl 2,4-trans-4-[benzyl(methyl)amino]-2-(hydroxymethyl)piperidine-1-carboxylate (2.22 g, 6.64 mmol) in CH2Cl2 (50 mL), a Teflon-coated stirring bar, and crystalline imidazole (0.610 g, 8.96 mmol, 1.35 eq.). After the imidazole had completely dissolved, tert-butyldiphenylsilyl chloride (1.90 mL, 7.33 mmol, 1.10 eq.) was added to the solution, inducing precipitation in about 5 minutes. The reaction mixture was gently stirred at room temperature for 1 h. Thereafter, the reaction mixture was diluted with CH2Cl2 (30 mL), transferred to a 125 mL separatory funnel, and washed with water (50 mL) and saturated aqueous NaHCO3 (50 mL). The organic phase is then dried over anhydrous Na2SO4, filtered, and the transparent colorless filtrate is concentrated on a rotary evaporator to obtain a thick transparent colorless oil. By silica gel column chromatography on an ISCO system (80-g silica gel column (CH2Cl2-balance)) (CH2Cl2 isocratic elution (10 minutes) is carried out, followed by CH2Cl2 / EtOAc gradient elution (1:0 to 1:9, through 40 minutes, 60mL / min)) crude product is purified to obtain a 50-mL fraction. The fractions containing the product are merged, and concentrated on a rotary evaporator, and further dried under high vacuum (0.3mm Hg, room temperature, overnight) to obtain (±) 2,4-trans 4-[benzyl (methyl) amino]-2-[[tert-butyl (diphenyl) silyl] oxymethyl] piperidine-1-carboxylic acid tert-butyl ester (2.76g, 73% yield) in a transparent colorless viscous oil.
[0584] 1 H NMR(CDCl3)δ:7.66(d,J=7.0Hz,4H),7.45–7.36(m,6H),7.36–7.26(m,4H),7.26–7.20(m,1H),4.74–4.36(m,1H),4.24–3.93(m,1H) ),3.73–3.45(m,4H),2.88–2.59(m,2H),2.32–2.05(m,4H),1.86–1.68(m,1H),1.68–1.54(m,1H),1.53–1.37(m,10H),1.06(s,9H).
[0585] Step 4:In a 100-mL Parr bomb reactor, (±) tert-butyl 4-[benzyl(methyl)amino]-2-[[tert-butyl(diphenyl)silyl]oxymethyl]piperidine-1-carboxylate (2.35 g, 4.10 mmol) was dissolved in MeOH (30 mL). The solution was purged with argon for 5 minutes, and then 20% Pd(OH)2 / C (0.30 g, 0.43 mmol, 0.10 eq.) was added. The bomb was fitted to a Parr oscillator apparatus, purged with H2 (5×20 psi), and then filled to a final H2 pressure of 50 psi. The reaction mixture was shaken at room temperature for 50 h. The reaction mixture was then filtered through a 45×20 mm celite bed, and the celite bed was washed with MeOH (200 mL). The clear, colorless filtrate was concentrated on a rotary evaporator to give a clear, very light amber oil. The crude product was purified by Kugelrohr distillation (260 °C, 0.8 mm Hg) to give the desired (±) tert-butyl 2,4-trans 2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-(methylamino)piperidine-1-carboxylate (1.22 g, 83% yield) as a clear, colorless, thick oil.
[0586] 1 H NMR(CDCl3)δ7.70–7.60(m,4H),7.47–7.34(m,6H),4.63–4.31(m,1H),4.20–3.87(m,1H),3.73–3.59(m,2H),2.70(br s,1H),2.56(br s,1H),2.41(s,3H),2.20(br s,1H),1.83(br s,1H),1.42(s,9H),1.31–1.19(m,2H),1.05(s,9H).
[0587] Example 1
[0588] Preparation of Compound 186
[0589]
[0590] Step 1:A mixture of 4-bromo-2,6-difluoro-aniline (4.16 g, 20.0 mmol, 1.00 eq.) and potassium ethoxythioformylsulfanyl (7.69 g, 48.0 mmol, 2.40 eq.) in DMF (25 mL) was stirred at 130 ° C overnight, then cooled to room temperature, diluted with 1N HCl (150 mL), and stirred at room temperature for 1 h. The resulting solid was filtered, washed with water and dried. The resulting material was suspended in CH2Cl2 (25 mL), SO2Cl2 (27.5 g, 16.5 mL, 200 mmol, 10.0 eq.) was slowly added, and stirred at room temperature for 48 h. At 0 ° C, water was slowly added to quench the reaction. The resulting precipitate was collected by filtration and purified on silica with ethyl acetate in hexanes (2% to 10% gradient) to give 6-bromo-2-chloro-4-fluoro-1,3-benzothiazole (5.08 g, 95.3%). MS m / z 266.1, 268.0, 270.0 [M+H] + .
[0591] Step 2: A mixture of 4-(methylamino)piperidine-1-carboxylate (88 mg, 0.41 mmol, 1.1 eq.), 6-bromo-2-chloro-4-fluoro-1,3-benzothiazole (100 mg, 0.38 mmol, 1.0 eq.) and Cs2CO3 (240 mg, 0.75 mmol, 2.0 eq.) in acetonitrile (1.0 mL) was stirred at 90°C overnight, then cooled, diluted with ethyl acetate, and concentrated. The residue was purified on silica with ethyl acetate in hexanes (2% to 10% gradient) to give tert-butyl 4-[(6-bromo-4-fluoro-1,3-benzothiazol-2-yl)-methyl-amino]piperidine-1-carboxylate (94 mg, 56%). MS m / z 388.2, 390.0 [M+H] + .
[0592] Step 3:A mixture of tert-butyl 4-[(6-bromo-4-fluoro-1,3-benzothiazol-2-yl)-methyl-amino]piperidine-1-carboxylate (94 mg, 0.21 mmol, 1.0 eq.), B2Pin2 (81 mg, 0.32 mmol, 1.5 eq.), PdCl2(dppf) (16 mg, 0.021 mmol, 0.10 eq.) and KOAc (63 mg, 0.63 mmol, 3.0 eq.) in dioxane (2.0 mL) was stirred at 90 °C under Ar atmosphere for 3 h, then cooled, diluted with ethyl acetate, and concentrated. The residue was purified on silica with ethyl acetate in hexanes (3% to 50% gradient) to give tert-butyl 4-[[4-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]-methyl-amino]piperidine-1-carboxylate (96 mg, 92%). MS m / z 492.1 [M+H] + .
[0593] Step 4: 4-[[4-Fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]-methyl-amino]piperidine-1-carboxylic acid tert-butyl ester (48 mg, 0.1 mmol, 1.1 eq.), 6-chloro-2,8-dimethyl-imidazo[1,2-b]pyridazine (16 mg, 0.088 mmol, 1.0 eq.), Pd2(dba)3 (4.1 mg, 0.0044 mmol, 0.05 eq.), (t-Bu)3P A mixture of HBF4 (2.6 mg, 0.0088 mmol, 0.1 eq.) and 2.0 M aqueous K2CO3 (0.13 mL, 0.26 mmol, 3.0 eq.) in dioxane (1.0 mL) was stirred at 90 °C under Ar atmosphere for 3 h, then cooled and diluted with ethyl acetate. The mixture was washed with water, brine, and the organic layer was dried over sodium sulfate and evaporated. The residue was purified on silica gel with ethyl acetate in dichloromethane (10% to 100% gradient) to give 4-[[6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-1,3-benzothiazol-2-yl]-methyl-amino]piperidine-1-carboxylic acid tert-butyl ester (12 mg, 27%). MS m / z 511.4 [M+H] + .
[0594] Step 5:TFA (1.0 mL) was added to a solution of 4-[[6-(2,8-dimethylimidazo[1,2-b]pyridazine-6-yl)-4-fluoro-1,3-benzothiazol-2-yl]-methyl-amino]piperidine-1-carboxylic acid tert-butyl ester in CH2Cl2 (1.0 mL). The mixture was stirred at room temperature for 1 h, and then organic volatiles were removed by a stream of nitrogen. The residue was purified by C18 chromatography and treated with HCl in ether to give 6-(2,8-dimethylimidazo[1,2-b]pyridazine-6-yl)-4-fluoro-N-methyl-N-(4-piperidinyl)-1,3-benzothiazol-2-amine hydrochloride (24 mg).
[0595] MS m / z 411.4[M+H] + ; 1 H NMR(methanol-d4)δ:8.41(s,1H),8.31(d,J=0.9Hz,1H),8.28(d,J=0.9Hz,1H),7.95-8.01(m,1H),4.67-4.77(m,1H),3. 57-3.64(m,2H),3.24-3.31(m,2H),3.23(s,3H),2.80(d,J=0.6Hz,3H),2.67(d,J=0.9Hz,3H),2.09-2.29(m,4H).
[0596] Using the procedure described in Example 1 above, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0597]
[0598]
[0599]
[0600] Example 2
[0601] Preparation of compound 20
[0602]
[0603] Step 1:A mixture of 6-bromo-2-chloro-1,3-benzothiazole (600 mg, 2.4 mmol, 1.0 eq.), N,2,2,6,6-pentamethylpiperidin-4-amine (490 mg, 0.54 mL, 2.9 mmol, 1.2 eq.) and K2CO3 (1000 mg, 7.2 mmol, 3.0 eq.) in acetonitrile (6.0 mL) was stirred overnight at 100° C., then cooled, diluted with ethyl acetate, and filtered. The filtrate was concentrated to give 6-bromo-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)-1,3-benzothiazol-2-amine, which was used without further purification.
[0604] Step 2: A mixture of 6-bromo-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)-1,3-benzothiazol-2-amine (60 mg, 0.16 mmol, 1.0 eq.), (2-methylindazol-5-yl)boronic acid (36 mg, 0.20 mmol, 1.3 eq.), Pd2(dba)3 (7.3 mg, 0.0078 mmol, 0.050 eq.), (t-Bu)3PHBF4 (4.6 mg, 0.016 mmol, 0.10 eq.) and K2CO3 (2.0 M aqueous) (0.24 mL, 0.47 mmol, 3.0 eq.) in dioxane (1.0 mL) was stirred at 100° C. for 1 h, then cooled, diluted with ethyl acetate, and washed with water and brine. The organic layer was separated, dried over sodium sulfate, and evaporated. The residue was purified on basic alumina with ethyl acetate in hexanes (10% to 100% gradient) to give N-methyl-6-(2-methylindazol-5-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)-1,3-benzothiazol-2-amine (57 mg, 84%).
[0605] MS m / z 434.4[M+H] + ; 1 H NMR(CDCl3)δ:7.85(s,1H),7.78(d,J=1.3Hz,1H),7.73-7.75(m,1H),7.68(d,J=9.1Hz,1H),7.47-7.55(m,3H),4.20-4.34(m ,1H),4.17(s,3H),3.04(s,3H),1.74(dd,J=12.5,3.3Hz,2H),1.36(d,J=10.7Hz,2H),1.27-1.33(m,6H),1.10-1.21(m,6H).
[0606] Using the procedure described above in Example 2, additional compounds described herein are prepared by substituting the appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0607]
[0608]
[0609]
[0610]
[0611] Example 3
[0612] Preparation of compound 37
[0613]
[0614] Step 1: A mixture of 6-bromo-2-chloro-4-fluoro-1,3-benzothiazole (530 mg, 2.0 mmol, 1.0 eq.), N,2,2,6,6-pentamethylpiperidin-4-amine (410 mg, 0.45 mL, 2.4 mmol, 1.2 eq.) and K2CO3 (840 mg, 6.0 mmol, 3.0 eq.) in acetonitrile (5.0 mL) was stirred at 100° C. for 4 h, then cooled, diluted with ethyl acetate, and filtered through celite. The filtrate was concentrated to give 6-bromo-4-fluoro-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)-1,3-benzothiazol-2-amine (840 mg, 100%), which was used directly in the next step without further purification.
[0615] Step 2:A mixture of 6-bromo-4-fluoro-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)-1,3-benzothiazol-2-amine (78 mg, 0.19 mmol, 1.0 eq.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (54 mg, 0.21 mmol, 1.1 eq.), PdCl2dppf dichloromethane complex (16 mg, 0.019 mmol, 0.10 eq.) and KOAc (58 mg, 0.58 mmol, 3.0 eq.) in dioxane (1.0 mL) was stirred at 90° C. for 4 h. LC / MS showed complete conversion to pinacol boronate. 6-Chloro-2-methyl-imidazo[1,2-b]pyridazine (26 mg, 0.16 mmol, 0.80 eq.) and PdCl2dppf dichloromethane complex (16 mg, 0.019 mmol, 0.10 eq.) were added to the mixture, followed by K2CO3 (2.0 M aqueous) (0.29 mL, 0.58 mmol, 3.0 eq.). The mixture was heated at 90°C overnight, then cooled, diluted with ethyl acetate, and washed with water and brine. The organic layer was separated, dried over sodium sulfate, and evaporated. The residue was purified on basic alumina with ethyl acetate in hexanes (10% to 100% gradient) to give 4-fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)-1,3-benzothiazol-2-amine (40 mg, 45%).
[0616] MS m / z 453.4[M+H] + ; 1 H NMR(CDCl3)δ:7.92(d,J=1.9Hz,1H),7.80(d,J=9.5Hz,1H),7.70(s,1H),7.59(dd,J=11.8,1.7Hz,1H),7.33(d,J=9.5Hz,1H),4.1 9-4.49(m,1H),3.09(s,3H),2.46(s,3H),1.76(dd,J=12.3,3.2Hz,2H),1.40-1.70(m,2H),1.29-1.39(m,6H),1.18-1.28(m,6H).
[0617] Using the procedure described in Example 3 above, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0618]
[0619]
[0620] Example 4
[0621] Preparation of compound 47
[0622]
[0623] Step 1: A mixture of 2,6-dichloro-4-fluoro-1,3-benzothiazole (3.54 g, 15.9 mmol, 1.00 eq., prepared according to step 1 of Example 1 starting from 4-chloro-2,6-difluoroaniline), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (5.91 g, 19.1 mmol, 1.20 eq.), PdCl2(dppf) (1.2 g, 1.59 mmol, 0.1 eq.) and K2CO3 (2.0 M aqueous) (24 mL, 47.8 mmol, 3.00 eq.) in dioxane (50 mL) was heated at 90° C. for 2 h, then cooled, diluted with ethyl acetate, and washed with water and brine. The organic layer was separated, dried over sodium sulfate, and evaporated. The residue was purified on silica gel with ethyl acetate and hexanes (3% to 20%) to give tert-butyl 4-(6-chloro-4-fluoro-1,3-benzothiazol-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (5.58 g, 94.9%).
[0624] 1 H NMR(CDCl3)δ:7.63(dd,J=1.7,0.8Hz,1H),7.21(dd,J=9.8,1.9Hz,1H),6.72(br.s.,1H) ,4.21(d,J=2.5Hz,2H),3.68(t,J=5.5Hz,2H),2.84(dd,J=4.3,2.7Hz,2H),1.52(s,9H).
[0625] Step 2:4-(6-chloro-4-fluoro-1,3-benzothiazol-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (4.0 g, 10.8 mmol, 1.0 eq.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (5.5 g, 21.7 mmol, A mixture of 4-[4-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (5.1 g, 100%) was prepared by heating at 110° C. overnight, then cooled, diluted with ethyl acetate, filtered, and concentrated. The crude product was purified on silica gel to give tert-butyl 4-[4-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (5.1 g, 100%).
[0626] 1 H NMR(CDCl3)δ:8.09(d,J=0.6Hz,1H),7.57(dd,J=10.7,0.6Hz,1H),6.76(s,1H),4. 21(br.s.,4H),3.68(br.s.,2H),2.86(d,J=1.6Hz,2H),1.52(s,9H),1.39(s,12H).
[0627] Step 3: A mixture of tert-butyl 4-[4-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (1.0 g, 2.2 mmol, 1.0 eq.), 5% Pd / C (0.5 g, 0.2 mmol, 0.1 eq.) and 10% Pd(OH)2 / C (0.5 g, 0.4 mmol, 0.2 eq.) in MeOH (200 mL) and CH2Cl2 (20 mL) was hydrogenated at 60 psi overnight. The mixture was then filtered through celite and purified on silica gel with ethyl acetate in hexanes (5% to 20% gradient) to give tert-butyl 4-[4-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]piperidine-1-carboxylate (0.75 g, 75%).
[0628] 1H NMR(CDCl3)δ:8.12(d,J=0.9Hz,1H),7.57(d,J=10.7Hz,1H),4.19-4.34(m,2H),3.28-3.38( m,1H),2.86-2.99(m,2H),2.15-2.25(m,2H),1.81-1.94(m,2H),1.50(s,9H),1.39(s,12H).
[0629] Step 4: Combine tert-butyl 4-[4-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]piperidine-1-carboxylate (520 mg, 1.1 mmol, 1.0 eq.) with 6-chloro-2,8-dimethyl-imidazo[1,2-b]pyridazine (204 mg, 1.1 mmol, 1.0 eq.), Pd2(dba)3 (52 mg, 0.056 mmol, 0.05 eq.), and (t-Bu)3PHBF4 (33 mg, 0.11 mmol, 0.1 eq.). Purge the vessel with N2. Add dioxane (7.0 mL) and K2CO3 (2.0 M aqueous) (3.5 mL, 7.0 mmol) to the vessel. The mixture was heated at 80°C for 1 h, then cooled and partitioned between EtOAc and H2O. The organic layer was concentrated and chromatographed on silica gel, eluting with 30-100% EtOAc in CH2Cl2 to give the desired tert-butyl 4-[6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-1,3-benzothiazol-2-yl]piperidine-1-carboxylate (500 mg, 92%). MS m / z 482.2 [M+H] + .
[0630] Step 5:Tert-butyl 4-[6-(2,8-dimethylimidazo[1,2-b]pyridazine-6-yl)-4-fluoro-1,3-benzothiazol-2-yl]piperidine-1-carboxylate (500 mg, 1.0 mmol) was suspended in 4.0 M HCl in 1,4-dioxane (3 mL, 12 mmol). The mixture was stirred for 30 min, then diluted with Et2O (10 mL), and filtered. The solid was distributed between CH2Cl2 and aqueous K2CO3 (1 M). The organic layer was then separated and concentrated. The residue was chromatographed on silica gel, eluting with 0-10% MeOH (2N NH3) in CH2Cl2. The purified material was dissolved in 1.25 M HCl in MeOH (3 mL) followed by removal of the volatiles to afford 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-2-(piperidin-4-yl)benzo[d]thiazole hydrochloride (340 mg, 72%).
[0631] MS m / z 382.3[M+H] + . 1 H NMR(methanol-d4)δ:8.49(d,J=1.9Hz,1H),7.98(dd,J=11.9,1.9Hz,1H),7.95(s,1H),7.66(d,J=1.3Hz,1H),3. 52(m,1H),3.44(m,2H),3.09(td,J=12.6,3.2Hz,2H),2.69(s,3H),2.51(s,3H),2.38(m,2H),2.09(m,2H).
[0632] Using the procedure described above in Example 4, additional compounds described herein are prepared by substituting the appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0633]
[0634]
[0635] Example 5
[0636] Preparation of Compound 201
[0637]
[0638] A mixture of 6-[8-[(2,4-dimethoxyphenyl)methylamino]-2-methyl-imidazo[1,2-b]pyridazin-6-yl]-4-fluoro-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)-1,3-benzothiazol-2-amine (10 mg, 0.016 mmol, 1.0 eq., prepared according to the procedure in Example 3) and triisopropylsilane (0.2 mL) in CH2Cl2 (1.0 mL) and TFA (1.0 mL) was stirred at room temperature for 1 h. The mixture was then concentrated and purified on a C18 column to give 6-(8-amino-2-methyl-imidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)-1,3-benzothiazol-2-amine hydrochloride (5.0 mg, 61%) after treatment with HCl in MeOH.
[0639] MS m / z 468.4[M+H] + . 1 H NMR(methanol-d4)δ:8.23(d,J=1.3Hz,1H),8.11(s,1H),7.75-7.83(m,1H),7.25(s,1H),4.9 8-5.08(m,1H),3.19(s,3H),2.63(s,3H),2.01-2.13(m,4H),1.68(s,6H),1.57(s,6H).
[0640] Using the procedure described above in Example 5, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0641]
[0642] Example 6
[0643] Preparation of Compound 224
[0644]
[0645] To a solution of 6-[2-(1-tert-butoxycarbonyl-4-piperidinyl)-4-fluoro-1,3-benzothiazol-6-yl]-2-methyl-imidazo[1,2-b]pyridazine-8-carboxylic acid (17 mg, 0.033 mmol, 1.0 eq.) in DMF (0.5 mL) was added TEA (20 mg, 0.028 mL, 0.20 mmol, 6.0 eq.) and after 10 min, ammonium chloride (5.4 mg, 0.10 mmol, 3.0 eq.) was added followed by 1-propanephosphonic anhydride (50 mass %) (63 mg, 0.10 mmol, 3.0 eq.) in DMF. The mixture was stirred at 40 °C overnight, then basified with aqueous K2CO3, filtered, the solid collected, and further purified on C18 to give 6-[4-fluoro-2-(4-piperidinyl)-1,3-benzothiazol-6-yl]-2-methyl-imidazo[1,2-b]pyridazine-8-carboxamide; 2,2,2-trifluoroacetic acid (10.0 mg, 57%).
[0646] MS m / z 411.3[M+H] + . 1 H NMR (methanol-d4) δ: 8.50 (d, J = 5.7 Hz, 2H), 8.17 (s, 1H), 7.94 (d, J = 11.3 Hz, 1H), 3.43-3.55 (m, 3H), 3.10-3.18 (m, 2H), 2.51 (s, 3H), 2.32-2.40 (m, 2H), 2.05-2.15 (m, 2H).
[0647] Example 7
[0648] Preparation of compound 44
[0649]
[0650] Step 1:4-[4-Fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (prepared in step 2 of Example 4, 66 mg, 0.14 mmol, 1.2 eq.), 6-chloro-2-methyl-imidazo[1,2-b]pyridazine (20 mg, 0.12 mmol, 1.0 eq.), Pd2(dba)3 (5.5 mg, 0.0060 mmol, 0.05 eq.), (t-Bu)3P A mixture of HBF4 (3.5 mg, 0.012 mmol, 0.10 eq.) and K2CO3 (2.0 M aqueous) (0.18 mL, 0.36 mmol, 3.0 eq.) in dioxane (1.0 mL) was stirred at 100°C for 1 h. The reaction mixture was then cooled, diluted with ethyl acetate, and washed with brine, then dried over sodium sulfate, and concentrated. The residue was purified on silica gel with methanol in dichloromethane (0 to 8% gradient) to give tert-butyl 4-[4-fluoro-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-1,3-benzothiazol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (59 mg, 100%). MS m / z 466.2 [M+H] + .
[0651] Step 2: To a suspension of tert-butyl 4-[4-fluoro-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-1,3-benzothiazol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (15 mg, 0.032 mmol, 1.0 eq.) in dioxane (0.2 mL) was added HCl (4M in dioxane) (1.0 mL). The mixture was stirred at room temperature for 1 h, then diluted with ether and filtered to give 4-fluoro-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride (12 mg, 85%).
[0652] MS m / z 366.3[M+H] + ; 1H NMR(DMSO-d6)δ:9.70(br s,1H),9.61(br s,1H),8.80(d,J=1.3Hz,1H),8.49(d,J=9.5Hz,1H),8.42(s,1H),8.30(d,J=9.5Hz,1H),8.13(dd,J=12.0,1.3Hz,1H),6.94(br s,1H),3.90(br s, 2H), 3.37 (d, J = 4.4Hz, 2H), 2.95 (br s, 2H), 2.54 (s, 3H).
[0653] Using the procedure described above in Example 7, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0654]
[0655]
[0656] Example 8
[0657] Preparation of Compound 65 and Compound 67
[0658]
[0659] Step 1: A mixture of 6-bromobenzo[d]thiazole (2.12 g), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole (1.2 eq.), PdCl2dppf (0.1 eq.), and K2CO3 (2.5 eq.) in dioxane and water was heated at 100°C under N2 atmosphere for 16 h, then cooled, diluted with ethyl acetate, and washed with water and brine. The organic layer was separated, dried over sodium sulfate, and concentrated. The residue was purified by flash silica gel chromatography to give 6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazole (1.3 g, 48%). MS m / z 266.1, 268.1 [M+H] + .
[0660] Step 2:To a solution of 6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazole (700 mg) in THF was slowly added a solution of n-BuLi (3.0 eq.) in hexanes at -78 °C. After 30 min, a solution of tert-butyl 2-methyl-4-oxopiperidine-1-carboxylate (2.0 eq.) in THF was added and the temperature was slowly raised to room temperature over 16 h. The mixture was treated with saturated NH4Cl solution and extracted with ethyl acetate. The organic extracts were combined, dried over sodium sulfate and evaporated. The residue was purified by silica gel flash column chromatography to give tert-butyl 4-hydroxy-2-methyl-4-(6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazole-2-yl)piperidine-1-carboxylate (0.56 g, 43%). MS m / z 479.2[M+H] + .
[0661] Step 3: A mixture of tert-butyl 4-hydroxy-2-methyl-4-(6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazol-2-yl)piperidine-1-carboxylate (0.56 g) and Burgess reagent (2.0 eq.) in THF was stirred at 90° C. for 48 h, then cooled, diluted with ice water, and basified with concentrated ammonium hydroxide. The mixture was extracted with ethyl acetate. The organic extracts were combined, dried over sodium sulfate, and then concentrated. The residue was purified by silica gel flash column chromatography to give a mixture of tert-butyl 6-methyl-4-(6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazol-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate and tert-butyl 2-methyl-4-(6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazol-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (410 mg, 76%). MS m / z 461.2 [M+H] + .
[0662] Step 4: A mixture of tert-butyl 6-methyl-4-(6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazol-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate and tert-butyl 2-methyl-4-(6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazol-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (300 mg) was stirred in 4.0 N HCl in dioxane for 16 h, then concentrated and the residue was purified by chiral prep-HPLC and C18 prep-HPLC to give 2-(6-methyl-1,2,3,6-tetrahydropyridin-4-yl)-6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazole hydrochloride (21 mg).
[0663] MS m / z 361.1[M+H]+ ; 1 H NMR(DMSO-d6)δ:9.81-9.93(m,1H),9.25-9.38(m,1H),8.45(d,J=8.5Hz,2H) ,8.02-8.12(m,2H),7.87(dd,J=8.7,1.7Hz,1H),7.64-7.74(m,2H),6.74(br s,1H),4.20(br s,3H),3.44-3.54(m,1H),3.20-3.33(m,1H),2.93(br s,2H),1.47(d,J=7.3Hz,3H)
[0664] and 2-(2-methyl-1,2,3,6-tetrahydropyridin-4-yl)-6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazole hydrochloride (11 mg).
[0665] MS m / z 361.2[M+H] + ; 1 H NMR(DMSO-d6)δ:9.73-9.83(m,1H),9.46-9.56(m,1H),8.44(d,J=1.9Hz,2H),8.08(s,1H) ,8.05(d,J=8.5Hz,1H),7.83-7.90(m,1H),7.69-7.73(m,1H),7.65-7.69(m,1H),6.80(br s,1H),4.20(s,3H),3.89(br s,2H),3.45-3.55(m,1H),3.11(d,J=14.8Hz,1H),2.60-2.69(m,1H),1.44(d,J=6.3Hz,3H).
[0666] Using the procedure described above in Example 8, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0667]
[0668] Example 9
[0669] Preparation of compound 45
[0670]
[0671] Step 1:To a solution of tert-butyl 4-[4-fluoro-6-(2-methylimidazo[1,2-b]pyridazine-6-yl)-1,3-benzothiazol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (prepared according to step 1 of Example 7, 48 mg, 0.10 mmol, 1.0 eq.) in MeOH (30 mL) was added 10% Pd / C (40 mg, 0.038 mmol, 0.36 eq.) and 10% Pd(OH)2 / C (30 mg, 0.021 mmol, 0.21 eq.), followed by a drop of 1N HCl. The mixture was shaken in a Parr shaker under H2 atmosphere at 50 psi for 16 h. LC / MS indicated a complete reaction. The mixture was filtered through celite, concentrated, and purified on silica gel with methanol in dichloromethane (0 to 6% gradient) to give tert-butyl 4-[4-fluoro-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-1,3-benzothiazol-2-yl]piperidine-1-carboxylate (39 mg, 81%). MS m / z 468.1 [M+H] + .
[0672] Step 2: To a suspension of tert-butyl 4-[4-fluoro-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-1,3-benzothiazol-2-yl]piperidine-1-carboxylate (15 mg, 0.032 mmol, 1.0 eq.) in dioxane (0.2 mL) was added HCl (4M in dioxane) (1.0 mL). The mixture was stirred at room temperature for 1 h, then diluted with ether and filtered to give 4-fluoro-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-2-(4-piperidinyl)-1,3-benzothiazole hydrochloride (25 mg, 74%).
[0673] MS m / z 368.3[M+H] + . 1 H NMR(DMSO-d6)δ:9.33(br s,1H),9.20(br s,1H),8.82(d,J=1.3Hz,1H),8.56(d,J=9.5Hz,1H),8.50(s,1H),8.40(d,J=9.8Hz,1H),8.13(dd,J=11.8,1.1Hz,1H ),3.57-3.65(m,1H),3.33-3.42(m,2H),3.02-3.12(m,2H),2.56(s,3H),2.31(d,J=12.3Hz,2H),2.06-2.17(m,2H).
[0674] Using the procedure described above in Example 9, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0675]
[0676]
[0677]
[0678] Example 10
[0679] Preparation of Compound 106
[0680]
[0681] To a mixture of 4-fluoro-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-2-(4-piperidinyl)-1,3-benzothiazole hydrochloride (prepared according to step 2 of Example 9, 100 mg, 0.25 mmol, 1.0 eq.) in CH2Cl2 (5.0 mL) was added NEt3 (25 mg, 0.035 mL, 0.25 mmol, 1.0 eq.), followed by acetaldehyde (0.36 mL, 2.5 mmol, 10 eq.), followed by NaBH(OAc)3 (160 mg, 0.74 mmol, 3.0 eq.). The mixture was stirred at room temperature for 2 h, after which LC / MS showed complete conversion. The mixture was treated with aqueous K2CO3, then extracted with ethyl acetate, dried, and concentrated. The residue was purified on silica gel with methanol in CH2Cl2 (3% to 20% gradient) to give 2-(1-ethyl-4-piperidinyl)-4-fluoro-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-1,3-benzothiazole (80 mg, 82%).
[0682] MS m / z 396.2[M+H] + ; 1 H NMR(CDCl3)δ:8.26(d,J=1.3Hz,1H),7.94(d,J=9.5Hz,1H),7.80-7.86(m,2H),7.47(d,J=9.5Hz,1H),3.51(d,J=5.4Hz,3H),3.28(br s,1H),3.18(d,J=10.1Hz,2H),2.50-2.65(m,2H),2.01-2.41(m,6H),1.14-1.25(m,3H).
[0683] Using the procedure described above in Example 10, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0684]
[0685]
[0686]
[0687]
[0688]
[0689] Embodiment 11
[0690] Preparation of compound 12
[0691]
[0692] Step 1: A mixture of 3,5-dibromopyridin-2-amine (2.5 g, 9.92 mmol, 1.00 eq.) and ethoxycarbothioylsulfanyl potassium (3.8 g, 24 mmol, 2.4 eq.) in DMF (12 mL) was stirred at 130 ° C overnight. The reaction mixture was then cooled to room temperature, diluted with 1N HCl (75 mL), and stirred at room temperature for 1 h. The resulting solid was filtered, washed with water, and dried. The resulting material was suspended in dichloromethane (15 mL), and SO2Cl2 (14 g, 8.5 mL, 100 mmol, 10 eq.) was slowly added. After 2 h, water was slowly added at 0 ° C to quench the reaction. The resulting precipitate was collected by filtration and dried to give 6-bromo-2-chloro-thiazolo[4,5-b]pyridine (1.7 g, 69%).
[0693] 1 H NMR(CDCl3)δ:8.79(br s,1H),8.33(s,1H).
[0694] Step 2:A mixture of 6-bromo-2-chloro-thiazolo[4,5-b]pyridine (250 mg, 1.0 mmol, 1.0 eq.), tert-butyl 4-(methylamino)piperidine-1-carboxylate (260 mg, 1.2 mmol, 1.2 eq.) and DIPEA (200 mg, 0.26 mL, 1.5 mmol, 1.5 eq.) in DMSO (2.0 mL) was stirred at 100 ° C for 1 h. LC / MS indicated a complete reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, washed with water and brine, then dried over sodium sulfate and concentrated. The residue was purified on silica gel with ethyl acetate in hexanes (5% to 15% gradient) to give tert-butyl 4-[(6-bromothiazolo[4,5-b]pyridin-2-yl)-methyl-amino]piperidine-1-carboxylate (280 mg, 65%).
[0695] 1 H NMR(CDCl3)δ:8.41(d,J=2.2Hz,1H),7.96(d,J=2.2Hz,1H),4.42-4.74(m,1H),4.15-4.41(m ,2H),3.04(s,3H),2.75-2.93(m,2H),1.82(d,J=1.6Hz,2H),1.63-1.77(m,2H),1.48(s,9H).
[0696] Step 3: A mixture of tert-butyl 4-[(6-bromothiazolo[4,5-b]pyridin-2-yl)-methyl-amino]piperidine-1-carboxylate (75 mg, 0.18 mmol, 1.0 eq.), (2-methylindazol-5-yl)boronic acid (37 mg, 0.21 mmol, 1.2 eq.), Pd2(dba)3 (16 mg, 0.018 mmol, 0.10 eq.), (t-Bu)3PHBF4 (10 mg, 0.035 mmol, 0.20 eq.) and K2CO3 (2.0 M aqueous) (0.26 mL, 0.53 mmol, 3.0 eq.) in dioxane (1.0 mL) was stirred at 90°C for 1 h, then diluted with ethyl acetate, washed with brine, dried and concentrated. The residue was purified on silica gel with ethyl acetate in dichloromethane (0 to 20% gradient) to give tert-butyl 4-[methyl-[6-(2-methylindazol-5-yl)thiazolo[4,5-b]pyridin-2-yl]amino]piperidine-1-carboxylate. MS m / z 479.4 [M+H] + .
[0697] Step 4:To a solution of tert-butyl 4-[methyl-[6-(2-methylindazol-5-yl)thiazolo[4,5-b]pyridin-2-yl]amino]piperidine-1-carboxylate (30 mg, 0.063 mmol, 1.0 eq.) in dioxane (0.25 mL) was added HCl (4M in dioxane) (1.0 mL). The mixture was then stirred at room temperature for 1 h before being diluted with ether, filtered and dried to give N-methyl-6-(2-methylindazol-5-yl)-N-(4-piperidinyl)thiazolo[4,5-b]pyridin-2-amine hydrochloride.
[0698] MS m / z 379.3[M+H] + ; 1 H NMR(DMSO-d6)δ:9.05-9.18(m,2H),9.03(br s,1H),8.72(d,J=1.9Hz,1H),8.48(s,1H),8.13(d,J=0.9Hz,1H),7.75(d,J=9.1Hz,1H),7.65(dd,J=9.1, 1.9Hz, 1H), 4.21 (s, 3H), 3.43 (d, J = 12.3Hz, 2H), 3.19 (m, 6H), 2.17-2.28 (m, 2H), 1.97 (d, J = 12.6Hz, 2H).
[0699] Using the procedure described above in Example 11, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0700]
[0701]
[0702] Example 12
[0703] Preparation of Compound 101
[0704]
[0705] Step 1:At -78 ° C, to a solution of tert-butyl N-(6-chloro-5-fluoro-3-pyridyl)carbamate (500 mg, 2.0 mmol, 1.0 eq.) and TMEDA (710 mg, 0.93 mL, 6.1 mmol, 3.0 eq.) in Et2O (10 mL), BuLi (1.6 M in hexane) (3.8 mL, 6.1 mmol, 3.0 eq.) was added dropwise while maintaining a temperature below -60 ° C. The solution turned purple. After complete addition, the temperature was raised to -20 ° C, the mixture was stirred at this temperature for 90 min, and a turbid mixture was formed. The mixture was cooled to -78 ° C again, C2Br2F4 (1700 mg, 0.77 mL, 6.4 mmol, 3.1 eq.) was added dropwise thereto, and the temperature was slowly raised to room temperature over 1 h. The reaction was quenched with 1N HCl (5.0 mL) and ice water. The mixture was diluted with ether, washed with water, sodium bicarbonate and brine, dried over sodium sulfate and concentrated to give solid tert-butyl N-(4-bromo-6-chloro-5-fluoro-3-pyridinyl)carbamate (660 mg, 100%) which was used in the next step without further purification.
[0706] Step 2: To N-(4-bromo-6-chloro-5-fluoro-3-pyridyl)carbamic acid tert-butyl ester (660mg, 2.0mmol, 1.0eq.) solution in CH2Cl2 (10.0mL) was added TFA (5.0mL). The mixture was stirred at room temperature for 1h, then concentrated and treated with ethyl acetate. The mixture was washed with aqueous sodium bicarbonate and brine, dried and concentrated to give 4-bromo-6-chloro-5-fluoro-pyridine-3-amine, which was used without further purification.
[0707] Step 3: A mixture of 4-bromo-6-chloro-5-fluoro-pyridin-3-amine (108 mg, 0.479 mmol, 1.00 eq.) and 2-(9H-fluoren-9-yloxy)acetyl isothiocyanate (148 mg, 0.527 mmol, 1.10 eq.) in acetone (1.0 mL) was stirred at 50°C overnight, then cooled, treated with ether, and filtered to give 9H-fluoren-9-ylmethyl N-(6-chloro-7-fluoro-thiazolo[4,5-c]pyridin-2-yl)carbamate as a solid. MS m / z 426.2, 428.3 [M+H] + .
[0708] Step 4:To a suspension of N-(6-chloro-7-fluoro-thiazolo[4,5-c]pyridin-2-yl)carbamic acid 9H-fluoren-9-ylmethyl ester (210 mg, 0.49 mmol, 1.0 eq.) in CH2Cl2 (7.0 mL) was added piperidine (427 mg, 0.5 mL, 4.9 mmol, 10 eq.), and the mixture was stirred at room temperature for 2 h. LC / MS showed complete reaction. The mixture was diluted with ethyl acetate, washed with aqueous NH4Cl and brine, dried, and then concentrated. The residue was purified on silica gel with methanol in dichloromethane (0 to 10% gradient) to give 6-chloro-7-fluoro-thiazolo[4,5-c]pyridin-2-amine (100 mg, 100%), 1 H NMR (methanol-d4) δ: 8.52 (s, 1H).
[0709] Step 5: To a suspension of 6-chloro-7-fluoro-thiazolo[4,5-c]pyridine-2-amine (100 mg, 0.49 mmol, 1.0 eq.) in acetonitrile (3.0 mL) was added tert-butyl nitrite (110 mg, 0.13 mL, 0.98 mmol, 2.0 eq.), followed by copper bromide (120 mg, 0.54 mmol, 1.1 eq.). The solid was slowly dissolved and the mixture was stirred at 60 ° C for 1 h. The mixture was diluted with ethyl acetate, washed with NH4Cl and brine, then dried and concentrated. The residue was purified with ethyl acetate in hexane to give 2-bromo-6-chloro-7-fluoro-thiazolo[4,5-c]pyridine in almost quantitative yield.
[0710] 1 H NMR (CDCl3) δ: 8.82 (d, J = 0.9 Hz, 1H).
[0711] Step 6: A mixture of 2-bromo-6-chloro-7-fluoro-thiazolo[4,5-c]pyridine (32 mg, 0.12 mmol, 1.0 eq.), N,2,2,6,6-pentamethylpiperidin-4-amine; dihydrochloride (32 mg, 0.13 mmol, 1.1 eq.) and Cs2CO3 (160 mg, 0.48 mmol, 4.0 eq.) in acetonitrile (0.5 mL) was stirred at 80 °C overnight, then cooled to room temperature, diluted with ethyl acetate, filtered and evaporated to give 6-chloro-7-fluoro-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)thiazolo[4,5-c]pyridine-2-amine (45 mg, 110%) which was used in the next step without further purification.
[0712] 1H NMR (CDCl3) δ: 8.32 (d, J = 0.9Hz, 1H), 4.21-4.46 (m, 1H), 3.03 (s, 3H), 1.71 (dd, J = 12.6, 3.5Hz, 2H), 1.33-1.43 (m, 2H), 1.29 (s, 6H), 1.15 (s, 6H).
[0713] Step 7: A mixture of 6-chloro-7-fluoro-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)thiazolo[4,5-c]pyridin-2-amine (39 mg, 0.11 mmol, 1.0 eq.), 2,7-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazole (45 mg, 0.16 mmol, 1.5 eq.), PdCl2dppf DCM complex (9.0 mg, 0.011 mmol, 0.1 eq.) and aqueous K2CO3 (2.0 M, 0.16 mL, 3.0 eq.) in dioxane (1.0 mL) was heated at 100° C. overnight, then cooled, diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate and concentrated. The residue was purified on basic alumina with ethyl acetate in hexanes (10% to 100% gradient) followed by methanol in dichloromethane (0 to 10% gradient) to give 6-(2,7-dimethylindazol-5-yl)-7-fluoro-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)thiazolo[4,5-c]pyridin-2-amine (7.0 mg, 14%).
[0714] MS m / z 467.4[M+H] + ; 1 H NMR(CDCl3)δ:8.76(d,J=2.2Hz,1H),8.09(s,1H),7.98(s,1H),7.75(d,J=0.9Hz,1H),4 .29(br.s.,4H),3.16(s,3H),2.73(s,3H),1.89(d,J=11.7Hz,2H),1.50-1.85(m,14H).
[0715] Embodiment 13
[0716] Preparation of compound 19
[0717]
[0718] Step 1:A mixture of 6-bromo-2-chloro-thiazolo[4,5-b]pyridine (500 mg, 2.0 mmol, 1.0 eq.), (2-methylindazol-5-yl)boronic acid (390 mg, 2.2 mmol, 1.1 eq.), Pd(PPh3)4 (230 mg, 0.20 mmol, 0.10 eq.), and K2CO3 (2.0 M aqueous) (3.0 mL, 6.0 mmol, 3.0 eq.) in dioxane (8.0 mL) was stirred at 100° C. overnight. The mixture was then treated with water, acidified with HCl, and filtered. The filter cake was washed with acetonitrile and ether, then dried to give 6-bromo-2-(2-methylindazol-5-yl)thiazolo[4,5-b]pyridine (100 mg, 14%), which was used in the next step without further purification.
[0719] Step 2: A mixture of 6-bromo-2-(2-methylindazol-5-yl)thiazolo[4,5-b]pyridine (100 mg, 0.29 mmol, 1.0 eq.), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (110 mg, 0.35 mmol, 1.2 eq.), (t-Bu)3PHBF4 (8.5 mg, 0.029 mmol, 0.10 eq.) and K2CO3 (2.0 M aqueous) (0.43 mL, 0.87 mmol, 3.0 eq.) in dioxane (1.0 mL) was stirred at 100° C. for 2 h, then cooled, diluted with water, and filtered. The filter cake was washed with acetonitrile and ether. The solid was treated with TFA, concentrated, purified by C18 ISCO, and further purified by prep-HPLC to give 2-(2-methylindazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)thiazolo[4,5-b]pyridine hydrochloride (22 mg, 20%) after treatment with HCl in ether.
[0720] MS m / z 348.3[M+H] + ; 1 H NMR(DMSO-d6)δ:9.30(br s,2H),8.79(d,J=1.9Hz,1H),8.68(d,J=2.2Hz,1H),8.55(d,J=11.7Hz,2H),7.96(dd,J=9.0,1.4Hz,1H),7.71(d,J=8.8Hz,1H),6.39(br s,1H),4.17(s,3H),3.74(br s,2H),3.23-3.36(m,2H),2.75(br s,2H).
[0721] Using the procedure described above in Example 13, additional compounds described herein are prepared by substituting the appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0722]
[0723] Embodiment 14
[0724] Preparation of compound 43
[0725]
[0726] Step 1: A mixture of 2-(2-methylindazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)thiazolo[4,5-b]pyridine hydrochloride (31 mg, 0.081 mmol, 1.0 eq., prepared in Example 13), Boc2O (36 mg, 0.16 mmol, 2.0 eq.) and NEt3 (25 mg, 0.034 mL, 0.24 mmol, 3.0 eq.) in CH2Cl2 (3.0 mL) was stirred at room temperature for three days. The mixture was then diluted with CH2Cl2, washed with water and brine, dried over sodium sulfate, and concentrated to give crude tert-butyl 4-[2-(2-methylindazol-5-yl)thiazolo[4,5-b]pyridin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (32 mg, 89%). MS m / z 448.4 [M+H] + .
[0727] Step 2: A mixture of 4-[2-(2-methylindazole-5-yl)thiazolo[4,5-b]pyridin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (32 mg, 0.071 mmol, 1.0 eq.), 10% Pd / C (30 mg, 0.028 mmol, 0.39 eq.), 10% Pd(OH)2 / C (30 mg, 0.021 mmol, 0.30 eq.) and 2 drops of 1N HCl in MeOH (25 mL) was hydrogenated at room temperature under a H2 balloon for 16 h. LC / MS indicated a complete reaction. The reaction mixture was treated with celite and then filtered. The filtrate was concentrated and the product was purified on silica gel with methanol in dichloromethane (0 to 6% gradient) to give tert-butyl 4-[2-(2-methylindazol-5-yl)thiazolo[4,5-b]pyridin-6-yl]piperidine-1-carboxylate (10 mg, 31%). MS m / z 450.4 [M+H] + .
[0728] Step 3:To a solution of tert-butyl 4-[2-(2-methylindazol-5-yl)thiazolo[4,5-b]pyridin-6-yl]piperidine-1-carboxylate (10 mg, 0.022 mmol, 1.0 eq.) in dioxane (0.2 mL) was added HCl (4M in dioxane) (1.0 mL). The mixture was then stirred at room temperature for 30 min, diluted with ether and filtered. The filter cake was collected and dried to give 2-(2-methylindazol-5-yl)-6-(4-piperidinyl)thiazolo[4,5-b]pyridine hydrochloride (4.0 mg, 47%).
[0729] MS m / z 350.2[M+H] + ; 1 H NMR(DMSO-d6)δ:9.38(br s,1H),9.22(br s,1H),8.98-9.08(m,3H),8.93(d,J=1.9Hz,1H),8.44(dd,J=9.1,1.6Hz,1H),8.21 (d,J=9.1Hz,1H),4.66(s,3H),3.84(d,J=11.7Hz,2H),3.41-3.57(m,3H),2.48(br s,2H),2.31-2.43(m,2H).
[0730] Using the procedure described above in Example 14, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0731]
[0732] Embodiment 15
[0733] Preparation of compound 49
[0734]
[0735] Step 1:A mixture of 2,6-dichloro-1,3-benzothiazole (200 mg, 0.98 mmol, 1.0 eq.), 2,7-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazole (320 mg, 1.2 mmol, 1.2 eq.), PdCl2dppf dichloromethane adduct (81 mg, 0.098 mmol, 0.10 eq.) and K2CO3 (2.0 M aqueous) (1.5 mL, 2.9 mmol, 3.0 eq.) in dioxane (4.0 mL) was stirred at 90° C. for 12 h. After cooling, the reaction mixture was diluted with ethyl acetate, washed with brine, dried, and then concentrated. The residue was purified on silica gel with ethyl acetate in dichloromethane (0 to 25% gradient) to give 6-chloro-2-(2,7-dimethylindazol-5-yl)-1,3-benzothiazole (200 mg, 65%).
[0736] 1 H NMR(CDCl3)δ:8.28(d,J=0.6Hz,1H),8.06(s,1H),8.00(d,J=8.8Hz,1H),7.90(d,J=1 .9Hz,1H),7.82-7.86(m,1H),7.47(dd,J=8.7,2.0Hz,1H),4.31(s,3H),2.74(s,3H).
[0737] Step 2: 6-Chloro-2-(2,7-dimethylindazol-5-yl)-1,3-benzothiazole (100 mg, 0.32 mmol, 1.0 eq.), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (120 mg, 0.38 mmol, 1.2 eq.), Pd2(dba)3 (15 mg, 0.0 A mixture of 4-[2-(2,7-dimethylindazol-5-yl)-1,3-benzothiazol-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (131 mg, 89%) was stirred at 100°C for 12 h, then cooled, diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate, and evaporated. The residue was purified on silica gel with methanol in dichloromethane (0 to 5% gradient) to give tert-butyl 4-[2-(2,7-dimethylindazol-5-yl)-1,3-benzothiazol-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (131 mg, 89%). MS m / z 461.4 [M+H] + .
[0738] Step 3: To a suspension of tert-butyl 4-[2-(2,7-dimethylindazol-5-yl)-1,3-benzothiazol-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (20 mg, 0.043 mmol, 1.0 eq.) in dioxane (0.25 mL) was added HCl (4M in dioxane) (1.0 mL, 4.0 mmol, 92 eq.). The mixture was stirred at room temperature for 30 min, then diluted with ether and filtered. The solid cake was washed with ether and dried to give 2-(2,7-dimethylindazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride (14 mg, 81%).
[0739] MS m / z 361.3[M+H] + ; 1 H NMR(DMSO-d6)δ:9.31(br s,2H),8.46(s,1H),8.26(s,1H),8.17(s,1H),7.93(d,J=8.5Hz,1H),7.72(s,1H),7.61(d,J=8.2Hz,1H),6.27(br s,1H),4.15(s,3H),3.72(br s,2H),3.27(br s,2H),2.73(br s,2H),2.53(s,3H).
[0740] Using the procedure described above in Example 15, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0741]
[0742] Example 16
[0743] Preparation of compound 50
[0744]
[0745] Step 1:A mixture of tert-butyl 4-[2-(2,7-dimethylindazol-5-yl)-1,3-benzothiazol-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (65 mg, 0.14 mmol, 1.0 eq., prepared in Step 2 of Example 15), 10% Pd / C (50 mg, 0.047 mmol, 0.33 eq.) and 10% Pd(OH)2 / C (50 mg, 0.036 mmol, 0.25 eq.) in MeOH (50 mL) and a drop of 1N HCl was shaken at 60 psi for 4 h using a Parr shaker. The mixture was filtered through celite, concentrated, and the residue was purified on silica gel with methanol in dichloromethane (0 to 10% gradient) to give tert-butyl 4-[2-(2,7-dimethylindazol-5-yl)-1,3-benzothiazol-6-yl]piperidine-1-carboxylate (22 mg, 34%). MS m / z 463.4 [M+H] + .
[0746] Step 2: The procedure of Example 15, Step 3, was applied to tert-butyl 4-[2-(2,7-dimethylindazol-5-yl)-1,3-benzothiazol-6-yl]piperidine-1-carboxylate (22 mg, 0.048 mmol, 1.0 eq.) to give 2-(2,7-dimethylindazol-5-yl)-6-(4-piperidinyl)-1,3-benzothiazole hydrochloride (14 mg, 74%).
[0747] MS m / z 363.3[M+H] + ; 1 H NMR(DMSO-d6)δ:8.98-9.18(m,2H),8.45(s,1H),8.24(d,J=0.6Hz,1H),7.84-7.96(m,2H),7.71(s,1H),7.3 4(dd,J=8.4,1.4Hz,1H),4.15(s,3H),3.25-3.37(m,2H),2.84-3.04(m,3H),2.52(s,3H),1.85-1.99(m,4H).
[0748] Using the procedure described above in Example 16, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0749]
[0750] Embodiment 17
[0751] Preparation of compound 11
[0752]
[0753] Step 1: A mixture of 6-bromo-2-(2-methyl-2H-indazol-5-yl)benzo[d]thiazole (160 mg, prepared according to step 1 of Example 15), tert-butyl 4-(methylamino)piperidine-1-carboxylate (2.0 eq.), Pd2(dba)3 (0.1 eq.), RuPhos (0.2 eq.), and t-BuONa (2.5 eq.) in dioxane (1.0 mL) was stirred at 70° C. under nitrogen atmosphere for 16 h, then cooled, diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate, and concentrated. The residue was purified on silica gel with ethyl acetate and hexanes (10% to 100% gradient) to give tert-butyl 4-(methyl(2-(2-methyl-2H-indazol-5-yl)benzo[d]thiazol-6-yl)amino)piperidine-1-carboxylate (60 mg, 21.5%). MS m / z 478.1 [M+H] + .
[0754] Step 2: The procedure of Example 15, Step 3, was applied to tert-butyl 4-(methyl(2-(2-methyl-2H-indazol-5-yl)benzo[d]thiazol-6-yl)amino)piperidine-1-carboxylate (60 mg) to give N-methyl-2-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)benzo[d]thiazol-6-amine hydrochloride (24 mg, 50%).
[0755] MS m / z 378.1[M+H] + . 1 H NMR(DMSO-d6)δ:8.89-9.01(m,1H),8.67-8.80(m,1H),8.52(s,1H),8.40(s,1H),7.94-7.98(m,1H),7.87-7.93(m,1H),7.64-7.75(m,2H),7.2 3-7.35(m,1H),4.22(s,3H),4.04-4.15(m,1H),3.37(d,J=12.6Hz,2H) ,2.98-3.09(m,2H),2.90(s,3H),1.95-2.07(m,2H),1.83-1.93(m,2H).
[0756] Embodiment 18
[0757] Preparation of Compound 120
[0758]
[0759] Step 1:A 100 mL round bottom flask was charged with 4-bromo-2,6-difluoro-aniline (2.5 g, 12 mmol), bis(pinacolato)diboron (3.40 g, 13 mmol), Pd(dppf)Cl2 (300 mg, 0.364 mmol), and KOAc (3.50 g, 36 mmol). The reaction vessel was evacuated and purged with N2 (3×). Anhydrous DMSO (15 mL) was added, and the reaction was heated at 80°C for 1.5 h, then cooled and diluted with EtOAc (100 mL) and NaHCO3 (100 mL). The organic layer was separated and washed with brine, dried, and concentrated. The residue was purified by column chromatography on silica gel with ethyl acetate and hexanes (0-10% gradient) to give a white solid (1.8 g, 59%). MS m / z 256.1 [M+H] + .
[0760] Step 2: A 100 mL flask was charged with 6-chloro-2,8-dimethyl-imidazo[1,2-b]pyridazine (0.62 g, 3.41 mmol), boric acid ester prepared as above (1.05 g, 4.12 mmol), Pd2(dba)3 (313 mg, 0.342 mmol), tBu3PHBF4 (200 mg, 0.682 mmol) and K2CO3 (1.42 g, 10.3 mmol). The reaction vessel was evacuated and purged with N2 (3×). Dioxane (18 mL) and H2O (6 mL) were added, and the reactants were heated at 90°C for 1.5 h, then cooled and diluted with CH2Cl2 (30 mL) and H2O (15 mL). The organic layer was separated, and the aqueous layer was further extracted with CH2Cl2 (2×). The combined organic extracts were washed with brine, dried and concentrated. The residue was purified by trituration with CH3CN to give the desired intermediate as a tan solid (630 mg, 67%). MS m / z 275.3 [M+H] + .
[0761] Step 3: A 20 mL vial was charged with 4-(2,8-dimethylimidazo[1,2-b]pyridazine-6-yl)-2,6-difluoro-aniline (0.415 g, 1.51 mmol) and ethyl xanthate potassium salt (0.606 g, 3.63 mmol), and 2.5 mL of anhydrous DMF was added. The resulting brown suspension was heated at 130 ° C for 2 h, then cooled to ambient temperature and diluted with 9 mL of 1N HCl. The resulting suspension was stirred for 1 h and then filtered. The solid cake was washed with H2O, collected and dried to give the desired intermediate (460 mg, 92%) as a brown solid. MS m / z 331.1 [M+H] + .
[0762] Step 4: To a mixture of 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-1,3-benzothiazole-2-thiol (0.46 g, 1.39 mmol) in 5.5 mL of anhydrous DMF was added K2CO3 (0.462 g, 3.34 mmol), followed by MeI (0.166 mL, 2.65 mmol) dropwise via syringe. The brown mixture was stirred at ambient temperature for 2 h. The resulting precipitate was filtered, washed with H2O, and dried to give the desired tan solid (320 mg, 67%). MS m / z 345.0 [M+H] + .
[0763] Step 5: To a suspension of the intermediate (0.317 g, 0.920 mmol) prepared above in MeOH (6.8 mL) was added Oxone (1.77 g, 2.85 mmol) in H2O (6.8 mL) dropwise via a syringe. The mixture was stirred overnight at ambient temperature and then filtered through a phase separator followed by washing with H2O. The solid was dried to provide a mixture of sulfone and sulfoxide in a ratio of 22:70 (330 mg, 95%). MS m / z 361.1, 377.1 [M+H] + .
[0764] Step 6: A mixture of sulfone and sulfoxide (50mg, 0.13mmol) and piperazine (17mg, 0.20mmol) are treated with DIPEA (0.046mL, 0.26mmol) in 0.17mL anhydrous DMSO and heated at 90 °C for 2h. The reactant is then cooled to ambient temperature and diluted with EtOAc and H2O. Each phase is separated, and the aqueous layer (2×) is further extracted with EtOAc. The combined organic extracts are washed with brine, dried over Na2SO4, filtered, and concentrated. The residue is purified by column chromatography on silica gel (with dichloromethane and methanol (0-15% gradient)). The desired fractions are combined, concentrated, and the residue is treated with HCl in Et2O to obtain the desired product (28mg, 49%) as a yellow solid.
[0765] MS m / z 383.1[M+H] + ; 1H NMR(DMSO-d6)δ:9.25-9.44(m,2H),8.49(d,J=1.3Hz,1H),8.21-8.34(m,1H),7.99-8.15 (m,1H),7.88-7.97(m,1H),3.85-3.95(m,4H),3.30(brs,4H),2.68(s,3H),2.45(s,3H).
[0766] Using the procedure described above in Example 18, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0767]
[0768] Embodiment 19
[0769] Preparation of Compound 210
[0770]
[0771] Step 1: To a solution of 1-tert-butoxycarbonyl-4-methyl-piperidine-4-carboxylic acid (240 mg, 0.99 mmol, 1.0 eq.) in CH2Cl2 (8.0 mL) was added pyridine (320 mg, 0.32 mL, 3.9 mmol, 4.0 eq.), (COCl)2 (130 mg, 0.088 mL, 0.99 mmol, 1.0 eq.), followed by 2 drops of DMF. After 1 h at room temperature, 4-bromo-2,6-difluoro-aniline (210 mg, 0.99 mmol, 1.0 eq.) was added, and the mixture was stirred at room temperature overnight, after which CH2Cl2 was added and washed with water and brine. The organic layer was dried, evaporated and purified on silica gel with ethyl acetate in hexanes (5% to 50% gradient) to give 4-[(4-bromo-2,6-difluoro-phenyl)carbamoyl]-4-methyl-piperidine-1-carboxylic acid tert-butyl ester (350 mg, 82%).
[0772] 1 H NMR(CDCl3)δ:7.43(s,1H),7.11(d,J=6.6Hz,2H),3.65-3.81(m,2H),3.14-3.2 2(m,2H),2.09(d,J=13.9Hz,2H),1.46-1.52(m,2H),1.45(s,9H),1.32(s,3H).
[0773] Step 2:A mixture of 4-[(4-bromo-2,6-difluoro-phenyl)carbamoyl]-4-methyl-piperidine-1-carboxylic acid tert-butyl ester (350 mg, 0.81 mmol, 1.0 eq.), Law's reagent (200 mg, 0.48 mmol, 0.60 eq.), Cs2CO3 (660 mg, 2.0 mmol, 2.5 eq.) in toluene (4.0 mL) and dioxane (2.0 mL) was stirred overnight at 100°C. After cooling, the reaction mixture was treated with saturated aqueous sodium bicarbonate and filtered. The filtrate was dried, concentrated, and the residue was purified on silica gel with ethyl acetate in hexane (5% to 35% gradient) to give 4-(6-bromo-4-fluoro-1,3-benzothiazol-2-yl)-4-methyl-piperidine-1-carboxylic acid tert-butyl ester (79 mg, 23%).
[0774] 1 H NMR(CDCl3)δ:7.81(dd,J=1.6,0.6Hz,1H),7.35(dd,J=9.8,1.6Hz,1H),3.68-3.7 6(m,2H),3.33(s,2H),2.29-2.37(m,2H),1.81(s,2H),1.49(s,3H),1.48(s,9H).
[0775] Step 3: A mixture of 4-(6-bromo-4-fluoro-1,3-benzothiazol-2-yl)-4-methyl-piperidine-1-carboxylic acid tert-butyl ester (79 mg, 0.18 mmol, 1.0 eq.), B2Pin2 (71 mg, 0.28 mmol, 1.5 eq.), PdCl2dppf dichloromethane adduct (15 mg, 0.018 mmol, 0.10 eq.) and KOAc (55 mg, 0.55 mmol, 3.0 eq.) in dioxane (1.8 mL) was stirred at 100 °C for 2 h, then cooled, diluted with ethyl acetate and filtered through celite. The filtrate was concentrated and purified on silica gel with ethyl acetate in hexanes (5% to 50% gradient) to give 4-[4-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]-4-methyl-piperidine-1-carboxylic acid tert-butyl ester (60 mg, 68%).
[0776] 1H NMR(CDCl3)δ:8.11(d,J=0.9Hz,1H),7.57(dd,J=10.9,0.8Hz,1H),3.68-3.78(m,2H), 3.34(s,2H),2.31-2.41(m,2H),1.82(s,2H),1.50(s,3H),1.48(s,9H),1.39(s,12H).
[0777] Step 4: A mixture of 4-[4-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]-4-methyl-piperidine-1-carboxylic acid tert-butyl ester (60 mg, 0.13 mmol, 1.0 eq.), 6-chloro-2,8-dimethyl-imidazo[1,2-b]pyridazine (23 mg, 0.13 mmol, 1.0 eq.), SPhos-Pd G2 (9.3 mg, 0.013 mmol, 0.10 eq.) and K2CO3 (2.0 M aqueous) (0.19 mL, 0.38 mmol, 3.0 eq.) in dioxane (1.0 mL) was stirred at 100° C. for 2 h, then cooled to room temperature, diluted with ethyl acetate, and washed with brine. The organic layer was dried and evaporated. The residue was purified on silica with ethyl acetate and dichloromethane (10% to 100% gradient) to give 4-[6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-1,3-benzothiazol-2-yl]-4-methyl-piperidine-1-carboxylic acid tert-butyl ester (35 mg, 56%). MS m / z 496.4 [M+H] + .
[0778] Step 5: TFA (1.0 mL) was added to tert-butyl 4-[6-(2,8-dimethylimidazo[1,2-b]pyridazine-6-yl)-4-fluoro-1,3-benzothiazol-2-yl]-4-methyl-piperidine-1-carboxylate (35 mg, 0.071 mmol, 1.0 eq.). The mixture was stirred at room temperature for 15 min, after which organic volatiles were removed by a stream of nitrogen. The residue was purified on a C18 column and treated with HCl to give 6-(2,8-dimethylimidazo[1,2-b]pyridazine-6-yl)-4-fluoro-2-(4-methyl-4-piperidinyl)-1,3-benzothiazole hydrochloride (28 mg, 92%).
[0779] MS m / z 396.5[M+H] + ; 1H NMR(methanol-d4)δ:8.52(d,J=1.3Hz,1H),8.14-8.22(m,2H),7.93(dd,J=11.3,1.3Hz,1H),3.20–3.27(m,2H), 3.08–3.15(m,2H),2.64(s,3H),2.49(d,J=0.6Hz,3H),2.42-2.48(m,2H),1.92–1.98(m,2H),1.44(s,3H).
[0780] Using the procedure described above in Example 19, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0781]
[0782] Embodiment 20
[0783] Preparation of compound 41
[0784]
[0785] Step 1: To a solution of tert-butyl 4-hydroxy-4-(6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazol-2-yl)piperidine-1-carboxylate (500 mg, prepared according to the procedure in step 2 of Example 8) in dichloromethane at 0°C was added DAST (2.0 eq) and the temperature was raised to room temperature and stirred for 16 h. The reaction was quenched with saturated sodium bicarbonate. The mixture was extracted with ethyl acetate, dried over sodium sulfate, and evaporated. The residue was purified by flash column chromatography on silica gel to give tert-butyl 4-fluoro-4-(6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazol-2-yl)piperidine-1-carboxylate (450 mg, 89%). MS m / z 467.1[M+H] + .
[0786] Step 2: Tert-butyl 4-fluoro-4-(6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazol-2-yl)piperidine-1-carboxylate (450 mg) was treated with 4.0 N HCl in dioxane. The mixture was stirred at room temperature for 16 h, then diluted with a large amount of ether and filtered. The solid was collected and dried to give 2-(4-fluoropiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)benzo[d]thiazole hydrochloride (0.38 g, 98%).
[0787] MS m / z 367.1[M+H] + ; 1H NMR(DMSO-d6)δ:9.37(br s,2H),8.53(d,J=1.6Hz,1H),8.44(s,1H),8.13(d,J=8.5Hz,1H),8.08(s,1H),7.92(dd,J=8.7,1.7Hz,1H), 7.64-7.74(m,2H),4.20(s,3H),3.39-3.46(m,2H),3.15-3.28(m,2H),2.54-2.69(m,2H),2.38-2.47(m,2H).
[0788] Embodiment 21
[0789] Preparation of Compound 229
[0790]
[0791] Step 1: To a solution of 1-tert-butoxycarbonyl-piperidine-4-carboxylic acid (2.29 g, 10.0 mmol, 1.00 eq.) in CH2Cl2 (100 mL) at room temperature was added pyridine (3.19 g, 3.26 mL, 40.0 mmol, 4.00 eq.), followed by (COCl)2 (1360 mg, 0.934 mL, 10.5 mmol, 1.05 eq.) and DMF (73 mg, 0.078 mL, 3 mmol, 0.1 eq.). After 1 h, 4-bromo-2,6-difluoro-aniline (2.29 g, 11.0 mmol, 1.10 eq.) was added, and the mixture was stirred at room temperature for 3 days. The mixture was then washed with water and brine, dried, and purified on silica gel with ethyl acetate in hexanes (5% to 50% gradient) to give tert-butyl 4-[(4-bromo-2,6-difluoro-phenyl)carbamoyl]piperidine-1-carboxylate (2.0 g, 48%). MS m / z 417.2, 419.2 [MH] - .
[0792] Step 2:A suspension of phosphorus pentasulfide (270 mg, 1.2 mmol, 1.0 eq.) in pyridine (4.0 mL) was stirred at 85 ° C for 30 min to give a clear solution, to which tert-butyl 4-[(4-bromo-2,6-difluoro-phenyl)carbamoyl]piperidine-1-carboxylate (500 mg, 1.2 mmol, 1.0 eq.) was added. The mixture was stirred at 85 ° C overnight, then cooled, poured into a mixture of saturated sodium bicarbonate and water (1: 1), stirred for 2 h, and then filtered. The solid was collected and dried, and then purified on silica gel with ethyl acetate and dichloromethane (0 to 10% gradient). The desired fractions were combined and evaporated. DMF (1.0 mL) was added to the residue, and the mixture was heated at 100 ° C for 16 h with Cs2CO3 (390 mg, 1.2 mmol, 1.0 eq.). Aqueous workup followed by purification with ethyl acetate and dichloromethane (0 to 30% gradient) afforded tert-butyl 4-(6-bromo-4-fluoro-1,3-benzothiazol-2-yl)piperidine-1-carboxylate (118 mg, 24%).
[0793] 1 H NMR(CDCl3)δ:7.81(dd,J=1.7,0.8Hz,1H),7.36(dd,J=9.6,1.7Hz,1H),4.19-4.32(m,2H) ,3.26-3.35(m,1H),2.85-2.98(m,2H),2.14-2.22(m,2H),1.80-1.90(m,2H),1.50(s,9H).
[0794] Step 3: Tert-butyl 4-(6-bromo-4-fluoro-1,3-benzothiazol-2-yl)piperidine-1-carboxylate (118 mg, 0.284 mmol, 1.00 eq.), tributyl(1-ethoxyvinyl)tin (212 mg, 0.198 mL, 0.568 mmol, 2.00 eq.), TEA (86.7 mg, 0.119 mL, 0.852 mmol, 3.00 eq.) and PdCl2 were added. A mixture of dppf dichloromethane adduct (23.4 mg, 0.0284 mmol, 0.100 eq.) in toluene (2.0 mL) was heated at 110 °C overnight, cooled, and then purified on basic alumina with ethyl acetate and hexanes (0 to 25% gradient) to give tert-butyl 4-[6-(1-ethoxyvinyl)-4-fluoro-1,3-benzothiazol-2-yl]piperidine-1-carboxylate (57 mg, 49%).
[0795] 1H NMR(acetone-d6)δ:8.15(d,J=1.6Hz,1H),7.55(dd,J=12.3,1.3Hz,1H),4.90(d,J=3.2Hz,1H),4.41(d,J=2.8Hz,1H),4.15-4.28(m,2H),4 .00(q,J=6.9Hz,2H),3.35-3.46(m,1H),2.90-3.11(m,2H),2.15-2.23(m,2H),1.75-1.87(m,2H),1.48(s,9H),1.45(t,J=7.1Hz,3H).
[0796] Step 4: To a solution of tert-butyl 4-[6-(1-ethoxyvinyl)-4-fluoro-1,3-benzothiazol-2-yl]piperidine-1-carboxylate (57 mg, 0.14 mmol, 1.0 eq.) in THF (1.0 mL) and water (0.3 mL) was added NBS (25 mg, 0.14 mmol, 1.0 eq.). The mixture was stirred at room temperature for 1 h, then diluted with ethyl acetate, washed with water, NaHCO3 and brine. The organic layer was dried and concentrated, then purified on silica gel with ethyl acetate and dichloromethane (0% to 20% gradient) to give tert-butyl 4-[6-(2-bromoacetyl)-4-fluoro-1,3-benzothiazol-2-yl]piperidine-1-carboxylate (62 mg, 97%).
[0797] 1 H NMR(CDCl3)δ:8.35(d,J=1.6Hz,1H),7.81(dd,J=10.7,1.6Hz,1H),4.49(s,2H),4.21-4.35(m, 2H),3.30-3.43(m,1H),2.87-3.01(m,2H),2.16-2.28(m,2H),1.82-1.95(m,2H),1.50(s,9H).
[0798] Step 5:A mixture of tert-butyl 4-[6-(2-bromoacetyl)-4-fluoro-1,3-benzothiazol-2-yl]piperidine-1-carboxylate (62 mg, 0.14 mmol, 1.0 eq.), 3,5-dimethylpyrazin-2-amine (20 mg, 0.16 mmol, 1.2 eq.) and DIPEA (18 mg, 0.024 mL, 0.14 mmol, 1.0 eq.) in acetonitrile (0.5 mL) was heated at 90 °C for 2 h. Aqueous workup followed by purification with ethyl acetate in dichloromethane (0 to 100% gradient) gave tert-butyl 4-[6-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-4-fluoro-1,3-benzothiazol-2-yl]piperidine-1-carboxylate (38 mg, 58%). MS m / z 482.3 [M+H] + .
[0799] Step 6: Tert-butyl 4-[6-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-4-fluoro-1,3-benzothiazol-2-yl]piperidine-1-carboxylate (38 mg, 0.079 mmol, 1.0 eq.) was treated with TFA (0.5 mL), then concentrated and purified using a C18 column and treated with HCl to give 6-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-4-fluoro-2-(4-piperidinyl)-1,3-benzothiazole hydrochloride (26 mg, 79%).
[0800] MS m / z 382.3[M+H] + ; 1 H NMR (methanol-d4) δ: 8.76 (s, 1H), 8.52 (s, 1H), 8.44 (d, J = 1.6 Hz, 1H), 7.85-7.91 (m, 1H), 3.36-3.49 (m, 3H), 3.04-3.11 (m, 2H), 2.97 (s, 3H), 2.46 (s, 3H), 2.25-2.33 (m, 2H), 1.98-2.09 (m, 2H).
[0801] Embodiment 22
[0802] Preparation of Compound 98
[0803]
[0804] Step 1:A mixture of 4-bromo-2-methoxy-aniline (1 g, 4.94 mmol), KSCN (1.46 g, 14.85 mmol) and CuSO4 (1.19 g, 7.42 mmol) in 50 mL of MeOH was heated to 60 °C for 16 h. The reaction was cooled to room temperature, filtered through celite, concentrated, and then purified on ISCO (eluting with EtOAc / hexanes (10-70% gradient)) to give 6-bromo-4-methoxy-1,3-benzothiazol-2-amine (1.1 g, 86%) as a dark brown solid, which was used directly in the next step (purity was about 85%).
[0805] Step 2: CuCl2 (1.1 g, 8.5 mmol) and isoamyl nitrite (1.2 mL, 8.5 mmol) were added to a solution of 6-bromo-4-methoxy-1,3-benzothiazole-2-amine (1.1 g, 4.2 mmol) in 200 mL of acetonitrile. The reaction mixture was stirred at room temperature for 1 h and then heated to 50 ° C for 3 h. The reactant was cooled to room temperature, filtered through diatomaceous earth, diluted with water, and extracted with EtOAc. The combined organic extracts were dried over Na2SO4, concentrated, and purified by eluting with EtOAc / hexane (0-40% gradient) on ISCO to obtain 6-bromo-2-chloro-4-methoxy-1,3-benzothiazole (675 mg, 57%) as a white solid.
[0806] MS m / z 279.9[M+H] + ; 1 H NMR (acetone-d6) δ: 7.84 (d, J = 1.9 Hz, 1H), 7.27 (d, J = 1.9 Hz, 1H), 4.07 (s, 3H).
[0807] Step 3:6-bromo-2-chloro-4-methoxy-1,3-benzothiazole (298 mg, 1.07 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (331 mg, 1.07 mmol), Pd(dppf)Cl2 (80 mg, 0.1 mmol) and K2CO3 (448 mg, 3.2 mmol) were added to a round-bottom flask. The reactants were degassed with N2 for 15 min, and dioxane (10 mL) and water (2.5 mL) were added. The reactants were heated to 90 ° C for 3 h. UPLC showed 90% of the desired product. The reactants were cooled to room temperature and partitioned between EtOAc and water. The organic phase was dried over Na2SO4, concentrated under reduced pressure, and then purified on ISCO by eluting with EtOAc / hexanes (0 to 20% gradient) on silica gel to give tert-butyl 4-(6-bromo-4-methoxy-1,3-benzothiazol-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (388 mg, 85.3%).
[0808] MS m / z 425.2,427.2[M+H] + ; 1 H NMR(acetone-d6)δ:7.79(d,J=1.9Hz,1H),7.19(d,J=1.9Hz,1H),6.72-6.82(m,1H),4. 12-4.24(m,2H),3.67(s,3H),2.80-2.84(m,2H),2.75-2.79(m,2H),1.50(s,9H).
[0809] Step 4:To a round bottom flask was added tert-butyl 4-(6-bromo-4-methoxy-1,3-benzothiazol-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (70 mg, 0.16 mmol), 2,7-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazole (54 mg, 0.19 mmol), PddppfCl2 (12 mg, 0.016 mmol) and K2CO3 (69 mg, 0.49 mmol). The reaction was degassed with N2 for 15 min, dioxane (10 mL) and water (2.5 mL) were added, and the reaction was heated to 90 ° C for 16 h. The reaction was cooled to room temperature and then partitioned between EtOAc and water. The organic phase was dried over Na2SO4, concentrated under reduced pressure, and purified on ISCO by eluting with EtOAc / hexane (0 to 100%) on silica gel to give tert-butyl 4-[6-(2,7-dimethylindazol-5-yl)-4-methoxy-1,3-benzothiazol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (80 mg, 99%). MS m / z 491.3 [M+H] + .
[0810] Step 5: 4-[6-(2,7-dimethylindazole-5-yl)-4-methoxy-1,3-benzothiazol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (12 mg, 0.025 mmol) was dissolved in 0.5 mL MeOH and HCl (4 M) in 1,4-dioxane (0.012 mL) was added. The reaction mixture was stirred at room temperature for 1 h until UPLC showed that the starting material was completely consumed. The reactant was concentrated, ground in Et2O, and the resulting precipitate was filtered to give 6-(2,7-dimethyl-2H-indazole-5-yl)-4-methoxy-2-(1,2,3,6-tetrahydropyridin-4-yl)benzo[d]thiazole hydrochloride (8 mg, 76.6%) as a yellow solid.
[0811] MS m / z 391.5[M+H] + ; 1 H NMR(DMSO-d6)δ:8.94-9.14(m,1H),8.40(s,1H),7.96(d,J=1.9Hz,1H),7.93(d,J=1.9Hz,1H),7.42-7.55(m,1H),7.31-7.39 (m,1H),6.67-6.80(m,1H),4.21(s,3H),4.08(s,3H),3.83-3.91(m,2H),3.33-3.42(m,2H),2.86-3.00(m,2H),2.59(s,3H).
[0812] Using the procedure described above in Example 22, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0813]
[0814] Embodiment 23
[0815] Preparation of compound 99
[0816]
[0817] 4-[6-(2,7-dimethylindazole-5-yl)-4-methoxy-1,3-benzothiazol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (46mg, 0.09mmol, prepared in step 4 of Example 23) is dissolved in 5mL MeOH. 10mg Pd / C is added, and the reactant is subjected to 70psi H2 48h in a Parr oscillator, then filtered, and concentrated to give crude 4-[6-(2,7-dimethylindazole-5-yl)-4-methoxy-1,3-benzothiazol-2-yl] piperidine-1-carboxylic acid tert-butyl ester (30mg). It is dissolved in 0.5mL MeOH and 4M HCl (30μL) in 1,4-dioxanes is added. The reaction mixture is stirred at room temperature for 1h until UPLC shows that the starting material is completely consumed. The reaction mixture was then concentrated, triturated in Et2O, and the precipitate was filtered to give 6-(2,7-dimethyl-2H-indazol-5-yl)-4-methoxy-2-(piperidin-4-yl)benzo[d]thiazole hydrochloride (11 mg, 46.0%) as a yellow solid.
[0818] MS m / z 393.5[M+H] + ; 1 H NMR(DMSO-d6): δ8.88-8.99(m,1H),8.43(s,1H),7.77-7.89(m,1H),7.42-7.55(m,1H),7.31-7.39(m,1H),6.67-6.80(m,1H),4.27 (s,3H),4.18(s,3H),3.45-3.52(m,2H),3.25-3.34(m,2H),3.15-3.20(m,1H),2.53(s,3H),2.41–2.48(m,2H),2.18-2.24(m,2H).
[0819] Embodiment 24
[0820] Preparation of Compound 100
[0821]
[0822] 6-(2,7-dimethylindazole-5-yl)-4-methoxy-2-(1,2,3,6-tetrahydropyridine-4-yl)-1,3-benzothiazole (40 mg, 0.10 mmol) was dissolved in 2 mL of CH2Cl2 and BBr3 (1.0 M) in CH2Cl2 (0.51 mL) was added dropwise. The reaction mixture was stirred at room temperature for 2 h until UPLC (quenched with MeOH) showed that the starting material was completely consumed. The reactant was quenched with MeOH, concentrated to dryness, ground in CH2Cl2, the precipitate was filtered, and dried to give 6-(2,7-dimethyl-2H-indazole-5-yl)-2-(1,2,3,6-tetrahydropyridine-4-yl)benzo[d]thiazole-4-ol hydrobromide (41 mg, 87.5%) as an orange solid.
[0823] MS m / z 377.5[M+H] + ; 1 H NMR(DMSO-d6): δ8.84-9.00(m,1H),8.29-8.46(m,1H),7.80(d,J=1.6Hz,1H),7.78(d,J=1.6Hz,1H),7.36(s,1H),7.1 4-7.26(m,1H),6.64-6.78(m,1H),4.20(s,3H),3.85-3.94(m,2H),3.36-3.46(m,2H),2.83-3.00(m,2H),2.57(s,3H).
[0824] Embodiment 25
[0825] Preparation of Compound 134
[0826]
[0827] 6-(2,7-Dimethyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)benzo[d]thiazol-4-ol (30 mg, 0.07 mmol) was dissolved in 5 mL MeOH. Approximately 10 mg Pd / C was added and the reaction was subjected to 70 psi H2 in a Parr shaker for 48 h. The reaction mixture was then filtered and concentrated to give the desired product (about 30 mg, about 80% purity, by 1H NMR confirmed). The product was purified on ISCO on silica gel eluting with CH2Cl2 / MeOH (0% to 30% gradient) containing NH4OH (2.5%) to give 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)benzo[d]thiazol-4-ol (14 mg, 56.4%) as a tan solid.
[0828] MS m / z 379.5[M+H] + ; 1 H NMR(methanol-d4)δ:8.42(br s,1H),8.24(s,1H),7.74-7.78(m,1H),7.68(d,J=1.9Hz,1H),7.40(d,J=1.9Hz,1H),7.38-7.39(m,1H),7.20(d,J=1.6Hz,1H),4.26(s ,3H),3.52-3.60(m,3H),3.27(td,J=12.5,3.0Hz,2H),2.64(s,3H),2.45(dd,J=14.8,3.8Hz,2H),2.22(tdd,J=14.8,12.5,3.0Hz,2H).
[0829] Embodiment 26
[0830] Preparation of Compound 172
[0831]
[0832] 4-[4-Chloro-6-(7-cyano-2-methyl-indazol-5-yl)-1,3-benzothiazol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (40 mg, 0.08 mmol, prepared as in Example 23), ZnCN (9.5 mg, 0.08 mmol), Pd2dba3 (4 mg, 0.004 mmol) and X-Phos (3.8 mg, 0.008 mmol) were mixed together in anhydrous DMF (1.2 mL) in a microwave tube and heated in a microwave to 120 °C for 30 min. The mixture was poured onto aqueous NaHCO3, the precipitate was filtered and dried to give 4-[4-cyano-6-(7-cyano-2-methyl-indazole-5-yl)-1,3-benzothiazol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (33 mg, 84.1%) as a dark grey-green solid. The solid was dissolved in 0.5 ml CH2Cl2, treated with 4M HCl in 1,4-dioxane solution (6 μL), and the reactant was stirred for 2 h. The reaction mixture was concentrated under reduced pressure and dried to give 6-(7-cyano-2-methyl-indazole-5-yl)-2-(1,2,3,6-tetrahydropyridine-4-yl)-1,3-benzothiazole-4-nitrile hydrochloride (3.7 mg, 71%) as a yellow solid.
[0833] MS m / z 397.5[M+H] + ; 1 H NMR (methanol-d4) δ: 8.64 (d, J = 1.9 Hz, 1H), 8.56 (s, 1H), 8.43 (d, J = 1.9 Hz, 1H), 8.29 (d, J = 1.9 Hz, 1H), 8.23 (d, J = 1.9 Hz, 1H), 8.01 (br s,1H),6.96-6.99(m,1H),4.34(s,3H),4.05(dd,J=6.3,2.5Hz,2H),3.55-3.61(m,2H),3.13-3.18(m,2H).
[0834] Embodiment 27
[0835] Preparation of Compound 86
[0836]
[0837] Step 1:A mixture of 4,6-dichloropyridin-3-amine (10 g, 61.35 mmol), potassium O-ethyldithiocarbonate (14.8 g, 92.3 mmol) and NMP (60 mL) was stirred at 150 ° C for 6 h. LC / MS showed that the starting dichloride disappeared. The reaction mixture was cooled to room temperature, and acetic acid (10 mL) was added, followed by water (500 mL). The formed precipitate was collected by filtration, washed with water, dried and used directly in the next step. LC-MS m / z 203.2,205.2 [M+H] + ,RT 1.10min.
[0838] Step 2: The above material was treated with sulfonyl dichloride (50 mL) at 50 ° C overnight and then added to a stirred mixture of ice-NaHCO3 / CH2Cl2 (about 1 L). The precipitate was removed by filtration and the filtrate was concentrated. The residue was chromatographed (silica gel, ethyl acetate in hexanes, 0-40%) to give 2,6-dichlorothiazolo[4,5-c]pyridine (3.62 g, 28.8%, 2 steps). LC-MS m / z 205.1, 207.1, 209.1 [M+H] + ,RT 1.27min.
[0839] Step 3: A mixture of 2,6-dichlorothiazolo[4,5-c]pyridine (3.62 g, 17.7 mmol), N,2,2,6,6-pentamethylpiperidin-4-amine dihydrochloride (4.51 g, 18.5 mmol), Cs2CO3 (25.9 g, 79.5 mmol) and acetonitrile (35 mL) was stirred at 50 ° C for 24 h. The reaction mixture was then diluted with ethyl acetate and filtered. The filtrate was concentrated and the residue was chromatographed (silica gel, MeOH in CH2Cl2, 0-20%) to give 6-chloro-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)thiazolo[4,5-c]pyridine-2-amine (4.92 g, 82.2%) as an off-white powder.
[0840] LC-MS m / z 339.2,341.3[M+H] + ,RT 0.99min; 1 H NMR(CDCl3)δ:8.54(d,J=0.6Hz,1H),7.54(d,J=0.6Hz,1H),4.42(br s,1H),3.09(s,3H),1.79(dd,J=12.6,3.5Hz,2H),1.43-1.56(m,2H),1.38(s,6H),1.26(br s,6H).
[0841] Step 4: To a mixture of 6-chloro-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)thiazolo[4,5-c]pyridin-2-amine (0.169 g, 0.50 mmol), 7-fluoro-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazole (0.166 g, 0.60 mmol), PdCl2(dppf) (0.042 g, 0.050 mmol) in 1,4-dioxane (2.0 mL) was added K2CO3 (0.63 mL, 1.3 mmol, 2.0 M) under argon atmosphere. The mixture was stirred at 90°C for 2 h, then cooled and diluted with ethyl acetate. The precipitate was removed by filtration and the filtrate was concentrated. The residue was chromatographed (silica gel, MeOH in CH2Cl2, 0-20%) to give, after trituration with ether, 6-(7-fluoro-2-methyl-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)thiazolo[4,5-c]pyridin-2-amine (180 mg, 79.8%).
[0842] LC-MS m / z 453.4[M+H] + ,RT 0.88min; 1 H NMR(CDCl3)δ:8.87(d,J=0.9Hz,1H),8.07(d,J=1.3Hz,1H),8.01(d,J=1.0Hz,1H),7.98(d,J=0.9Hz,1H),7.66(dd,J=12.8,1.4Hz,1H),4.55(br s,1H),4.27(s,3H),3.14(s,3H),1.02-1.89(m,16H).
[0843] Using the procedure described above in Example 27, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0844]
[0845]
[0846]
[0847]
[0848]
[0849]
[0850]
[0851]
[0852]
[0853] Embodiment 28
[0854] Preparation of Compound 137
[0855]
[0856] Step 1: At -10 ° C, 1-bromo-4-iodo-2-methoxybenzene (50g, 160mmol) was suspended in dichloromethane (75mL). Boron tribromide (250mL, 250mmol, 1M in CH2Cl2) was added with a cannula over 30 minutes, and the internal temperature was kept below 0 ° C during the entire addition process. After the addition, the mixture was stirred at 0 ° C for 1h and then at room temperature for 16h. The mixture was cooled in an ice bath and 10% aqueous Na2CO3 (250mL) was added portionwise. The mixture was then distributed between H2O and dichloromethane. The dichloromethane layer was dried over MgSO4 and then filtered. 2-bromo-5-iodophenol (46g, 96%) was obtained as a pink-white solid from the filtrate.
[0857] 1 H NMR (acetone-d6) δ: 9.24 (br s, 1H), 7.38 (d, J=2 Hz, 1H), 7.31 (d, J=8.5 Hz, 1H), 7.17 (dd, J=8.5 Hz, 2 Hz, 1H).
[0858] Step 2: At 0 ° C, 2-bromo-5-iodophenol (54.9 g, 184 mmol) was dissolved in DMF (240 mL). Sodium tert-amyl alcohol (2.5 M in THF, 90 mL, 230 mmol) was then added dropwise. After the addition was complete, the reactant was stirred at 0 ° C for 15 min. Chloromethyl methyl ether (18 mL, 225 mmol) was added dropwise over 30 min. The mixture was warmed to ambient temperature and stirred for 16 h. The mixture was diluted with 1.5 L H2O and extracted into EtOAc (2 × 400 mL). The combined organic layer was washed with H2O (300 mL) and then with brine. The organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The crude product was rinsed through a silica plug using CH2Cl2 (0-10%) in hexane to obtain 1-bromo-4-iodo-2-(methoxymethoxy)benzene (61 g, 97%) as a transparent liquid.
[0859] 1 H NMR (acetone-d6) δ: 7.56 (d, J = 2 Hz, 1H), 7.38 (d, J = 8 Hz, 1H), 7.33 (dd, J = 8 Hz, 2 Hz, 1H), 5.35 (s, 2H), 3.50 (s, 3H).
[0860] Step 3: 1-Bromo-4-iodo-2-(methoxymethoxy)benzene (49 g, 143 mmol), 1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (48.4 g, 174 mmol), PdCl2(dppf)-dichloromethane adduct (3.1 g, 3.6 mmol), dioxane (500 mL) and aqueous K2CO3 (350 mL, 350 mmol, 1 M) were heated at 90°C for 2 h. The reaction mixture was then partitioned between H2O and EtOAc. The organic layer was dried over MgSO4, filtered, and concentrated under vacuum. Purification by silica gel chromatography (EtOAc in hexanes, 20-50%) followed by trituration with hexanes gave 4-(4-bromo-3-(methoxymethoxy)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole as an off-white solid (40.4 g, 77%).
[0861] 1 H NMR (acetone-d6) δ: 8.22 (s, 1H), 7.88 (s, 1H), 7.55 (d, J = 8.5Hz, 1H), 7.47 (d, J = 2Hz, 1H), 7.23 (dd, J = 8.5Hz, 2Hz, 1H), 5.44 (dd, J = 9.5Hz, 2.5Hz,1H),5.38(S,2H),4.01(m,1H),3.72(m,1H),3.51(s,3H),2.1-2.23(m,1H),2.0-2.1(m,2H),1.7-1.8(m,1H),1.6-1.7(m,2H).
[0862] Step 4:Potassium acetate (22 g, 224 mmol) was dry pumped at 180 °C for 2 h, and then the flask was filled with argon. 4-(4-bromo-3-(methoxymethoxy)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (20 g, 54.5 mmol), PdCl2(dppf)-dichloromethane adduct (1.22 g, 1.47 mmol), bis(pinacolato)diboron (20.8 g, 81.9 mmol) and anhydrous toluene (200 mL) were added. The mixture was heated at 110 °C for 2 days. The mixture was filtered through celite, eluted with ether. The filtrate was concentrated under vacuum, redissolved in ether, and filtered through celite again to remove solid impurities. Purification by silica gel chromatography (EtOAc, in hexanes, 20-50%) afforded a crude product (12 g) essentially free of protodeboronated byproducts. It was dissolved in ether (100 mL) and washed with aqueous NaHCO3 (2×1.5 L), brine, dried over MgSO4, and then filtered. The filtrate was concentrated to provide the pure product (7.05 g, 32%) as a glassy semisolid.
[0863] 1 H NMR (acetone-d6): δ: 8.24 (s, 1H), 7.90 (s, 1H), 7.65 (d, J = 8Hz, 1H), 7.33 (d, J = 1.5Hz, 1H), 7.29 (dd, J = 8Hz, 1.5Hz, 1H), 5.45 (dd, J = 10Hz, 2.5Hz, 1H) ,5.25(s,2H),4.01(m,1H),3.69-3.74(m,1H),3.52(s,3H),2.15-2.2(m ,1H),2.0-2.1(m,2H),1.7-1.8(m,1H),1.6-1.68(m,2H),1.35(s,12H).
[0864] Step 5:To a mixture of 6-chloro-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)thiazolo[4,5-c]pyridin-2-amine (169 mg, 0.50 mmol), 3-[3-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-tetrahydropyran-2-yl-pyrazole (249 mg, 0.60 mmol), PdCl2(dppf) (50 mg, 0.06 mmol) in 1,4-dioxane (2.0 mL) was added K2CO3 (0.63 mL, 1.3 mmol, 2.0 M) under argon. The mixture was stirred at 90° C. for 2 h, cooled, and then diluted with EtOAc. The precipitate was removed by filtration. The filtrate was concentrated and chromatographed (CH2Cl2, in MeOH, 0-20%) to give the coupled product, which was treated with HCl (5 mL, 3M, in CPME) at room temperature overnight. The precipitate was collected by filtration and dried to give 2-[2-[methyl-(2,2,6,6-tetramethyl-4-piperidinyl)amino]thiazolo[4,5-c]pyridin-6-yl]-5-(1H-pyrazol-3-yl)phenol hydrochloride (102 mg, 41%).
[0865] LC-MS 463.2m / z[M+H] + ,RT 0.95min; 1 H NMR(DMSO-d6)δ:9.50(br d,J=11.3Hz,1H),8.73-8.88(m,2H),8.44(br d,J=12.0Hz,1H),8.13(s,2H),7.78(br d,J=8.5Hz,1H),7.21-7.31(m,2H),4.65(br s,1H),3.13(s,3H),2.12(br t,J=12.8Hz,2H),1.83-1.94(m,2H),1.42-1.60(m,12H).
[0866] Embodiment 29
[0867] Preparation of Compound 128
[0868]
[0869] Step 1:A mixture of 6-bromopyridin-3-amine (11.7 g, 67.6 mmol), 1-chloropyrrolidine-2,5-dione (9.93 g, 74.4 mmol) and acetic acid (70 mL) was stirred at 90 °C for 2 h. The solvent was removed on a rotary evaporator, and the residue was washed with water and dried to give 6-bromo-2-chloro-pyridin-3-amine (13.1 g, 93.4%). LC-MS m / z 207.1, 209.1 [M+H] + ,RT:1.12min.
[0870] Step 2: A mixture of 6-bromo-2-chloro-pyridin-3-amine (13.1 g, 63.1 mmol), potassium ethyl xanthate (15.2 g, 94.8 mmol) and NMP (60 mL) was stirred at 150 ° C for 6 h. LC / MS showed that the starting pyridine disappeared. The reactants were then cooled to room temperature, acetic acid (10 mL) was added, and then diluted with water (500 mL). The precipitate was collected by filtration, washed with water, dried and used directly in the next step.
[0871] Step 3: The above material was treated with sulfonyl chloride (20 mL, 247.9 mmol) and heated at 50 ° C overnight, then the mixture was added to ice and NaHCO3 / CH2Cl2 (about 0.5 L). The precipitate was removed by filtration and the filtrate was concentrated. The residue was chromatographed (silica gel, ethyl acetate in hexanes, 0-40%) to give 5-bromo-2-chlorothiazolo[5,4-b]pyridine (3.94 g, 63.5%). LC-MS m / z 251.0 [M+H] + ,RT:1.44min.
[0872] Step 4: A mixture of 6-bromo-2-chloro-thiazolo[4,5-c]pyridine (3.94 g, 15.8 mmol), N,2,2,6,6-pentamethylpiperidin-4-amine (2.82 g, 16.6 mmol), Cs2CO3 (12.9 g, 39.6 mmol) and acetonitrile (32 mL) was heated at 50 ° C for 24 h. The reaction mixture was then diluted with ethyl acetate and filtered. The filtrate was concentrated and the residue was chromatographed (silica gel, MeOH in CH2Cl2, 0-20%) to give 5-bromo-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)thiazolo[5,4-b]pyridine-2-amine (5.41 g, 89.4%) as an off-white powder. LC-MS m / z 383.2,385.1[M+H] + ,RT:1.02min.
[0873] Step 5:To a mixture of 5-bromo-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)thiazolo[5,4-b]pyridin-2-amine (95.8 mg, 0.25 mmol), 7-fluoro-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazole (82.8 mg, 0.30 mmol) and PdCl2(dppf) (21 mg, 0.025 mmol) in 1,4-dioxane (1.0 mL) was added K2CO3 (0.31 mL, 0.62 mmol, 2.0 M) under argon atmosphere. The mixture was heated at 90° C. for 2 h, then cooled and diluted with ethyl acetate. The precipitate was removed by filtration and the filtrate was concentrated and chromatographed (silica gel, MeOH in CH2Cl2, 0-20%) to give, after trituration with ether, 5-(7-fluoro-2-methyl-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)thiazolo[5,4-b]pyridin-2-amine (65 mg, 57.5%).
[0874] LC-MS m / z 453.3[M+H] + ,RT 1.04min.; 1 H NMR(CDCl3)δ:8.04(d,J=0.9Hz,1H),7.99(d,J=2.5Hz,1H),7.64-7.77(m,2H),7.27(s,1H),4.46(br s,1H),4.26(s,3H),3.12(s,3H),1.82(dd,J=12.5,3.3Hz,2H),1.16-1.60(m,14H).
[0875] Using the procedure described above in Example 29, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0876]
[0877]
[0878]
[0879] Embodiment 30
[0880] Preparation of compound 59
[0881]
[0882] Step 1:At room temperature, under argon, zinc powder (2.11g, 32.3mmol) was suspended in dimethylacetamide (5.2mL). A mixture of 1,2-dibromoethane (260μL, 3mmol) and TMSCl (365μL, 8.22mmol) was added dropwise to the zinc suspension at such a rate that the internal temperature was kept below 45°C. After the addition was completed, the reaction mixture was stirred for another 15min, and the internal temperature was reduced to 30°C. A solution of 4-iodopiperidine-1-carboxylic acid tert-butyl ester (8.25g, 26mmol) in DMA (13mL) was added to the mixture at a rate that the internal temperature did not rise to above 55°C. After the addition was completed, the mixture was cooled to ambient temperature. The mixture was filtered through glass wool under an inert argon atmosphere to obtain 20mL of about 1M (1-(tert-butoxycarbonyl)piperidin-4-yl) zinc iodide (II) in DMA.
[0883] Step 2: Under argon, a mixture of 2-bromo-6-chlorothiazol [4,5-c] pyridine (300 mg, 1.2 mmol), Pd (dppf) Cl2-CH2Cl2 (50 mg, 0.06 mmol) and dioxane (2.5 mL) was stirred, and 1.8 mL of zinc iodide solution prepared in step 1 was added simultaneously. The mixture was heated at 90 ° C for 2 h. The reaction mixture was then quenched with aqueous NH4Cl, and the mixture was distributed between EtOAc and H2O. The organic layer was dried over MgSO4, filtered, and then concentrated under vacuum. Purified by silica gel chromatography (20% of EtOAc in CH2Cl2), then ground with 1:4 ether / hexane, 4- (6-chlorothiazol [4,5-c] pyridine -2- bases) piperidine -1- carboxylic acid tert-butyl ester (196 mg, 46%) was obtained as an off-white solid. 1 H NMR showed 20 mol % of the des-bromo byproduct 6-chlorothiazolo[4,5-c]pyridine, as well as the desired intermediate.
[0884] 1 H NMR (acetone-d6): δ: 8.98 (s, 1H), 8.19 (s, 1H), 4.20 (m, 2H), 3.46 (m, 1H), 3.0 (brs, 2H), 2.18-2.23 (m, 2H), 1.78-1.86 (m, 2H), 1.48 (s, 9H).
[0885] Step 3:Crude tert-butyl 4-(6-chlorothiazolo[4,5-c]pyridin-2-yl)piperidine-1-carboxylate (60 mg, 80% purity, 0.17 mmol), 2,7-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole (60 mg, 0.22 mmol), SPhos Pd G2 (10 mg, 0.014 mmol), 2M K2CO3 (0.2 mL, 0.4 mmol) and dioxane (0.6 mL) were heated at 90° C. for 15 h. The mixture was then partitioned between EtOAc and H2O. The organic layer was dried over MgSO4, filtered, and then concentrated under vacuum. Purification by silica gel chromatography (20-50% acetone in CH2Cl2) followed by ether trituration afforded tert-butyl 4-(6-(2,7-dimethyl-2H-indazol-5-yl)thiazolo[4,5-c]pyridin-2-yl)piperidine-1-carboxylate (58 mg, 73%) as a tan solid. UPLC showed 80% purity with 20% of 6-(2,7-dimethyl-2H-indazol-5-yl)thiazolo[4,5-c]pyridine present. MS m / z 464.4 [M+H] + .
[0886] Step 4: Crude tert-butyl 4-(6-(2,7-dimethyl-2H-indazole-5-yl)thiazolo[4,5-c]pyridin-2-yl)piperidine-1-carboxylate (58 mg, 80% purity, 0.12 mmol) was heated at 90 °C for 1 h with 4N HCl (1.0 mL, 1 mmol) in dioxane. The mixture was diluted in ether and filtered. The solid was purified by C18 preparative HPLC. The collected fractions were treated with concentrated HCl and then concentrated under vacuum to give the title compound (29 mg, 60%) as a pure yellow solid.
[0887] MS m / z 364.3[M+H] + ; 1 H NMR(DMSO-d6): δ:9.31(s,1H),8.80(s,1H),8.47(s,1H),8.33(s,1H),7.84(s,1H),4.20(s,3H),3.57- 3.63(m,1H),3.39-3.43(m,2H),3.05-3.13(m,2H),2.59(s,3H),2.30-2.36(m,2H),2.00-2.11(m,2H).
[0888] Using the procedure described above in Example 30, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0889]
[0890] Embodiment 31
[0891] Preparation of Compound 122
[0892]
[0893] Step 1: Under argon, at room temperature, chloroformic acid (9H-fluorene-9-yl) methyl ester (2.0g, 7.77mmol), potassium thiocyanate (826mg, 8.51mmol) and EtOAc (15mL) were stirred for 15h. The reaction mixture was then passed through silica and rinsed with EtOAc to remove inorganic matter. The filtrate was then concentrated under vacuum. Purified by silica gel chromatography (1: 1 hexane / CH2Cl2) to obtain isothiocyanatoformic acid O-((9H-fluorene-9-yl) methyl) ester (1.71g, 78%) as a white solid.
[0894] 1 H NMR (CDCl3): δ: 7.81 (d, J = 7.5Hz, 2H), 7.62 (d, J = 7.5Hz, 2H), 7.47 (t, J = 7.5Hz, 2H), 7.37 (t, J = 7.5Hz, 2H), 4.50 (d, J = 7.5Hz, 2H), 4.30 (t, J = 7.5Hz, 1H).
[0895] Step 2: O-((9H-fluoren-9-yl)methyl)isothiocyanatoformate (562 mg, 2 mmol), 2,4-dichloropyrimidin-5-amine (328 mg, 2 mmol) and acetone (5 mL) were heated at 60° C. for 15 h. The reaction mixture was filtered and the solid was washed with acetone to give (9H-fluoren-9-yl)methyl (5-chlorothiazolo[5,4-d]pyrimidin-2-yl)carbamate (716 mg, 88%) as a yellow solid.
[0896] 1H NMR(DMSO-d6): δ:12.9(s,1H),9.07(s,1H),7.93(d,J=7.5Hz,2H),7.81(d,J=7.5Hz,2H ), 7.45 (t, J = 7.5Hz, 2H), 7.37 (t, J = 7.5Hz, 2H), 4.62 (d, J = 7Hz, 2H), 4.38 (t, J = 7Hz, 1H).
[0897] Step 3: (9H-fluoren-9-yl)methyl (5-chlorothiazolo[5,4-d]pyrimidin-2-yl)carbamate (650 mg, 1.56 mmol) was stirred in CH2Cl2 (25 mL) and piperidine (2.5 mL, 25 mmol) at room temperature for 3 h. Afterwards, the precipitated solid was filtered and washed with CH2Cl2 to give 5-chlorothiazolo[5,4-d]pyrimidin-2-amine (211 mg, 72%) as an off-white solid.
[0898] 1 H NMR (DMSO-d6): δ: 8.55 (s, 1H), 8.30 (br s, 2H).
[0899] Step 4: 5-Chlorothiazolo[5,4-d]pyrimidine-2-amine (180 mg, 0.96 mmol), acetonitrile (6.6 mL), tert-butyl nitrite (0.25 mL, 2.1 mmol) and CuBr2 (252 mg, 1.14 mmol) were heated at 60 ° C for 30 min. The reaction mixture was distributed between EtOAc and H2O. The organic layer was dried over MgSO4, filtered, and concentrated under vacuum. Purified by silica gel chromatography (0-2% EtOAc in CH2Cl2) to obtain 2-bromo-5-chlorothiazole [5,4-d] pyrimidine (211 mg, 87%) as a white solid.
[0900] 1 H NMR (acetone-d6): δ: 9.29 (s, 1H).
[0901] Step 5:2-Bromo-5-chlorothiazolo[5,4-d]pyrimidine (180 mg, 0.72 mmol), N,2,2,6,6-pentamethylpiperidin-4-amine (204 mg, 0.84 mmol), K2CO3 (490 mg, 3.54 mmol) and acetonitrile (3 mL) were heated at 100 ° C for 15 h. The reaction mixture was diluted with ether and filtered. The filtrate was concentrated under vacuum, redissolved in ether, and then filtered to remove orange particulate matter. The filtrate was concentrated under vacuum. Trituration with hexane gave 5-chloro-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)thiazolo[5,4-d]pyrimidin-2-amine (193 mg, 79%) as a white solid.
[0902] 1 H NMR (acetone-d6): δ: 8.55 (s, 1H), 4.40-4.70 (br s,1H),3.18(s,3H),1.75(dd,J=12.5Hz,3.5Hz,2H),1.58(t,J=12.5Hz,2H),1.31(s,6H),1.16(s,6H).
[0903] Step 6: 5-Chloro-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)thiazolo[5,4-d]pyrimidin-2-amine (40 mg, 0.12 mmol), 2,7-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole (44 mg, 0.16 mmol), Pd(dppf)Cl2-CH2Cl2 (10 mg, 0.012 mmol), dioxane (0.45 mL) and 2M K2CO3 (0.15 mL, 0.3 mmol) were heated at 90°C for 15 h. The reaction mixture was partitioned between H2O and EtOAc. The organic layer was dried over MgSO4, filtered, and then concentrated under vacuum. Purification by silica gel chromatography (20% MeOH in CH2Cl2 followed by 9 / 1 / 0.1 H2Cl2 / MeOH / NH4OH) followed by ether trituration gave the title product as a white solid (34 mg, 64%).
[0904] MS m / z 450.5[M+H] + ; 1H NMR(DMSO-d6): δ:8.82(s,1H),8.58(s,1H),8.45(s,1H),8.06(s,1H),4.30-4.70(br s,1H),4.20(s,3H),3.10(s,3H),2.58(s,3H),1.45-1.75(m,4H),1.29(br s,6H),1.17(br s,6H).
[0905] Using the procedure described above in Example 31, additional compounds described herein are prepared by substituting the intermediates shown in Step 5 (if any), appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0906]
[0907]
[0908]
[0909] Embodiment 32
[0910] Preparation of Compound 265
[0911]
[0912] Step 1: 1-(1H-pyrrole-2-yl)ethan-1-one (1.09 g, 10 mmol) was dissolved in CH2Cl2 (50 mL) at -78 °C. A solution of Br2 (0.62 mL, 12.1 mmol) in CH2Cl2 (12 mL) was added by syringe. After the addition was complete, the mixture was poured onto ice. The double layers were separated and the organic layer was then washed with aqueous 1N NaOH to remove the dibrominated byproducts. The organic layer was dried over MgSO4, filtered, and concentrated under vacuum to give 1-(4-bromo-1H-pyrrole-2-yl)ethan-1-one (1.42 g, 76%) as a light grey solid.
[0913] 1 H NMR (acetone-d6) δ: 11.08 (br s, 1H), 7.19 (t, J = 1.5 Hz, 1H), 7.02 (t, J = 1.5 Hz, 1H), 2.36 (s, 3H).
[0914] Step 2:1-(4-bromo-1H-pyrrole-2-yl) ethyl-1-one (1.36 g, 7.23 mmol) was dissolved in DMF (15 mL) at 0 ° C. NaH (60%, 316 mg, 7.9 mmol) was added. The reaction mixture was then stirred at room temperature for 30 minutes. Chloroacetone (0.6 mL, 7 mmol) was then added dropwise. The mixture was stirred at room temperature for 15 h and then distributed between EtOAc and H2O. The organic layer was dried over MgSO4, filtered, and concentrated under vacuum. Purified by silica gel chromatography (30% EtOAc in hexane) to obtain 1-(2-acetyl-4-bromo-1H-pyrrole-1-yl) propan-2-one (1.2 g, 68%) as a white solid.
[0915] 1 H NMR (acetone-d6) δ: 7.13 (d, J = 2 Hz, 1H), 7.10 (d, J = 2 Hz, 1H), 5.17 (s, 2H), 2.36 (s, 3H), 2.18 (s, 3H).
[0916] Step 3: 1-(2-acetyl-4-bromo-1H-pyrrol-1-yl)propan-2-one (1.15 g, 4.71 mmol), NH4OAc (7.2 g, 93 mmol) and HOAc (40 mL) were heated at 120 ° C for 15 h. The solvent was then removed under vacuum, and the concentrate was treated with aqueous NaOH and then extracted into EtOAc. The organic layer was dried over MgSO4, filtered, and concentrated under vacuum. Purification by silica gel chromatography (10-50% EtOAc in CH2Cl2) gave 7-bromo-1,3-dimethylpyrrolo[1,2-a]pyrazine (975 mg, 92%) as a light tan solid.
[0917] 1 H NMR (acetone-d6) δ: 7.86 (s, 1H), 7.63 (d, J = 1.5 Hz, 1H), 6.84 (t, J = 1 Hz, 1H), 2.56 (s, 3H), 2.31 (s, 3H).
[0918] Step 4:7-Bromo-1,3-dimethylpyrrolo[1,2-a]pyrazine (32 mg, 0.14 mmol), KOAc (46 mg, 0.47 mmol), bis(pinacolato)diboron (46 mg, 0.18 mmol), Pd(dppf)Cl2-CH2Cl2 (8 mg, 0.016 mmol) and dioxane (0.6 mL) were heated at 90°C for 1 h and then cooled. 5-Chloro-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)thiazolo[5,4-d]pyrimidin-2-amine (40 mg, 0.12 mmol, prepared as in Example 32), Pd(dppf)Cl2-CH2Cl2 (8 mg, 0.016 mmol) and 2M K2CO3 (0.2 mL, 0.4 mmol) were added. The mixture was heated at 90°C for 15 h. The mixture was partitioned between CH2Cl2 and H2O. The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. Purification by silica gel chromatography (5% MeOH in CH2Cl2 then 9 / 1 / 0.1 CH2Cl2 / MeOH / NH4OH) followed by ether trituration gave the title compound as a white solid (16 mg, 30%).
[0919] MS m / z 450.5[M+H] + ; 1 H NMR(methanol-d4)δ:8.68(s,1H),8.15(d,J=1.5Hz,1H),7.88(s,1H),7.47(s,1H),4.2-4.4(br s,1H),3.19(s,3H),2.67(s,3H),2.36(s,3H),1.87-1.93(m,2H),1.68-1.78(m,2H),1.47(br s,6H),1.35(s,6H).
[0920] Using the procedure described above in Example 32, additional compounds described herein are prepared by substituting the appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0921]
[0922] Embodiment 33
[0923] Preparation of Compound 131
[0924]
[0925] Step 1:3,5-Dibromopyrazin-2-amine (1.0 g, 4 mmol) was dissolved in DMF (8.0 mL) and CS2 (0.5 mL, 8 mmol, 2 eq.) was added. The solution was cooled, stirred at 0°C, and t-BuOK (1 M solution, 8 mL, 2 eq) in THF was added to the cold solution. The resulting solution was stirred at 0°C for 1 h, and additional CS2 (0.25 mL, 4 mmol, 1 eq) and tBuOK (4 mL, 1 eq) in THF were added. The solution was stirred for another hour, and the disappearance of SM was observed by UPLC. MeI (1 mL, 4 eq) was added, and the reaction was stirred for 1 h. The reaction was then quenched with ice-cold water. The resulting precipitate was filtered, washed with hexane, and dried to give 6-bromo-2-(methylthio)thiazolo[4,5-b]pyrazine (0.84 g, 81%). MS m / z 262.1,264.1[M+H] + .
[0926] Step 2: 6-Bromo-2-(methylthio)thiazolo[4,5-b]pyrazine (0.5 g, 1.9 mmol) was dissolved in CH2Cl2, and the solution was cooled to 0°C. mCPBA (0.95 g, 3.8 mmol, 70% purity, 2 eq.) was added to the solution. The solution was then stirred at 0°C for 1 h and then slowly warmed to room temperature. The reaction was then quenched with NaHCO3, and the mixture was extracted with CH2Cl2. The organic layer was dried and evaporated to give a mixture of 6-bromo-2-(methylsulfonyl)thiazolo[4,5-]pyrazine and 6-bromo-2-(methylsulfinyl)thiazolo[4,5-b]pyrazine (600 mg), which was used in the next step without any further purification.
[0927] Step 3: A mixture of 6-bromo-2-(methylsulfonyl)thiazolo[4,5-]pyrazine and 6-bromo-2-(methylsulfinyl)thiazolo[4,5-b]pyrazine prepared above (0.375 g, 1.28 mmol) was dissolved in THF (4 mL). N-2,2,6,6-pentamethylpiperidin-4-amine (0.45 mL, 2.56 mmol) was added to the solution and the mixture was heated at 80 °C for 1 h. The reaction was complete and the mixture was purified on silica gel eluting with 0-30% MeOH in dichloromethane to give 6-bromo-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)thiazolo[4,5-b]pyrazine-2-amine (0.34 g, 70%). MS m / z 384.1,386.1 [M+H] + .
[0928] Step 4:6-Bromo-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)thiazolo[4,5-b]pyrazin-2-amine was combined with 2,7-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazole (50 mg, 0.13 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (10 mg, 0.013 mmol), 1,4-dioxane (2 mL) and aqueous 1M K2CO3 (0.4 mL). The mixture was heated at 80° C. under an Ar atmosphere for 8 h, then cooled and partitioned between EtOAc and H2O. The organic layer was washed with brine, dried over Na2SO4, filtered, and then concentrated. The residue was chromatographed on silica gel eluting with 10-100% EtOAc in hexanes to give 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)thiazolo[4,5-b]pyrazin-2-amine (35 mg, 60%).
[0929] MS m / z 450.4[M+H] + ; 1 H NMR (methanol-d4, 500MHz): δ: 8.86 (s, 1H), 8.30 (s, 1H), 8.22 (d, J = 0.6Hz, 1H), 7.80 (s, 1H), 5.04-5.15 (m,1H),4.27(s,3H),3.23(s,3H),2.66(s,3H),2.01-2.16(m,4H),1.67(s,6H),1.56ppm(s,6H).
[0930] Using the procedure described above in Example 33, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0931]
[0932]
[0933]
[0934] Embodiment 34
[0935] Preparation of compound 312
[0936]
[0937] Step 1:NaH (150 mg, 3.75 mmol, 60% by mass in oil) was added to a solution of 2,2,6,6-tetramethylpiperidin-4-ol (472 mg, 3.00 mmol) in DMF (8.5 mL). The mixture was stirred at room temperature for 5 min, followed by addition of 2-bromo-6-chloro-thiazole [4,5-c] pyridine (624 mg, 2.50 mmol), and then stirred at room temperature overnight. The mixture was diluted with ice water and extracted with EtOAc. The organic phase was washed with water, brine, and dried over Na2SO4. The solvent was removed, and the residue was chromatographed (0-20% of MeOH in dichloromethane), providing 6-chloro-2-[(2,2,6,6-tetramethyl-4-piperidinyl)oxy]thiazole [4,5-c] pyridine (487 mg, 59.8%) as a white solid.
[0938] MS m / z 326.3,328.2[M+H] + ,RT 0.94min; 1 H NMR (CDCl3) δ: 8.67-8.72 (m, 1H), 7.61-7.65 (m, 1H), 5.58-5.68 (m, 1H), 2.20-2.44 (m, 2H), 1.08-1.82 (m, 14H), NH proton was not observed.
[0939] Step 2: Following the procedure of step 4 of example 28, 6-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)thiazolo[4,5-c]pyridin-2-amine was obtained.
[0940] MS m / z[M+H] + 440.2; 1 H NMR (500 MHz, DMSO-d6) δ: 8.94 (s, 1H), 8.63 (s, 1H), 8.60 (d, J = 1.00 Hz, 1H), 8.30 (d, J = 1.26 Hz, 1H), 7.81 (dd, J = 13.56, 1.26 Hz, 1H), 5.54-5.68 (m, 1H), 4.22 (s, 3H), 2.15-2.35 (m, 2H), 1.02-1.70 (m, 14H), NH proton was not observed.
[0941] Using the procedure described above in Example 34, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0942]
[0943]
[0944] Embodiment 35 Preparation of compound 359
[0945]
[0946] Step 1: 6-Bromo-2-chloro-4-fluorobenzo[d]thiazole (800 mg, 3.0 mmol), (2S,6R)-1-benzyl-2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine (1.0 g, 2.75 mmol, 90% purity), Pd(dppf)Cl2-CH2Cl2 (100 mg, 0.12 mmol), dioxane (12 mL) and 2M aqueous K2CO3 (6 mL, 12 mmol) were heated at 60°C for 15 h. After cooling, the reaction mixture was partitioned between H2O and CH2Cl2. The organic layer was dried over MgSO4, filtered, and then concentrated under vacuum. Purification by silica chromatography (10% EtOAc in hexanes) gave 2-((2S,6R)-1-benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-6-bromo-4-fluorobenzo[d]thiazole (833 mg, 70%) as a white solid.
[0947] 1 H NMR(methanol-d4)δ:7.97(s,1H),7.40-7.47(m,3H),7.30-7.35(m,2H),7.20-7.26(m,1H),6.69(s,1H),4.00(d,J=15.5Hz,1H),3.90(d,J =15.5Hz,1H),3.50-3.54(m,1H),3.05-3.11(m,1H),2.80-2.86(m,1H),2.48-2.55(m,1H),1.33(d,J=7Hz,3H),1.26(d,J=7Hz,3H).
[0948] Step 2:Potassium acetate (1.25 g, 12.7 mmol) was dried at 180 ° C for 15 minutes under argon purge and then cooled to room temperature. 2-((2S, 6R)-1-benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-6-bromo-4-fluorobenzo[d]thiazole (900 mg, 2.09 mmol), Pd(dppf)Cl2-CH2Cl2 (100 mg, 0.12 mmol), bis(pinacolatodiboron) (800 mg, 3.15 mmol) and dioxane (7 mL) were added. The reaction mixture was heated at 90 ° C for 15 h, cooled, then diluted in EtOAc and filtered through diatomaceous earth. The filtrate was concentrated under vacuum. The crude product was purified by silica chromatography (10-20% EtOAc in CH2Cl2), then the product was dissolved in ether and filtered to remove red solid impurities. The filtrate was concentrated to afford 2-((2S,6R)-1-benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-4-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole (970 mg, 90% purity, 87% yield) as a tan oil.
[0949] 1 H NMR(methanol-d4)δ:8.10(s,1H),7.49(d,J=11Hz,1H),7.42-7.46(m,2H),7.31 -7.35(m,2H),7.22-7.27(m,1H),6.73(s,1H),4.03(d,J=15.5Hz,1H),3. 91(d,J=15.5Hz,1H),3.46-3.53(m,1H),3.10(m,1H),2.83-2.89(m,1H), 2.52-2.57(m,1H),1.39(s,12H),1.35(d,J=7Hz,3H),1.27(d,J=7Hz,3H).
[0950] Step 3: 2-((2S,6R)-1-benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-4-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole (970 mg, 90% purity, 1.82 mmol) was suspended in MeOH (10 mL) at 0°C. Hydrogen peroxide (0.22 mL, 35%, 2.5 mmol) was added dropwise. The mixture was then stirred at room temperature for 30 min. The MeOH was removed under vacuum. Purification by silica chromatography (20-30% EtOAc in CH2Cl2) gave 2-((2S,6R)-1-benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-4-fluorobenzo[d]thiazol-6-ol (492 mg, 70%) as a light tan solid.
[0951] 1 H NMR (Methanol-d4) δ: 7.41-7.45 (m, 2H), 7.31-7.35 (m, 2H), 7.21-7.26 (m, 1H), 7.07 (s, 1H), 6.72 (d, J = 12 Hz, 1H), 6.52 (s, 1H), 4.01 (d, J = 15.5 Hz, 1H), 3.90 (d, J = 15.5 Hz, 1H), 3.45-3.51 (m, 1H), 3.04-3.09 (m, 1H), 2.79-2.84 (m, 1H), 2.45-2.53 (m, 1H), 1.32 (d, J = 7 Hz, 3H), 1.27 (d, J = 7 Hz, 3H), OH was not observed.
[0952] Step 4 : 2-((2S,6R)-1-benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-4-fluorobenzo[d]thiazole-6-ol (490 mg, 1.26 mmol), CHCl (5 mL), MeOH (5 mL) and 10% palladium on carbon (240 mg) were combined and hydrogenated at 50 psi for 15 h. The mixture was filtered through celite and the filter pad was washed with MeOH / CHCl. The filtrate was concentrated under vacuum. Purification by silica chromatography (95:5:0.5 CHCl / MeOH / NHOH) gave crude 2-((2S,4r,6R)-1-benzyl-2,6-dimethylpiperidin-4-yl)-4-fluorobenzo[d]thiazole-6-ol (425 mg, approximately 5:1 cis- / trans-).
[0953] Step 5:Crude 2-((2S,4r,6R)-1-benzyl-2,6-dimethylpiperidin-4-yl)-4-fluorobenzo[d]thiazole-6-ol (420mg), KCO (291mg, 2.1mmoL), N,N-bis(trifluoromethylsulfonyl)aniline (593mg, 1.66mmol) and DMF (3.8mL) were stirred at room temperature for 2h. It was distributed between H2O and EtOAc. Purification by silica (10-20% EtOAc in CH2Cl2) gave trifluoromethanesulfonic acid 2-((2S,4r,6R)-1-benzyl-2,6-dimethylpiperidin-4-yl)-4-fluorobenzo[d]thiazole-6-yl ester (439mg, 70%, over 2 steps) as a brown oil.
[0954] 1 H NMR (acetone-d6) δ: 8.14 (s, 1H), 7.56 (d, J = 13Hz, 1H), 7.42-7.46 (m, 2H), 7.29-7.33 (m, 2H), 7.17-7.21 (m, 1H), 3. 87(s,2H),3.35-3.42(m,1H),2.79-2.83(m,2H),2.15-2.19(m,2H),1.74(q,J=12Hz,2H),1.13(d,J=7Hz,6H).
[0955] Step 6: 2-((2S,4r,6R)-1-benzyl-2,6-dimethylpiperidin-4-yl)-4-fluorobenzo[d]thiazole-6-yl trifluoromethanesulfonate (100mg, 0.2mmol), potassium acetate (70mg, 0.71mmol), bis(pinacolatodiboron) (61mg, 0.24mmol), Pd(dppf)Cl2-CH2Cl2 (15mg, 0.018mmol) and dioxane (0.8mL) were heated at 90°C for 2h. The reaction mixture was then diluted with EtOAc and filtered through diatomaceous earth. The filtrate was then concentrated under vacuum. The product was redissolved in CH2Cl2 and filtered through diatomaceous earth to remove black insoluble material. The filtrate was concentrated to give 160mg of crude boronic acid. To the boronic acid was added 5-chloro-2,7-dimethyl-oxazolo[5,4-b]pyridine (87 mg, 0.2 mmol), Pd(dppf)Cl2-CH2Cl2 (10 mg, 0.012 mmol), dioxane (0.7 mL) and 2M aqueous K2CO3 (0.35 mL, 0.7 mmol). The mixture was heated at 90°C for 1 h. The reaction mixture was then partitioned between CH2Cl2 and H2O. The organic layer was dried over MgSO4, filtered, and concentrated under vacuum. Purification by silica chromatography (20-30% EtOAc in CH2Cl2) followed by trituration with ether / hexanes gave 5-(2-((2S,4r,6R)-1-benzyl-2,6-dimethylpiperidin-4-yl)-4-fluorobenzo[d]thiazol-6-yl)-2,7-dimethyloxazolo[5,4-b]pyridine (63 mg, 60%).
[0956] 1 H NMR (acetone-d6) δ: 8.63 (s, 1H), 8.06 (d, J = 12.5 Hz, 1H), 7.98 (s, 1H), 7.48 (m, 2H), 7.31 (m, 2H), 7.19 (m, 1H), 3.87 (s, 2H), 3.32-3.40 (m, 1H), 2.80 (m, 2H, obscured by HDO peak), 2.69 (s, 3H), 2.67 (s, 3H), 2.16-2.20 (m, 2H), 1.75 (q, J = 12 Hz, 2H), 1.14 (d, J = 6 Hz, 6H).
[0957] Step 7: 5-(2-((2S,4r,6R)-1-benzyl-2,6-dimethylpiperidin-4-yl)-4-fluorobenzo[d]thiazol-6-yl)-2,7-dimethyloxazolo[5,4-b]pyridine (61 mg, 0.12 mmol) was dissolved in CHCl(1 mL) and methanol (1 mL). Pd(OH)(20% on C, 200 mg) was added. It was hydrogenated at 50 psi for 3 h, during which HCl was generated from the catalytic reduction of dichloromethane. The mixture was filtered through diatomaceous earth and rinsed with CHCl / MeOH. The filtrate was concentrated under vacuum and purified by silica chromatography (5-10% MeOH in CHCl). Trituration with 9:1 CHCl / MeOH gave the title product (28 mg, 49% yield) as an off-white solid.
[0958] MS m / z 411.3[M+H] + ; 1 H NMR (methanol-d4) δ: 8.52 (s, 1H), 8.01 (d, J = 12 Hz, 1H), 7.88 (s, 1H), 3.65 (m, 1H), 3.45 (m, 2H), 2.71 (s, 3H), 2.68 (s, 3H), 2.50 (m, 2H), 1.85 (q, J = 13 Hz, 2H), 1.45 (d, J = 6.5 Hz, 6H).
[0959] Embodiment 36
[0960] Preparation of compound 329
[0961]
[0962] Step 1:A mixture of tert-butyl 4-((3-bromothiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (427 mg, 1 mmol) (prepared from 2-amino-6-bromopyridazine according to the procedure described in Example 34), 3-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl 4-methylbenzenesulfonate (434 mg, 1 mmol), Pd(dppf)Cl2 (73 mg, 0.1 mmol) and K2CO3 (345 mg, 2.5 mmol) in a mixture of 1,4-dioxane (4 mL) and water (1 mL) was stirred at 90°C under N2 for 2 h. The solution was concentrated and the residue was purified by flash column chromatography eluting with 5% MeOH in CH2Cl2 to give the desired compound tert-butyl 4-((3-(2-(methoxymethoxy)-4-(tosyloxy)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (393 mg, 60% yield). MS m / z: 656 [M+H] + .
[0963] Step 2: A mixture of tert-butyl 4-((3-(2-(methoxymethoxy)-4-(tosyloxy)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (400 mg, 0.61 mmol) and NaOH (122 mg, 3.05 mmol) in EtOH (3 mL) and water (1 mL) was stirred at 85 °C for 1 h. The solution was concentrated and the residue was purified by flash column chromatography eluting with 5%-10% MeOH in CH2Cl2 to give the desired compound tert-butyl 4-((3-(4-hydroxy-2-(methoxymethoxy)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (269 mg, 88% yield) as a white solid. MS m / z: 502 [M+H] + .
[0964] Step 3:To a mixture of tert-butyl 4-((3-(4-hydroxy-2-(methoxymethoxy)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (269 mg, 0.54 mmol) and Et3N (227 μL, 1.63 mmol) in CH2Cl2 (2 mL) was added PhNTf2 (289 mg, 0.81 mmol). The resulting mixture was stirred at room temperature for 16 h. The solution was concentrated and the residue was purified by flash column chromatography eluting with 5% MeOH in CH2Cl2 to give the desired compound tert-butyl 4-((3-(2-(methoxymethoxy)-4-(((trifluoromethyl)sulfonyl)oxy)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (214 mg, 65% yield) as a white solid. MS m / z: 634 [M+H] + .
[0965] Step 4: Tert-butyl 4-((3-(2-(methoxymethoxy)-4-(((trifluoromethyl)sulfonyl)oxy)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (214 mg, 0.34 mmol), B2(pin)2 (104 mg, 0.41 mmol), Pd(dppf)Cl2 (25 mg, 0.034 mmol) and KOAc (100 mg, A mixture of 4-((3-(2-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylic acid tert-butyl ester was stirred at 95 °C under N2 for 2 h to give a mixture containing tert-butyl 4-((3-(2-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate, which was used in the next step without any work-up. MS m / z: 612 [M+H]+.
[0966] Step 5:A mixture of tert-butyl 4-((3-(2-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate obtained in step 4 (1.3 mL of the mixture from step 4, theoretical 0.15 mmol), 4-bromo-3-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (37 mg, 0.15 mmol), Pd(dppf)Cl2 (11 mg, 0.015 mmol) and K2CO3 (62 mg, 0.45 mmol) in a mixture of 1,4-dioxane (0.8 mL) and water (0.2 mL) was stirred at 95 °C under N2 for 2 h. The solution was concentrated and the residue was purified by preparative-HPLC to give tert-butyl 4-((3-(4-(3-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)-2-(methoxymethoxy)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (58 mg, 70% yield). MS m / z: 654 [M+H] + .
[0967] Step 6: To a solution of tert-butyl 4-((3-(4-(3-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)-2-(methoxymethoxy)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (58 mg, 0.09 mmol) in CH2Cl2 (1 mL) was added TFA (1 mL). The mixture was stirred at room temperature for 2 h. The solution was concentrated and the residue was basified by excess NH3 in MeOH. The volatiles were removed again and the residue was purified by preparative-HPLC to give 5-(3-fluoro-1H-pyrazol-4-yl)-2-(6-(methyl(piperidin-4-yl)amino)thiazolo[4,5-c]pyridazin-3-yl)phenol (17 mg, 46% yield).
[0968] MS m / z:426[M+H] + ; 1 H NMR (DMSO-d6) δ8.94 (s, 1H), 8.30 (d, J = 2.1 Hz, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.20 (d, J = 7.6 Hz, 2H), 3.16 (s, 3H), 3.06 (d, J = 13.4 Hz, 2H), 2.95–2.86 (m, 1H), 2.69–2.55 (m, 2H), 1.82–1.64 (m, 4H), 2NH and OH protons were not observed.
[0969] Using the procedure described above in Example 36, additional compounds described herein are prepared by substituting appropriate starting materials, suitable reagents and reaction conditions to obtain compounds such as those selected from the group consisting of:
[0970]
[0971]
[0972]
[0973]
[0974] Embodiment 37
[0975] Preparation of 328
[0976]
[0977] Step 1: A mixture of 4-(4-bromo-2,5-difluorophenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (1.0 g, 3.7 mmol), 1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.24 g, 4.4 mmol), Pd(dppf)Cl2 (267 mg, 0.37 mmol) and K2CO3 (1.02 mg, 7.4 mmol) in dioxane-H2O (12 mL, 9 / 3, v / v) was stirred at 90 °C under N2 for 2 h. The solution was concentrated and the residue was purified by silica gel chromatography eluting with 10%-20% EtOAc in petroleum ether to give 4-(4-bromo-2,5-difluorophenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (470 mg, 37% yield) as a light yellow solid. MS m / z: 343, 345 [M+H] + .
[0978] Step 2: A mixture of 4-(4-bromo-2,5-difluorophenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (100 mg, 0.29 mmol), B2(Pin)2 (89 mg, 0.35 mmol), Pd(dppf)Cl2 (22 mg, 0.03 mmol) and KOAc (57 mg, 0.58 mmol) in dioxane (5 mL) was stirred at 90 °C under N2 for 2 h. The resulting solution was used in the next step without purification. MS m / z: 309 [M+H] + .
[0979] Step 3: The reaction mixture from step 2 and tert-butyl 4-((3-bromothiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (139 mg, 0.32 mmol), Pd(dppf)Cl2 (24 mg, 0.03 mmol) and K2CO3 (88 mg, 0.64 mmol) were stirred in dioxane-H2O (5 mL, 9 / 3, v / v) at 90 °C under N2 for 2 h. The solution was concentrated and the residue was purified by silica gel chromatography eluting with 20%-30% EtOAc in petroleum ether to give tert-butyl 4-((3-(2,5-difluoro-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (50 mg, 35% yield) as a light yellow solid. MS m / z: 612 [M+H] + .
[0980] Step 4: 4-((3-(2,5-difluoro-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)thiazolo[4,5-c]pyridazine-6-yl)(methyl)amino)piperidine-1-carboxylic acid tert-butyl ester (80 mg, 0.13 mmol) was dissolved in TFA (1 mL). After 15 min, the volatiles were removed. NH3-MeOH (15 ml) was added to the above residue, and the resulting mixture was stirred at room temperature for 1 h. The volatiles were then removed again under reduced pressure. The residue was purified by preparative-HPLC to give 3-(2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl)-N-methyl-N-(piperidin-4-yl)thiazolo[4,5-c]pyridazine-6-amine (22 mg, 39% yield) as a white solid.
[0981] MS m / z:428[M+H] + ; 1 H NMR (DMSO-d6) δ: 8.55 (s, 1H), 8.32 (s, 2H), 7.92-7.83 (m, 2H), 3.20-3.14 (m, 6H), 2.77-2.72 (m, 2H), 1.86-1.76 (m, 4H), 2NH proton was not observed.
[0982] Embodiment 38
[0983] Preparation of 327
[0984]
[0985] Step 1:A mixture of tert-butyl 4-((3-(2-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (90 mg, 0.15 mmol) (prepared according to the procedure described in Example 37), imidazole (20 mg, 0.3 mmol) and CuO (4 mg, 0.03 mmol) in MeOH (2 mL) was stirred at 40 °C under air for 16 h. The solution was concentrated and the residue was purified by preparative-TLC eluting with 7% MeOH in CH2Cl2 to give tert-butyl 4-((3-(4-(1H-imidazol-1-yl)-2-(methoxymethoxy)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (49 mg, 60% yield). MS m / z: 552 [M+H] + .
[0986] Step 2: To a solution of tert-butyl 4-((3-(4-(1H-imidazole-1-yl)-2-(methoxymethoxy)phenyl)thiazolo[4,5-c]pyridazin-6-yl)(methyl)amino)piperidine-1-carboxylate (49 mg, 0.09 mmol) in CH2Cl2 (1 mL) was added TFA (1 mL). The mixture was stirred at room temperature for 2 h. The solution was concentrated and the residue was basified by excess NH3 in MeOH. The volatiles were removed and the residue was purified by preparative-HPLC to give 5-(1H-imidazole-1-yl)-2-(6-(methyl(piperidin-4-yl)amino)thiazolo[4,5-c]pyridazin-3-yl)phenol (15 mg, 42% yield).
[0987] MS m / z:408.2[M+H] + ; 1 H NMR (DMSO-d6) δ: 9.02 (s, 1H), 8.41 (s, 1H), 8.29 (s, 1H), 8.06 (d, J = 8.6 Hz, 1H), 7.88 (s, 1H), 7.42–7.26 (m, 2H), 7.13 (s, 1H), 3.27 (d, J = 11.3 Hz, 3H), 3.16 (s, 3H), 2.99–2.87 (m, 2H), 2.03–1.79 (m, 4H), 1NH proton was not observed.
[0988] Biological Examples
[0989] The following in vitro biological examples demonstrate the usefulness of the compounds herein for treating Huntington's disease.
[0990] In order to describe in more detail and help understand this article, the following non-limiting biological examples are provided to more fully illustrate the scope of this article, and should not be interpreted as explicitly limiting its scope. These variations of this article that are now known or developed later (which will be within the scope determined by those skilled in the art) are considered to fall within the scope of this article and as claimed below.
[0991] Compounds of Formula (I) or Formula (II) were tested using the Meso Scale Discovery (MSD) assay provided in International Application No. PCT / US2016 / 066042, filed on December 11, 2016 and claiming priority to U.S. Provisional Application No. US62 / 265,652 filed on December 10, 2015, the entire contents of which are incorporated herein by reference.
[0992] The endogenous huntingtin protein assay used in Example 1 was developed using the MSD ELISA-based electrochemiluminescent assay platform.
[0993] Example 1
[0994] Endogenous Huntington protein assay
[0995] Meso Scale Discovery (MSD) 96-well or 384-well plates were coated with MW1 (amplified polyglutamine) or MAB2166 monoclonal antibodies (for capture) at 1 μg / mL concentration (30 μL per well) in PBS overnight at 4° C. The plates were then washed three times with 300 μL wash buffer (0.05% Tween-20 in PBS), blocked (100 μL blocking buffer; 5% BSA in PBS) for 4-5 hours at room temperature with rotation and shaking, and then washed three times with wash buffer.
[0996] The samples (25 μL) were transferred to the antibody-coated MSD plates and incubated overnight at 4°C. After removing the lysate, the plates were washed three times with wash buffer, and 25 μL #5656S (Cell signaling; rabbit monoclonal) secondary antibodies (diluted to 0.25 μg / mL in 0.05% Tween-20 in blocking buffer) were added to each well and incubated for 1 hour with shaking at room temperature. After incubation with the secondary antibodies, the wells were rinsed with wash buffer, after which 25 μL goat anti-rabbit SULFO TAG secondary detection antibodies (required aspects of the MSD system) (diluted to 0.25 μg / mL in 0.05% Tween-20 in blocking buffer) were added to each well and incubated for 1 hour with shaking at room temperature. After three rinses with wash buffer, 150 μL of Read Buffer T (MSD) with surfactant was added to each empty well and the plates were imaged on a SI 6000 Imager (MSD) according to the manufacturer's instructions for 96-well or 384-well plates. 50 The values (μM) are shown in Table 1.
[0997] As shown in Table 1, the test compounds described herein had the following IC 50 values, IC between >3μM and ≤9μM 50 Values are indicated by a single star (*), IC values between >1 μM and ≤3 μM 50 Values are indicated by two stars (**), IC values between >0.5 μM and ≤1 μM 50 Values are indicated by three stars (***), IC values between >0.1 μM and ≤0.5 μM 50 Values are indicated by four stars (****) and have an IC of ≤0.1 μM 50 Values are indicated by five stars (*****).
[0998] Table 1
[0999]
[1000]
[1001]
[1002]
[1003]
[1004] Regardless of whether or not a document cited herein is specifically and individually indicated as incorporated by reference, all documents mentioned herein are incorporated by reference into this application for any and all purposes to the same extent as if each individual reference was fully set forth herein.
[1005] Having now fully described the subject matter of the claims, one of ordinary skill in the art will appreciate that the subject matter of the claims may be carried out within a broad range of equivalents without affecting the scope of the subject matter or specific aspects described herein. It is intended that the appended claims be interpreted to include all such equivalents.
Claims
1. A compound, or a form thereof, selected from the group consisting of: 6-(2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 6-(2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(2-methyl-2H-indazol-5-yl)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 2-(2-methyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 2-(2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)-1,3-benzothiazole; 2-(2-methyl-2H-indazol-5-yl)-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 6-(2-methyl-2H-indazol-5-yl)-2-(piperazin-1-yl)-1,3-benzothiazole; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-2-(1-methylpiperidin-4-yl)-1,3-benzothiazole; 2-(2-methyl-2H-indazol-5-yl)-6-(1-methylpiperidin-4-yl)-1,3-benzothiazole; N-methyl-2-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-6-amine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine; 6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 2-(2-methyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)[1,3]thiazolo[4,5-b]pyridine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 4-Fluoro-N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-4-fluoro-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; N-methyl-5-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine; N-methyl-5-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N,N-dimethyl-1-[6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-yl]piperidin-4-amine; 1-[6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-yl]piperidin-4-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(1H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 5-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(pyrrolidin-3-yl)-1,3-benzothiazol-2-amine; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-4-fluoro-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 2-(4-fluoropiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole; 2-(Azepan-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole; 2-(2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridine; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; N-methyl-6-(2-methyl[1,2,4]triazolo[1,5-b]pyridazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 2-(2,7-dimethyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 2-(2,7-dimethyl-2H-indazol-5-yl)-6-(piperidin-4-yl)-1,3-benzothiazole; N-methyl-6-[2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-2-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazole; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-a]pyrazine; 6-(7-ethyl-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-2-(2,3,6,7-tetrahydro-1H-azepan-4-yl)-1,3-benzothiazole; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-2-(2-methylpiperidin-4-yl)-1,3-benzothiazole; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine; 6-[2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl]-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridine; 2-methyl-5-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2H-indazole-7-carbonitrile; N-methyl-6-(2-methylimidazo[1,2-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,3-benzothiazole; 6-(2-methyl-2H-indazol-5-yl)-2-(2-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2-methylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-2-(6-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,3-benzothiazole; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-1,3-benzoxazole; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-4-fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 4-Fluoro-6-(2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 4-Fluoro-6-(2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 2-methyl-5-[2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-6-yl]-2H-indazole-7-carbonitrile; 6-(7-ethyl-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine; 6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine; 6-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-1H-pyrazolo[4,3-b]pyridine; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-pyrazolo[4,3-b]pyridine; 6-(7-cyclopropyl-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2-methylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 2-methyl-5-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2H-indazole-7-carbonitrile; 6-(7-ethyl-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-methyl-6-(2-methylimidazo[1,2-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-{4-fluoro-2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methyl-2H-indazole-7-carbonitrile; 6-[4-Fluoro-2-(1-methylpiperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine; 6-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2,4-dimethyl-1H-benzimidazol-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(2-methyl-1H-benzimidazol-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; N-methyl-6-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 2-methyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]imidazo[1,2-b]pyridazine; 6-(2,7-dimethyl-2H-indazol-5-yl)-4-methoxy-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 6-(2,7-dimethyl-2H-indazol-5-yl)-4-methoxy-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-4-ol; 6-(2,7-dimethyl-2H-indazol-5-yl)-7-fluoro-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazole-7-carbonitrile; 1-{5-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazol-7-yl}methanamine; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazole-7-carbonitrile; N-methyl-6-(2-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-[2-(1-ethylpiperidin-4-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(1-methylpiperidin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-(1,2-dimethylpiperidin-4-yl)-N-methyl-1,3-benzothiazol-2-amine; 2-methyl-5-[2-(piperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-5-yl]-2H-indazole-7-carbonitrile; 5-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidine; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 2-methyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-1,3-benzoxazole; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 2-(2,2-dimethylpiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole; N-methyl-6-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-5-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 3-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridazin-6-amine; 2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 6-[4-Fluoro-2-(piperazin-1-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 6-[2-(1,4-diazepan-1-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 5-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 2-methyl-5-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2H-indazole-7-carbonitrile; 5-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-[2-(4,7-diazaspiro[2.5]octan-7-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 4-Fluoro-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 5-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine; N-methyl-5-(2-methylimidazo[1,2-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-b]pyrazin-6-yl}-5-(1H-pyrazol-4-yl)phenol; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine; 6-[2-(3,5-dimethylpiperazin-1-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 6-{4-fluoro-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazol-4-ol; 6-{2-[(2,6-dimethylpiperidin-4-yl)oxy]-4-fluoro-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine; N-methyl-6-(2-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-5-(1H-pyrazol-4-yl)phenol; 2-methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 2,8-Dimethyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]imidazo[1,2-b]pyridazine; 2-methyl-5-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-b]pyrazin-6-yl}-2H-indazole-7-carbonitrile; N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-5-(1H-pyrazol-4-yl)phenol; 1-[6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-1,3-benzothiazol-2-yl]piperidin-4-ol; 6-{4-fluoro-2-[(2R)-2-methylpiperidin-4-yl]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-8-methoxy-2-methylimidazo[1,2-b]pyridazine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-(2,2-dimethylpiperidin-4-yl)-N-methyl-1,3-benzothiazol-2-amine; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-5-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2H-indazole-7-carbonitrile; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-5-(1H-pyrazol-4-yl)phenol; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-8-methoxy-2-methylimidazo[1,2-b]pyridazine; 4-Fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 4-Chloro-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 5-[4-Chloro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazole-7-carbonitrile; N-(2,2-dimethylpiperidin-4-yl)-N-methyl-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-amine; 2-methyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]imidazo[1,2-a]pyrimidine; 3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridazin-6-amine; 2-methyl-5-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-2H-indazole-7-carbonitrile; 6-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine; 2-methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-b]pyrazin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-[(2S)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-N-[(2S)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine; 6-[4-Fluoro-2-(octahydroindolizine-7-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-N,2-dimethylimidazo[1,2-b]pyridazin-8-amine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-N,N,2-trimethylimidazo[1,2-b]pyridazin-8-amine; 2-methyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]imidazo[1,2-a]pyrazine; 2-methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-(7-cyano-2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole-4-carbonitrile; 2-methyl-6-[2-(piperazin-1-yl)[1,3]thiazolo[4,5-b]pyrazin-6-yl]imidazo[1,2-a]pyridine-8-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperazin-1-yl)[1,3]thiazolo[4,5-b]pyrazine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-(2,6-dimethylpiperidin-4-yl)-N-methyl-1,3-benzothiazol-2-amine; N-(2,6-dimethylpiperidin-4-yl)-N-methyl-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-amine; 5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine; 2-methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 2-methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy][1,3]thiazolo[4,5-b]pyrazine; 2-methyl-6-{2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy][1,3]thiazolo[4,5-b]pyrazin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-2-(piperazin-1-yl)[1,3]thiazolo[4,5-b]pyrazine; 5-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 5-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 8-(Benzyloxy)-6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-amine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-ol; 2-(2,6-dimethylpiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole; 4-Fluoro-6-(4-fluoro-3-methoxyphenyl)-2-(piperidin-4-yl)-1,3-benzothiazole; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-1,3-benzothiazol-2-amine; 2-methyl-5-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2H-indazole-7-carbonitrile; 6-[2-(1-azabicyclo[2.2.2]oct-4-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-8-phenoxyimidazo[1,2-b]pyridazine; 2-methyl-6-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 5-(7-methoxy-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 2-methyl-6-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 4-Fluoro-6-(8-methoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-{4-fluoro-2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazin-8-amine; 4-Fluoro-6-(8-methoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-N-methyl-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methyl-2H-indazole-7-carbonitrile; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-1,3-benzothiazol-2-amine; 6-[4-Fluoro-2-(4-methylpiperidin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-6-(7-fluoro-2-methyl-2H-indazol-5-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile; 2-methyl-5-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-5-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine-8-carboxylic acid; {6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}acetic acid methyl ester; {6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}acetic acid; 2-methyl-6-{2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine-8-carboxamide; 6-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-4-fluoro-N-methyl-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 6-{4-fluoro-2-[methyl(piperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(8-trans)-3-azabicyclo[3.2.1]oct-8-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-{2-[(8-trans)-3-azabicyclo[3.2.1]oct-8-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 2-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-6,8-dimethylimidazo[1,2-a]pyrazine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile; 6-{4-fluoro-2-[methyl(piperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-5-{2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]-4-fluoro-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]-4-fluoro-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine-8-carboxamide; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro-N-methyl-6-(2-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-1,3-benzothiazol-2-amine; 2-methyl-5-(2-{methyl[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2H-indazole-7-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl][1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-6-(2-{methyl[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)imidazo[1,2-a]pyridine-8-carbonitrile; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl][1,3]thiazolo[4,5-c]pyridin-2-amine; 6-{2-[ethyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-ethyl-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 2-methyl-5-(2-{[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2H-indazole-7-carbonitrile; 2-methyl-6-(2-{[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)imidazo[1,2-a]pyridine-8-carbonitrile; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl][1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl][1,3]thiazolo[4,5-c]pyridin-2-amine; N-(azetidin-3-yl)-6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-1,3-benzothiazol-2-amine; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylpyrazolo[1,5-a]pyrimidine; 4-Fluoro-N-methyl-6-(2-methylpyrazolo[1,5-a]pyrimidin-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 6-{2-[9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 5-{2-[9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile; N-(9-azabicyclo[3.3.1]non-3-yl)-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-{2-[(1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl)(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methyl-2H-indazole-7-carbonitrile; 6-(2-{[(1R)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[5,4-d]pyrimidin-5-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 6-{2-[(1R,5S)-9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(1R,5S)-9-azabicyclo[3.3.1]non-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-[(2S,4S)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-[(2S,4R)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine; N-(9-azabicyclo[3.3.1]non-3-yl)-N-methyl-6-(2-methylimidazo[1,2-a]pyridin-6-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-(9-azabicyclo[3.3.1]nonan-3-yl)-6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; N-(9-azabicyclo[3.3.1]non-3-yl)-N-methyl-6-(2-methyl-2H-indazol-5-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-(9-azabicyclo[3.3.1]non-3-yl)-6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; N-(9-azabicyclo[3.3.1]non-3-yl)-6-(7-methoxy-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 2-methyl-6-{2-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-5-{2-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-6-{2-[methyl(9-methyl-9-azabicyclo[3.3.1]non-3-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-5-{2-[methyl(9-methyl-9-azabicyclo[3.3.1]non-3-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-b]pyrazin-6-yl}-5-(1H-pyrazol-4-yl)phenol; 2-methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-1,3-benzoxazole-4-carbonitrile; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methyl-2H-indazole-7-carbonitrile; 6-{2-[(3-exo)-9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(3-exo)-9-azabicyclo[3.3.1]non-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine; 5-{2-[(3-exo)-9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methyl-2H-indazole-7-carbonitrile; 2-{6-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[methyl(1-methylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-(2-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-(2-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2-methyl-2H-indazole-7-carbonitrile; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine; N-[(1R)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-5-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-(2-{[(1R)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[5,4-d]pyrimidin-5-yl)-2-methyl-1,3-benzoxazole-4-carbonitrile; 6-(2-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[5,4-b]pyridin-5-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine; 5-(2-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[5,4-b]pyridin-5-yl)-2-methyl-2H-indazole-7-carbonitrile; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-5-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine; N-(9-azabicyclo[3.3.1]non-3-yl)-5-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine; 6-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-N-methyl-6-(2-methylimidazo[1,2-a]pyridin-6-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(2-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2-methyl-1,3-benzoxazole-4-carbonitrile; N-methyl-6-(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(2-{[(1R,3r,5S)-1,5-diethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[5,4-d]pyrimidin-5-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(1R,3r,5S)-1,5-diethyl-8-azabicyclo[3.2.1]octan-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; N-methyl-6-(3-methylimidazo[2,1-b][1,3]thiazol-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-{4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine; 4-Fluoro-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-[(piperidin-4-yl)oxy]-1,3-benzothiazole; N-methyl-6-(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-6-{2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridine; 2-methyl-5-{2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridine; 2-methyl-6-{2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridine; 2-methyl-5-{2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridine; 6-{4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 5-{4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2-methyl-2H-indazole-7-carbonitrile; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazole; 6-{4-fluoro-2-[(1-methylpiperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine; 6-{2-[(1-ethylpiperidin-4-yl)oxy]-4-fluoro-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl]-5-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-(2-{[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[5,4-d]pyrimidin-5-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 6-(2-{[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(1R,2S,3S,5S)-2-fluoro-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-(1H-imidazol-1-yl)-2-{6-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol; 3-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridazin-6-amine; 5-(3-Fluoro-1H-pyrazol-4-yl)-2-{6-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol; 5-(1H-imidazol-1-yl)-2-{6-[methyl(1-methylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol; 3-[2,5-difluoro-4-(3-fluoro-1H-pyrazol-4-yl)phenyl]-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridazin-6-amine; 5-(3-Fluoro-1H-pyrazol-4-yl)-2-{6-[methyl(1-methylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol; 2-{6-[(3R,5S)-3,5-dimethylpiperazin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-[6-(Piperazin-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 5-(1H-pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-yl]phenol; 2-(6-{[(3R,4S)-4-fluoro-1-methylpyrrolidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 5-(1H-pyrazol-4-yl)-2-[6-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-yl]phenol; 2-[6-(2,6-diazaspiro[3.5]nonan-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 2-[6-(7-methyl-1,7-diazaspiro[3.5]nonan-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 2-[6-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 2-[6-(2,7-diazaspiro[3.5]nonan-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(3-fluoro-1H-pyrazol-4-yl)phenol; 2-(6-{[(3S,4S)-4-fluoro-1-methylpyrrolidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[methyl(1-methylazetidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(3aS,7aR)-octahydro-1H-pyrrolo[3,2-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(1s,4s)-4-(methylamino)cyclohexyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(3R,4S)-4-fluoropyrrolidin-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(3aS,7aR)-5-methyloctahydro-1H-pyrrolo[3,2-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(3R)-piperidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(3S)-piperidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[3-(methylamino)cyclobutyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(1r,4r)-4-(dimethylamino)cyclohexyl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(3S)-1-methylpiperidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(azetidin-3-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-[6-(1,7-diazaspiro[3.5]non-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(3,3-dimethylpiperidin-4-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(2-azaspiro[3.3]hept-6-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(3R,4S)-3-fluoropiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 5-{2-[(2R,4r,6S)-2,6-dimethylpiperidin-4-yl]-4-fluoro-1,3-benzothiazol-6-yl}-2,7-dimethyl[1,3]oxazolo[5,4-b]pyridine; 2-{6-[methyl(1,3,3-trimethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(1s,3s)-3-(methylamino)cyclobutyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(3aR,7aS)-octahydro-1H-pyrrolo[2,3-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-[6-(1,6-diazaspiro[3.5]nonan-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(1s,3s)-3-(dimethylamino)cyclobutyl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(3R,4R)-3-fluoropiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(1-methylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 5-(1H-pyrazol-4-yl)-2-{6-[(pyrrolidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol; 2-[6-(2,6-diazaspiro[3.3]hept-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(3-fluoro-1H-pyrazol-4-yl)phenol; 2-{6-[(3aR,7aS)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-[6-(6-methyl-1,6-diazaspiro[3.5]nonan-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(2S,4S)-2-(Hydroxymethyl)piperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(2S,4S)-2-(hydroxymethyl)-1-methylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(1-methylpyrrolidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[methyl(pyrrolidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[methyl(1-methylpyrrolidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(1r,3r)-3-(methylamino)cyclobutyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 5-{2-[(1,2-dimethylpiperidin-4-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile; N-(1,2-dimethylpiperidin-4-yl)-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-{2-[(1,2-dimethylpiperidin-4-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-(1,2-dimethylpiperidin-4-yl)-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-(6-{[(3S,4S)-4-fluoropyrrolidin-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(3S,4S)-4-fluoro-1-methylpyrrolidin-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(1-cyclopropylpiperidin-4-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[1-(2-fluoroethyl)piperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 5-(3-Fluoro-1H-pyrazol-4-yl)-2-[6-(6-methyl-2,6-diazaspiro[3.3]hept-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]phenol; 2-{6-[(1S,6R)-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 5-(3-Fluoro-1H-pyrazol-4-yl)-2-{6-[methyl(pyrrolidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol; 2-{6-[(1S,6R)-3-methyl-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(1R,6S)-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(1R,6S)-3-methyl-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 5-(3-Fluoro-1H-pyrazol-4-yl)-2-{6-[methyl(1-methylpyrrolidin-3-yl)amino][1,3]thiazol- [4,5-c]pyridazin-3-yl}phenol; 5-(3-Fluoro-1H-pyrazol-4-yl)-2-[6-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)[1,3]thiazol- [4,5-c]pyridazin-3-yl]phenol; 2-{6-[methyl(1-propylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(2S,4S)-2-methylpiperidin-4-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(2S,4S)-1,2-dimethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(2R,4S)-2-methylpiperidin-4-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(2R,4S)-1,2-dimethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(azepan-4-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(3-fluoro-1H-pyrazol-4-yl)phenol; and 2-(6-{[1-(2-hydroxyethyl)piperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; wherein the compound is in a form selected from the group consisting of salts, racemates, enantiomers, diastereomers, stereoisomers and tautomeric forms of the compound.
2. The compound according to claim 1, wherein the compound is a salt of a compound selected from the group consisting of: 2-(2-methyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 2-(2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 2-(2-methyl-2H-indazol-5-yl)-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 2-(2-methyl-2H-indazol-5-yl)-6-(1-methylpiperidin-4-yl)-1,3-benzothiazole hydrochloride; N-methyl-2-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-6-amine hydrochloride; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine hydrochloride; 6-(2,7-Dimethyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine hydrochloride; 6-(2,7-Dimethyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine hydrochloride; 6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 2-(2-methyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)[1,3]thiazolo[4,5-b]pyridine hydrochloride; 6-(2,7-Dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; N-methyl-5-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine hydrochloride; N-methyl-5-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine hydrochloride; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N,N-Dimethyl-1-[6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-yl]piperidin-4-amine hydrochloride; 1-[6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-yl]piperidin-4-amine hydrochloride; 6-(2,7-Dimethyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-(1H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 5-(2,7-Dimethyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine hydrochloride; N-Methyl-6-(2-methyl-2H-indazol-5-yl)-N-(pyrrolidin-3-yl)-1,3-benzothiazol-2-amine hydrochloride; N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 2-(4-fluoropiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole hydrochloride; 2-(Azepan-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole hydrochloride; 2-(2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridine hydrochloride; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 2-(2,7-dimethyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 2-(2,7-Dimethyl-2H-indazol-5-yl)-6-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; N-Methyl-6-[2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-a]pyrazine hydrochloride; 6-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2-methyl-2H-indazol-5-yl)-2-(2-methylpiperidin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2,7-Dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine hydrochloride; 6-[2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl]-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine hydrochloride; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridine hydrochloride; 2-Methyl-5-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2H-indazole-7-carbonitrile hydrochloride; N-methyl-6-(2-methylimidazo[1,2-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2-methyl-2H-indazol-5-yl)-2-(2-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2,7-Dimethyl-2H-indazol-5-yl)-N-methyl-N-(2-methylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2-methyl-2H-indazol-5-yl)-2-(6-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,3-benzothiazole hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-1,3-benzoxazole hydrochloride; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-4-fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 4-Fluoro-6-(2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 4-Fluoro-6-(2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 2-Methyl-5-[2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-6-yl]-2H-indazole-7-carbonitrile hydrochloride; 6-(7-ethyl-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine hydrochloride; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine hydrochloride; 6-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine hydrochloride; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-1H-pyrazolo[4,3-b]pyridine hydrochloride; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-pyrazolo[4,3-b]pyridine hydrochloride; 6-(7-cyclopropyl-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; N-Methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2-methylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 2-Methyl-5-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2H-indazole-7-carbonitrile hydrochloride; 6-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2,4-dimethyl-1H-benzimidazol-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2-methyl-1H-benzimidazol-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole dihydrochloride; 2-Methyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]imidazo[1,2-b]pyridazine hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-4-methoxy-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-4-methoxy-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-4-ol hydrobromide; 5-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 1-{5-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazol-7-yl}methanamine dihydrochloride; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 2-Methyl-5-[2-(piperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-5-yl]-2H-indazole-7-carbonitrile hydrochloride; 5-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidine hydrochloride; 6-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 2-(2,2-dimethylpiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole hydrochloride; 2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-b]pyrazin-6-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 6-[2-(3,5-dimethylpiperazin-1-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 6-{4-fluoro-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 6-{2-[(2,6-dimethylpiperidin-4-yl)oxy]-4-fluoro-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 2-Methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 2,8-Dimethyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]imidazo[1,2-b]pyridazine hydrochloride; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 6-{4-fluoro-2-[(2R)-2-methylpiperidin-4-yl]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-8-methoxy-2-methylimidazo[1,2-b]pyridazine hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-(2,2-dimethylpiperidin-4-yl)-N-methyl-1,3-benzothiazol-2-amine hydrochloride; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-8-methoxy-2-methylimidazo[1,2-b]pyridazine hydrochloride; 4-Fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 4-Chloro-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 5-[4-Chloro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazole-7-carbonitrile hydrochloride; N-(2,2-dimethylpiperidin-4-yl)-N-methyl-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine hydrochloride; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-[(2S)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine hydrochloride; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-N-[(2S)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine hydrochloride; 6-[4-Fluoro-2-(octahydroindolizine-7-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-N,2-dimethylimidazo[1,2-b]pyridazin-8-amine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-N,N,2-trimethylimidazo[1,2-b]pyridazin-8-amine hydrochloride; 6-(7-Cyano-2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole-4-carbonitrile hydrochloride; 2-Methyl-6-[2-(piperazin-1-yl)[1,3]thiazolo[4,5-b]pyrazin-6-yl]imidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperazin-1-yl)[1,3]thiazolo[4,5-b]pyrazine hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-(2,6-dimethylpiperidin-4-yl)-N-methyl-1,3-benzothiazol-2-amine hydrochloride; N-(2,6-dimethylpiperidin-4-yl)-N-methyl-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-2-(piperazin-1-yl)[1,3]thiazolo[4,5-b]pyrazine hydrochloride; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 8-(Benzyloxy)-6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-amine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-ol hydrochloride; 2-(2,6-dimethylpiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole hydrochloride; 4-Fluoro-6-(4-fluoro-3-methoxyphenyl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-1,3-benzothiazol-2-amine hydrochloride; 2-Methyl-5-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2H-indazole-7-carbonitrile hydrochloride; 6-[2-(1-azabicyclo[2.2.2]oct-4-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-8-phenoxyimidazo[1,2-b]pyridazine hydrochloride; 2-Methyl-6-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}imidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 2-Methyl-6-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 6-{4-fluoro-2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazin-8-amine hydrochloride; 4-Fluoro-6-(8-methoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-N-methyl-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-4-fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-[4-Fluoro-2-(4-methylpiperidin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-6-(7-fluoro-2-methyl-2H-indazol-5-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 2-Methyl-5-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile hydrochloride; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-5-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine-8-carboxylic acid hydrochloride; {6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}acetic acid methyl ester hydrochloride; {6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}acetic acid hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine-8-carboxamide trifluoroacetate; 6-{4-fluoro-2-[methyl(piperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; N-[(8-trans)-3-azabicyclo[3.2.1]octan-8-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine hydrochloride; 6-{2-[(8-trans)-3-azabicyclo[3.2.1]oct-8-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 2-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-6,8-dimethylimidazo[1,2-a]pyrazine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile hydrochloride; 6-{4-fluoro-2-[methyl(piperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile hydrochloride; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]-4-fluoro-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]-4-fluoro-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine-8-carboxamide hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro-N-methyl-6-(2-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-1,3-benzothiazol-2-amine hydrochloride; N-(azetidin-3-yl)-6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-1,3-benzothiazol-2-amine hydrochloride; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylpyrazolo[1,5-a]pyrimidine hydrochloride; 4-Fluoro-N-methyl-6-(2-methylpyrazolo[1,5-a]pyrimidin-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-{2-[9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 5-{2-[9-Azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; N-(9-azabicyclo[3.3.1]non-3-yl)-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-{2-[(1R,5S)-9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; N-[(1R,5S)-9-azabicyclo[3.3.1]non-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine hydrochloride; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-[(2S,4S)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine hydrochloride; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-[(2S,4R)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine hydrochloride; N-(9-azabicyclo[3.3.1]non-3-yl)-N-methyl-6-(2-methylimidazo[1,2-a]pyridin-6-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-(9-azabicyclo[3.3.1]nonan-3-yl)-6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-(9-azabicyclo[3.3.1]non-3-yl)-N-methyl-6-(2-methyl-2H-indazol-5-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-(9-azabicyclo[3.3.1]non-3-yl)-6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-(9-azabicyclo[3.3.1]non-3-yl)-6-(7-methoxy-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 2-Methyl-6-{2-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 2-Methyl-5-{2-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile hydrochloride; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 2-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-b]pyrazin-6-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine hydrochloride; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 6-{2-[(3-exo)-9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; N-[(3-exo)-9-azabicyclo[3.3.1]non-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine hydrochloride; 5-{2-[(3-exo)-9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 2-{6-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 2-{6-[methyl(1-methylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine hydrochloride; N-(9-azabicyclo[3.3.1]non-3-yl)-5-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine hydrochloride; 6-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-(2-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2-methyl-1,3-benzoxazole-4-carbonitrile trifluoroacetate; N-methyl-6-(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-{4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 4-Fluoro-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-[(piperidin-4-yl)oxy]-1,3-benzothiazole hydrochloride; N-methyl-6-(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 2-Methyl-6-{2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridine hydrochloride; 2-Methyl-5-{2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile hydrochloride; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridine hydrochloride; 6-{4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 5-{4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazole hydrochloride; 6-(2-{[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[5,4-d]pyrimidin-5-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile dihydrochloride; 6-(2-{[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile dihydrochloride; N-[(1R,2S,3S,5S)-2-fluoro-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine dihydrochloride; 5-(1H-imidazol-1-yl)-2-{6-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol formate; 3-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridazin-6-amine formate; 3-[2,5-difluoro-4-(3-fluoro-1H-pyrazol-4-yl)phenyl]-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridazin-6-amine formate; 2-[6-(Piperazin-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol formate; 5-(1H-pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-yl]phenol hydrochloride; 2-(6-{[(3R,4S)-4-fluoro-1-methylpyrrolidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol formate; 5-(1H-pyrazol-4-yl)-2-[6-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-yl]phenol hydrochloride; 2-[6-(2,6-diazaspiro[3.5]nonan-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-[6-(7-methyl-1,7-diazaspiro[3.5]nonan-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-[6-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-[6-(2,7-diazaspiro[3.5]nonan-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(3-fluoro-1H-pyrazol-4-yl)phenol formate; 2-(6-{[(3S,4S)-4-fluoro-1-methylpyrrolidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol formate; 2-{6-[(3aS,7aR)-octahydro-1H-pyrrolo[3,2-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[(1s,4s)-4-(methylamino)cyclohexyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{[(3R,4S)-4-fluoropyrrolidin-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol formate; 2-{6-[(3aS,7aR)-5-methyloctahydro-1H-pyrrolo[3,2-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[(3R)-piperidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[(3S)-piperidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[3-(methylamino)cyclobutyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol bis(trifluoroacetate); 2-(6-{[(1r,4r)-4-(dimethylamino)cyclohexyl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[(3S)-1-methylpiperidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-{6-[(azetidin-3-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-[6-(1,7-diazaspiro[3.5]non-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-{6-[(3,3-dimethylpiperidin-4-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-{6-[(2-azaspiro[3.3]hept-6-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 5-{2-[(2R,4r,6S)-2,6-dimethylpiperidin-4-yl]-4-fluoro-1,3-benzothiazol-6-yl}-2,7-dimethyl[1,3]oxazolo[5,4-b]pyridine hydrochloride; 2-{6-[methyl(1,3,3-trimethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[(1s,3s)-3-(methylamino)cyclobutyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-{6-[(3aR,7aS)-octahydro-1H-pyrrolo[2,3-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-[6-(1,6-diazaspiro[3.5]non-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{[(1s,3s)-3-(dimethylamino)cyclobutyl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{[(3R,4R)-3-fluoropiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol formate; 5-(1H-pyrazol-4-yl)-2-{6-[(pyrrolidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol formate; 2-[6-(2,6-diazaspiro[3.3]hept-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(3-fluoro-1H-pyrazol-4-yl)phenol formate; 2-{6-[(3aR,7aS)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-[6-(6-methyl-1,6-diazaspiro[3.5]nonan-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{[(2S,4S)-2-(Hydroxymethyl)piperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{[(2S,4S)-2-(Hydroxymethyl)-1-methylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[(1r,3r)-3-(methylamino)cyclobutyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; N-(1,2-dimethylpiperidin-4-yl)-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine trifluoroacetate; 2-{6-[(1S,6R)-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol trifluoroacetate; 2-{6-[(1S,6R)-3-methyl-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol trifluoroacetate; 2-{6-[(1R,6S)-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol trifluoroacetate; 2-{6-[(1R,6S)-3-methyl-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol trifluoroacetate; 2-(6-{methyl[(2S,4S)-2-methylpiperidin-4-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol trifluoroacetate; 2-(6-{[(2S,4S)-1,2-dimethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol trifluoroacetate; 2-(6-{methyl[(2R,4S)-2-methylpiperidin-4-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol trifluoroacetate, and 2-(6-{[(2R,4S)-1,2-Dimethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol trifluoroacetate.
3. The compound according to claim 1, or a form thereof, selected from the group consisting of: 6-(2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 6-(2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(2-methyl-2H-indazol-5-yl)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 2-(2-methyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 2-(2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)-1,3-benzothiazole; 2-(2-methyl-2H-indazol-5-yl)-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 6-(2-methyl-2H-indazol-5-yl)-2-(piperazin-1-yl)-1,3-benzothiazole; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-2-(1-methylpiperidin-4-yl)-1,3-benzothiazole; 2-(2-methyl-2H-indazol-5-yl)-6-(1-methylpiperidin-4-yl)-1,3-benzothiazole; N-methyl-2-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-6-amine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine; 6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 2-(2-methyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)[1,3]thiazolo[4,5-b]pyridine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 4-Fluoro-N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-4-fluoro-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; N-methyl-5-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine; N-methyl-5-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N,N-dimethyl-1-[6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-yl]piperidin-4-amine; 1-[6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-yl]piperidin-4-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(1H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 5-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(pyrrolidin-3-yl)-1,3-benzothiazol-2-amine; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-4-fluoro-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 2-(4-fluoropiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole; 2-(Azepan-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole; 2-(2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridine; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; N-methyl-6-(2-methyl[1,2,4]triazolo[1,5-b]pyridazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 2-(2,7-dimethyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 2-(2,7-dimethyl-2H-indazol-5-yl)-6-(piperidin-4-yl)-1,3-benzothiazole; N-methyl-6-[2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-2-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazole; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-a]pyrazine; 6-(7-ethyl-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-2-(2,3,6,7-tetrahydro-1H-azepan-4-yl)-1,3-benzothiazole; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-2-(2-methylpiperidin-4-yl)-1,3-benzothiazole; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine; 6-[2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl]-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridine; 2-methyl-5-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2H-indazole-7-carbonitrile; N-methyl-6-(2-methylimidazo[1,2-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,3-benzothiazole; 6-(2-methyl-2H-indazol-5-yl)-2-(2-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2-methylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methyl-2H-indazol-5-yl)-2-(6-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,3-benzothiazole; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-1,3-benzoxazole; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-4-fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 4-Fluoro-6-(2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 4-Fluoro-6-(2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 2-methyl-5-[2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-6-yl]-2H-indazole-7-carbonitrile; 6-(7-ethyl-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine; 6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine; 6-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-1H-pyrazolo[4,3-b]pyridine; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-pyrazolo[4,3-b]pyridine; 6-(7-cyclopropyl-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2-methylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 2-Methyl-5-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2H-indazole-7-carbonitrile; 6-(7-ethyl-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-methyl-6-(2-methylimidazo[1,2-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-{4-fluoro-2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methyl-2H-indazole-7-carbonitrile; 6-[4-Fluoro-2-(1-methylpiperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine; 6-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2,4-dimethyl-1H-benzimidazol-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(2-methyl-1H-benzimidazol-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; N-methyl-6-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 2-methyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]imidazo[1,2-b]pyridazine; 6-(2,7-dimethyl-2H-indazol-5-yl)-4-methoxy-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 6-(2,7-dimethyl-2H-indazol-5-yl)-4-methoxy-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-4-ol; 6-(2,7-dimethyl-2H-indazol-5-yl)-7-fluoro-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazole-7-carbonitrile; 1-{5-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazol-7-yl}methanamine; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazole-7-carbonitrile; N-methyl-6-(2-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-[2-(1-ethylpiperidin-4-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(1-methylpiperidin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-(1,2-dimethylpiperidin-4-yl)-N-methyl-1,3-benzothiazol-2-amine; 2-methyl-5-[2-(piperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-5-yl]-2H-indazole-7-carbonitrile; 5-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidine; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 2-methyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-1,3-benzoxazole; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 2-(2,2-dimethylpiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole; N-methyl-6-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-5-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 3-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridazin-6-amine; 2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 6-[4-Fluoro-2-(piperazin-1-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 6-[2-(1,4-diazepan-1-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 5-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 2-methyl-5-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2H-indazole-7-carbonitrile; 5-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-[2-(4,7-diazaspiro[2.5]octan-7-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 4-Fluoro-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 5-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine; N-methyl-5-(2-methylimidazo[1,2-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-b]pyrazin-6-yl}-5-(1H-pyrazol-4-yl)phenol; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine; 6-[2-(3,5-dimethylpiperazin-1-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 6-{4-fluoro-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazol-4-ol; 6-{2-[(2,6-dimethylpiperidin-4-yl)oxy]-4-fluoro-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine; N-methyl-6-(2-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-5-(1H-pyrazol-4-yl)phenol; 2-methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 2,8-Dimethyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]imidazo[1,2-b]pyridazine; 2-methyl-5-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-b]pyrazin-6-yl}-2H-indazole-7-carbonitrile; N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-5-(1H-pyrazol-4-yl)phenol; 1-[6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-1,3-benzothiazol-2-yl]piperidin-4-ol; 6-{4-fluoro-2-[(2R)-2-methylpiperidin-4-yl]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-8-methoxy-2-methylimidazo[1,2-b]pyridazine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-(2,2-dimethylpiperidin-4-yl)-N-methyl-1,3-benzothiazol-2-amine; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-5-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2H-indazole-7-carbonitrile; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-5-(1H-pyrazol-4-yl)phenol; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-8-methoxy-2-methylimidazo[1,2-b]pyridazine; 4-Fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole; 4-Chloro-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole; 5-[4-Chloro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazole-7-carbonitrile; N-(2,2-dimethylpiperidin-4-yl)-N-methyl-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-amine; 2-methyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]imidazo[1,2-a]pyrimidine; 3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridazin-6-amine; 2-methyl-5-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-2H-indazole-7-carbonitrile; 6-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine; 2-methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-b]pyrazin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-[(2S)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-N-[(2S)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine; 6-[4-Fluoro-2-(octahydroindolizine-7-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-N,2-dimethylimidazo[1,2-b]pyridazin-8-amine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-N,N,2-trimethylimidazo[1,2-b]pyridazin-8-amine; 2-methyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]imidazo[1,2-a]pyrazine; 2-methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-(7-cyano-2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole-4-carbonitrile; 2-methyl-6-[2-(piperazin-1-yl)[1,3]thiazolo[4,5-b]pyrazin-6-yl]imidazo[1,2-a]pyridine-8-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperazin-1-yl)[1,3]thiazolo[4,5-b]pyrazine; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-(2,6-dimethylpiperidin-4-yl)-N-methyl-1,3-benzothiazol-2-amine; N-(2,6-dimethylpiperidin-4-yl)-N-methyl-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-amine; 5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine; 2-methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 2-methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy][1,3]thiazolo[4,5-b]pyrazine; 2-methyl-6-{2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy][1,3]thiazolo[4,5-b]pyrazin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-2-(piperazin-1-yl)[1,3]thiazolo[4,5-b]pyrazine; 5-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 5-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 8-(Benzyloxy)-6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-amine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-ol; 2-(2,6-dimethylpiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole; 4-Fluoro-6-(4-fluoro-3-methoxyphenyl)-2-(piperidin-4-yl)-1,3-benzothiazole; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-1,3-benzothiazol-2-amine; 2-methyl-5-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2H-indazole-7-carbonitrile; 6-[2-(1-azabicyclo[2.2.2]oct-4-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; 6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-8-phenoxyimidazo[1,2-b]pyridazine; 2-methyl-6-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 5-(7-methoxy-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 2-methyl-6-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 4-Fluoro-6-(8-methoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine; 6-{4-fluoro-2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazin-8-amine; 4-Fluoro-6-(8-methoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-N-methyl-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methyl-2H-indazole-7-carbonitrile; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-1,3-benzothiazol-2-amine; 6-[4-Fluoro-2-(4-methylpiperidin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-6-(7-fluoro-2-methyl-2H-indazol-5-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile; 2-methyl-5-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-5-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine-8-carboxylic acid; {6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}acetic acid methyl ester; {6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}acetic acid; 2-methyl-6-{2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine-8-carboxamide; 6-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-4-fluoro-N-methyl-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 6-{4-fluoro-2-[methyl(piperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(8-trans)-3-azabicyclo[3.2.1]oct-8-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-{2-[(8-trans)-3-azabicyclo[3.2.1]oct-8-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 2-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-6,8-dimethylimidazo[1,2-a]pyrazine; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile; 6-{4-fluoro-2-[methyl(piperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-5-{2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]-4-fluoro-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]-4-fluoro-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine-8-carboxamide; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro-N-methyl-6-(2-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-1,3-benzothiazol-2-amine; 2-methyl-5-(2-{methyl[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2H-indazole-7-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl][1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-6-(2-{methyl[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)imidazo[1,2-a]pyridine-8-carbonitrile; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl][1,3]thiazolo[4,5-c]pyridin-2-amine; 6-{2-[ethyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-ethyl-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 2-methyl-5-(2-{[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2H-indazole-7-carbonitrile; 2-methyl-6-(2-{[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)imidazo[1,2-a]pyridine-8-carbonitrile; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl][1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl][1,3]thiazolo[4,5-c]pyridin-2-amine; N-(azetidin-3-yl)-6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-1,3-benzothiazol-2-amine; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylpyrazolo[1,5-a]pyrimidine; 4-Fluoro-N-methyl-6-(2-methylpyrazolo[1,5-a]pyrimidin-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine; 6-{2-[9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 5-{2-[9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile; N-(9-azabicyclo[3.3.1]non-3-yl)-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-{2-[(1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl)(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methyl-2H-indazole-7-carbonitrile; 6-(2-{[(1R)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[5,4-d]pyrimidin-5-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 6-{2-[(1R,5S)-9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(1R,5S)-9-azabicyclo[3.3.1]non-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-[(2S,4S)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-[(2S,4R)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine; N-(9-azabicyclo[3.3.1]non-3-yl)-N-methyl-6-(2-methylimidazo[1,2-a]pyridin-6-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-(9-azabicyclo[3.3.1]nonan-3-yl)-6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; N-(9-azabicyclo[3.3.1]non-3-yl)-N-methyl-6-(2-methyl-2H-indazol-5-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-(9-azabicyclo[3.3.1]non-3-yl)-6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; N-(9-azabicyclo[3.3.1]non-3-yl)-6-(7-methoxy-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 2-methyl-6-{2-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-5-{2-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-6-{2-[methyl(9-methyl-9-azabicyclo[3.3.1]non-3-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-5-{2-[methyl(9-methyl-9-azabicyclo[3.3.1]non-3-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-b]pyrazin-6-yl}-5-(1H-pyrazol-4-yl)phenol; 2-methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-1,3-benzoxazole-4-carbonitrile; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methyl-2H-indazole-7-carbonitrile; 6-{2-[(3-exo)-9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(3-exo)-9-azabicyclo[3.3.1]non-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine; 5-{2-[(3-exo)-9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methyl-2H-indazole-7-carbonitrile; 2-{6-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[methyl(1-methylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-(2-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-(2-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2-methyl-2H-indazole-7-carbonitrile; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine; N-[(1R)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-5-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-(2-{[(1R)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[5,4-d]pyrimidin-5-yl)-2-methyl-1,3-benzoxazole-4-carbonitrile; 6-(2-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[5,4-b]pyridin-5-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine; 5-(2-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[5,4-b]pyridin-5-yl)-2-methyl-2H-indazole-7-carbonitrile; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-5-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine; N-(9-azabicyclo[3.3.1]non-3-yl)-5-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine; 6-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-N-methyl-6-(2-methylimidazo[1,2-a]pyridin-6-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(2-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2-methyl-1,3-benzoxazole-4-carbonitrile; N-methyl-6-(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-(2-{[(1R,3r,5S)-1,5-diethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[5,4-d]pyrimidin-5-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(1R,3r,5S)-1,5-diethyl-8-azabicyclo[3.2.1]octan-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; N-methyl-6-(3-methylimidazo[2,1-b][1,3]thiazol-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-{4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine; 4-Fluoro-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-[(piperidin-4-yl)oxy]-1,3-benzothiazole; N-methyl-6-(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-methyl-6-{2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridine; 2-methyl-5-{2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridine; 2-methyl-6-{2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridine; 2-methyl-5-{2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile; 6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridine; 6-{4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; 5-{4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2-methyl-2H-indazole-7-carbonitrile; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazole; 6-{4-fluoro-2-[(1-methylpiperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine; 6-{2-[(1-ethylpiperidin-4-yl)oxy]-4-fluoro-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine; N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; and 6-(2-{[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[5,4-d]pyrimidin-5-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; wherein the form of the compound is selected from the group consisting of salts, racemates, enantiomers, diastereomers, stereoisomers and tautomeric forms of the compound.
4. The compound according to claim 1, or a form thereof, selected from the group consisting of: N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl]-5-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine; 6-(2-{[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-[(1R,2S,3S,5S)-2-fluoro-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 5-(1H-imidazol-1-yl)-2-{6-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol; 3-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridazin-6-amine; 5-(3-Fluoro-1H-pyrazol-4-yl)-2-{6-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol; 5-(1H-imidazol-1-yl)-2-{6-[methyl(1-methylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol; 3-[2,5-difluoro-4-(3-fluoro-1H-pyrazol-4-yl)phenyl]-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridazin-6-amine; 5-(3-Fluoro-1H-pyrazol-4-yl)-2-{6-[methyl(1-methylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol; 2-{6-[(3R,5S)-3,5-dimethylpiperazin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-[6-(Piperazin-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 5-(1H-pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-yl]phenol; 2-(6-{[(3R,4S)-4-fluoro-1-methylpyrrolidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 5-(1H-pyrazol-4-yl)-2-[6-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-yl]phenol; 2-[6-(2,6-diazaspiro[3.5]nonan-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 2-[6-(7-methyl-1,7-diazaspiro[3.5]nonan-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 2-[6-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 2-[6-(2,7-diazaspiro[3.5]nonan-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(3-fluoro-1H-pyrazol-4-yl)phenol; 2-(6-{[(3S,4S)-4-fluoro-1-methylpyrrolidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[methyl(1-methylazetidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(3aS,7aR)-octahydro-1H-pyrrolo[3,2-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(1s,4s)-4-(methylamino)cyclohexyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(3R,4S)-4-fluoropyrrolidin-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(3aS,7aR)-5-methyloctahydro-1H-pyrrolo[3,2-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(3R)-piperidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(3S)-piperidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[3-(methylamino)cyclobutyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(1r,4r)-4-(dimethylamino)cyclohexyl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(3S)-1-methylpiperidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(azetidin-3-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-[6-(1,7-diazaspiro[3.5]non-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(3,3-dimethylpiperidin-4-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(2-azaspiro[3.3]hept-6-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(3R,4S)-3-fluoropiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 5-{2-[(2R,4r,6S)-2,6-dimethylpiperidin-4-yl]-4-fluoro-1,3-benzothiazol-6-yl}-2,7-dimethyl[1,3]oxazolo[5,4-b]pyridine; 2-{6-[methyl(1,3,3-trimethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(1s,3s)-3-(methylamino)cyclobutyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(3aR,7aS)-octahydro-1H-pyrrolo[2,3-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-[6-(1,6-diazaspiro[3.5]nonan-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(1s,3s)-3-(dimethylamino)cyclobutyl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(3R,4R)-3-fluoropiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(1-methylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 5-(1H-pyrazol-4-yl)-2-{6-[(pyrrolidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol; 2-[6-(2,6-diazaspiro[3.3]hept-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(3-fluoro-1H-pyrazol-4-yl)phenol; 2-{6-[(3aR,7aS)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-[6-(6-methyl-1,6-diazaspiro[3.5]nonan-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(2S,4S)-2-(Hydroxymethyl)piperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(2S,4S)-2-(hydroxymethyl)-1-methylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(1-methylpyrrolidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[methyl(pyrrolidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[methyl(1-methylpyrrolidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(1r,3r)-3-(methylamino)cyclobutyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 5-{2-[(1,2-dimethylpiperidin-4-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile; N-(1,2-dimethylpiperidin-4-yl)-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 6-{2-[(1,2-dimethylpiperidin-4-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile; N-(1,2-dimethylpiperidin-4-yl)-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine; 2-(6-{[(3S,4S)-4-fluoropyrrolidin-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(3S,4S)-4-fluoro-1-methylpyrrolidin-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(1-cyclopropylpiperidin-4-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[1-(2-fluoroethyl)piperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 5-(3-Fluoro-1H-pyrazol-4-yl)-2-[6-(6-methyl-2,6-diazaspiro[3.3]hept-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]phenol; 2-{6-[(1S,6R)-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 5-(3-Fluoro-1H-pyrazol-4-yl)-2-{6-[methyl(pyrrolidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol; 2-{6-[(1S,6R)-3-methyl-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(1R,6S)-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(1R,6S)-3-methyl-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 5-(3-Fluoro-1H-pyrazol-4-yl)-2-{6-[methyl(1-methylpyrrolidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol; 5-(3-Fluoro-1H-pyrazol-4-yl)-2-[6-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]phenol; 2-{6-[methyl(1-propylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(2S,4S)-2-methylpiperidin-4-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(2S,4S)-1,2-dimethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{methyl[(2R,4S)-2-methylpiperidin-4-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-(6-{[(2R,4S)-1,2-dimethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; 2-{6-[(azepan-4-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(3-fluoro-1H-pyrazol-4-yl)phenol; and 2-(6-{[1-(2-hydroxyethyl)piperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol; wherein the form of the compound is selected from the group consisting of salts, racemates, enantiomers, diastereomers, stereoisomers and tautomeric forms of the compound.
5. The compound or form thereof according to claim 2, wherein the compound is a salt of a compound selected from the group consisting of: 2-(2-methyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 2-(2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 2-(2-methyl-2H-indazol-5-yl)-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 2-(2-methyl-2H-indazol-5-yl)-6-(1-methylpiperidin-4-yl)-1,3-benzothiazole hydrochloride; N-methyl-2-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-6-amine hydrochloride; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine hydrochloride; 6-(2,7-Dimethyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine hydrochloride; 6-(2,7-Dimethyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine hydrochloride; 6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridin-2-amine hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 2-(2-methyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)[1,3]thiazolo[4,5-b]pyridine hydrochloride; 6-(2,7-Dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; N-methyl-5-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine hydrochloride; N-methyl-5-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine hydrochloride; N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N,N-Dimethyl-1-[6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-yl]piperidin-4-amine hydrochloride; 1-[6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-yl]piperidin-4-amine hydrochloride; 6-(2,7-Dimethyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-(1H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2-methyl-2H-indazol-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 5-(2,7-Dimethyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[5,4-b]pyridin-2-amine hydrochloride; N-Methyl-6-(2-methyl-2H-indazol-5-yl)-N-(pyrrolidin-3-yl)-1,3-benzothiazol-2-amine hydrochloride; N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 2-(4-fluoropiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole hydrochloride; 2-(Azepan-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole hydrochloride; 2-(2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridine hydrochloride; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 2-(2,7-dimethyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 2-(2,7-Dimethyl-2H-indazol-5-yl)-6-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; N-Methyl-6-[2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-a]pyrazine hydrochloride; 6-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2-methyl-2H-indazol-5-yl)-2-(2-methylpiperidin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2,7-Dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine hydrochloride; 6-[2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl]-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine hydrochloride; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyridine hydrochloride; 2-Methyl-5-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2H-indazole-7-carbonitrile hydrochloride; N-methyl-6-(2-methylimidazo[1,2-a]pyridin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2-methyl-2H-indazol-5-yl)-2-(2-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2,7-Dimethyl-2H-indazol-5-yl)-N-methyl-N-(2-methylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2-methyl-2H-indazol-5-yl)-2-(6-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,3-benzothiazole hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-1,3-benzoxazole hydrochloride; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-4-fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 4-Fluoro-6-(2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 4-Fluoro-6-(2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 2-Methyl-5-[2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-6-yl]-2H-indazole-7-carbonitrile hydrochloride; 6-(7-ethyl-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine hydrochloride; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine hydrochloride; 6-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridine hydrochloride; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-1H-pyrazolo[4,3-b]pyridine hydrochloride; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-pyrazolo[4,3-b]pyridine hydrochloride; 6-(7-cyclopropyl-2-methyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; N-Methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2-methylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 2-Methyl-5-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2H-indazole-7-carbonitrile hydrochloride; 6-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2,4-dimethyl-1H-benzimidazol-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2-methyl-1H-benzimidazol-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole dihydrochloride; 2-Methyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]imidazo[1,2-b]pyridazine hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-4-methoxy-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-4-methoxy-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-4-ol hydrobromide; 5-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 1-{5-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazol-7-yl}methanamine dihydrochloride; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 2-Methyl-5-[2-(piperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidin-5-yl]-2H-indazole-7-carbonitrile hydrochloride; 5-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidine hydrochloride; 6-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 2-(2,2-dimethylpiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole hydrochloride; 2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-b]pyrazin-6-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 6-[2-(3,5-dimethylpiperazin-1-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 6-{4-fluoro-2-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 6-{2-[(2,6-dimethylpiperidin-4-yl)oxy]-4-fluoro-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 2-Methyl-6-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 2,8-Dimethyl-6-[2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]imidazo[1,2-b]pyridazine hydrochloride; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 6-{4-fluoro-2-[(2R)-2-methylpiperidin-4-yl]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-8-methoxy-2-methylimidazo[1,2-b]pyridazine hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-(2,2-dimethylpiperidin-4-yl)-N-methyl-1,3-benzothiazol-2-amine hydrochloride; 2-{2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-8-methoxy-2-methylimidazo[1,2-b]pyridazine hydrochloride; 4-Fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; 4-Chloro-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole hydrochloride; 5-[4-Chloro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-2H-indazole-7-carbonitrile hydrochloride; N-(2,2-dimethylpiperidin-4-yl)-N-methyl-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine hydrochloride; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-[(2S)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine hydrochloride; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-N-[(2S)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine hydrochloride; 6-[4-Fluoro-2-(octahydroindolizine-7-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-N,2-dimethylimidazo[1,2-b]pyridazin-8-amine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-N,N,2-trimethylimidazo[1,2-b]pyridazin-8-amine hydrochloride; 6-(7-Cyano-2-methyl-2H-indazol-5-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-benzothiazole-4-carbonitrile hydrochloride; 2-Methyl-6-[2-(piperazin-1-yl)[1,3]thiazolo[4,5-b]pyrazin-6-yl]imidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperazin-1-yl)[1,3]thiazolo[4,5-b]pyrazine hydrochloride; 6-(2,7-dimethyl-2H-indazol-5-yl)-N-(2,6-dimethylpiperidin-4-yl)-N-methyl-1,3-benzothiazol-2-amine hydrochloride; N-(2,6-dimethylpiperidin-4-yl)-N-methyl-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-2-(piperazin-1-yl)[1,3]thiazolo[4,5-b]pyrazine hydrochloride; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 8-(Benzyloxy)-6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-amine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-ol hydrochloride; 2-(2,6-dimethylpiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)-1,3-benzothiazole hydrochloride; 4-Fluoro-6-(4-fluoro-3-methoxyphenyl)-2-(piperidin-4-yl)-1,3-benzothiazole hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-1,3-benzothiazol-2-amine hydrochloride; 2-Methyl-5-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2H-indazole-7-carbonitrile hydrochloride; 6-[2-(1-azabicyclo[2.2.2]oct-4-yl)-4-fluoro-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methyl-8-phenoxyimidazo[1,2-b]pyridazine hydrochloride; 2-Methyl-6-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}imidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 2-Methyl-6-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 6-{4-fluoro-2-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazin-8-amine hydrochloride; 4-Fluoro-6-(8-methoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-N-methyl-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-4-fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-[4-Fluoro-2-(4-methylpiperidin-4-yl)-1,3-benzothiazol-6-yl]-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-6-(7-fluoro-2-methyl-2H-indazol-5-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 2-Methyl-5-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile hydrochloride; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-5-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine-8-carboxylic acid hydrochloride; {6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}acetic acid methyl ester hydrochloride; {6-[4-fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}acetic acid hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine-8-carboxamide trifluoroacetate; 6-{4-fluoro-2-[methyl(piperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; N-[(8-trans)-3-azabicyclo[3.2.1]octan-8-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine hydrochloride; 6-{2-[(8-trans)-3-azabicyclo[3.2.1]oct-8-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 2-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-6,8-dimethylimidazo[1,2-a]pyrazine hydrochloride; 6-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile hydrochloride; 6-{4-fluoro-2-[methyl(piperidin-4-yl)amino]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile hydrochloride; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]-4-fluoro-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]-4-fluoro-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-b]pyridazine-8-carboxamide hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-4-fluoro-N-methyl-6-(2-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-1,3-benzothiazol-2-amine hydrochloride; N-(azetidin-3-yl)-6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-fluoro-N-methyl-1,3-benzothiazol-2-amine hydrochloride; 5-[4-Fluoro-2-(piperidin-4-yl)-1,3-benzothiazol-6-yl]-2-methylpyrazolo[1,5-a]pyrimidine hydrochloride; 4-Fluoro-N-methyl-6-(2-methylpyrazolo[1,5-a]pyrimidin-5-yl)-N-(piperidin-4-yl)-1,3-benzothiazol-2-amine hydrochloride; 6-{2-[9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 5-{2-[9-Azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; N-(9-azabicyclo[3.3.1]non-3-yl)-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-{2-[(1R,5S)-9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; N-[(1R,5S)-9-azabicyclo[3.3.1]non-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-d]pyrimidin-2-amine hydrochloride; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-[(2S,4S)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine hydrochloride; 4-Fluoro-N-methyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-N-[(2S,4R)-2-methylpiperidin-4-yl]-1,3-benzothiazol-2-amine hydrochloride; N-(9-azabicyclo[3.3.1]non-3-yl)-N-methyl-6-(2-methylimidazo[1,2-a]pyridin-6-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-(9-azabicyclo[3.3.1]nonan-3-yl)-6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-(9-azabicyclo[3.3.1]non-3-yl)-N-methyl-6-(2-methyl-2H-indazol-5-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-(9-azabicyclo[3.3.1]non-3-yl)-6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; N-(9-azabicyclo[3.3.1]non-3-yl)-6-(7-methoxy-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 2-Methyl-6-{2-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 2-Methyl-5-{2-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile hydrochloride; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 2-{2-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-b]pyrazin-6-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 6-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine hydrochloride; 5-{2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 6-{2-[(3-exo)-9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; N-[(3-exo)-9-azabicyclo[3.3.1]non-3-yl]-5-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine hydrochloride; 5-{2-[(3-exo)-9-azabicyclo[3.3.1]non-3-yl(methyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 2-{6-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 2-{6-[methyl(1-methylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride; 6-(7-Fluoro-2-methyl-2H-indazol-5-yl)-2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridine hydrochloride; 6-{4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2-methylimidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 5-{4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2-methyl-2H-indazole-7-carbonitrile hydrochloride; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazole hydrochloride; and 6-(2-{[(3R,4R)-3-Fluoro-2,2,6,6-tetramethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[5,4-d]pyrimidin-5-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile dihydrochloride.
6. The compound or form thereof according to claim 2, wherein the compound is a salt of a compound selected from the group consisting of: N-[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-b]pyrazin-2-amine hydrochloride; N-(9-azabicyclo[3.3.1]non-3-yl)-5-(7-fluoro-2-methyl-2H-indazol-5-yl)-N-methyl[1,3]thiazolo[5,4-b]pyridin-2-amine hydrochloride; 6-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-(2-{[(1R,3s,5S)-1,5-dimethyl-8-azabicyclo[3.2.1]oct-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2-methyl-1,3-benzoxazole-4-carbonitrile trifluoroacetate; N-methyl-6-(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 6-{4-fluoro-2-[(piperidin-4-yl)oxy]-1,3-benzothiazol-6-yl}-2,8-dimethylimidazo[1,2-b]pyridazine hydrochloride; 4-Fluoro-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-[(piperidin-4-yl)oxy]-1,3-benzothiazole hydrochloride; N-methyl-6-(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-amine hydrochloride; 2-Methyl-6-{2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridin-6-yl}imidazo[1,2-a]pyridine-8-carbonitrile hydrochloride; 6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridine hydrochloride; 2-Methyl-5-{2-[(piperidin-4-yl)oxy][1,3]thiazolo[4,5-c]pyridin-6-yl}-2H-indazole-7-carbonitrile hydrochloride; 6-(2-{[(3R,4R)-3-fluoro-2,2,6,6-tetramethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridin-6-yl)-2-methylimidazo[1,2-a]pyridine-8-carbonitrile dihydrochloride; N-[(1R,2S,3S,5S)-2-fluoro-1,5-dimethyl-8-azabicyclo[3.2.1]octan-3-yl]-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine dihydrochloride; 5-(1H-imidazol-1-yl)-2-{6-[methyl(piperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol formate; 3-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridazin-6-amine formate; 3-[2,5-difluoro-4-(3-fluoro-1H-pyrazol-4-yl)phenyl]-N-methyl-N-(piperidin-4-yl)[1,3]thiazolo[4,5-c]pyridazin-6-amine formate; 2-[6-(Piperazin-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol formate; 5-(1H-pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-yl]phenol hydrochloride; 2-(6-{[(3R,4S)-4-fluoro-1-methylpyrrolidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol formate; 5-(1H-pyrazol-4-yl)-2-[6-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)[1,3]thiazolo[4,5-c]pyridin-2-yl]phenol hydrochloride; 2-[6-(2,6-diazaspiro[3.5]nonan-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-[6-(7-methyl-1,7-diazaspiro[3.5]nonan-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-[6-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-[6-(2,7-diazaspiro[3.5]nonan-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(3-fluoro-1H-pyrazol-4-yl)phenol formate; 2-(6-{[(3S,4S)-4-fluoro-1-methylpyrrolidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol formate; 2-{6-[(3aS,7aR)-octahydro-1H-pyrrolo[3,2-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[(1s,4s)-4-(methylamino)cyclohexyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{[(3R,4S)-4-fluoropyrrolidin-3-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol formate; 2-{6-[(3aS,7aR)-5-methyloctahydro-1H-pyrrolo[3,2-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[(3R)-piperidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[(3S)-piperidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[3-(methylamino)cyclobutyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol bis(trifluoroacetate); 2-(6-{[(1r,4r)-4-(dimethylamino)cyclohexyl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[(3S)-1-methylpiperidin-3-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-{6-[(azetidin-3-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-[6-(1,7-diazaspiro[3.5]non-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-{6-[(3,3-dimethylpiperidin-4-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-{6-[(2-azaspiro[3.3]hept-6-yl)(methyl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 5-{2-[(2R,4r,6S)-2,6-dimethylpiperidin-4-yl]-4-fluoro-1,3-benzothiazol-6-yl}-2,7-dimethyl[1,3]oxazolo[5,4-b]pyridine hydrochloride; 2-{6-[methyl(1,3,3-trimethylpiperidin-4-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[(1s,3s)-3-(methylamino)cyclobutyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-{6-[(3aR,7aS)-octahydro-1H-pyrrolo[2,3-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-[6-(1,6-diazaspiro[3.5]non-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{[(1s,3s)-3-(dimethylamino)cyclobutyl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{[(3R,4R)-3-fluoropiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol formate; 5-(1H-pyrazol-4-yl)-2-{6-[(pyrrolidin-3-yl)amino][1,3]thiazolo[4,5-c]pyridazin-3-yl}phenol formate; 2-[6-(2,6-diazaspiro[3.3]hept-2-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(3-fluoro-1H-pyrazol-4-yl)phenol formate; 2-{6-[(3aR,7aS)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridin-1-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-[6-(6-methyl-1,6-diazaspiro[3.5]nonan-1-yl)[1,3]thiazolo[4,5-c]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{[(2S,4S)-2-(Hydroxymethyl)piperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{[(2S,4S)-2-(Hydroxymethyl)-1-methylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; 2-(6-{methyl[(1r,3r)-3-(methylamino)cyclobutyl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol dihydrochloride; N-(1,2-dimethylpiperidin-4-yl)-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-N-methyl[1,3]thiazolo[4,5-c]pyridin-2-amine trifluoroacetate; 2-{6-[(1S,6R)-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol trifluoroacetate; 2-{6-[(1S,6R)-3-methyl-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol trifluoroacetate; 2-{6-[(1R,6S)-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol trifluoroacetate; 2-{6-[(1R,6S)-3-methyl-3,8-diazabicyclo[4.2.0]oct-8-yl][1,3]thiazolo[4,5-c]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol trifluoroacetate; 2-(6-{methyl[(2S,4S)-2-methylpiperidin-4-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol trifluoroacetate; 2-(6-{[(2S,4S)-1,2-dimethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol trifluoroacetate; 2-(6-{methyl[(2R,4S)-2-methylpiperidin-4-yl]amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol trifluoroacetate, and 2-(6-{[(2R,4S)-1,2-Dimethylpiperidin-4-yl](methyl)amino}[1,3]thiazolo[4,5-c]pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol trifluoroacetate.
7. Use of a compound according to any one of claims 1 or 2 in the preparation of a medicament for treating or ameliorating Huntington's disease (HD) in a subject in need thereof.
8. The compound according to any one of claims 1 or 2, for use in admixture with one or more pharmaceutically acceptable excipients for the preparation of a pharmaceutical composition for treating or ameliorating Huntington's disease (HD) in a subject in need thereof.
9. A pharmaceutical composition comprising the compound of any one of claims 1 or 2 and at least one pharmaceutically acceptable excipient.
10. A compound according to any one of claims 3 or 5 for use in the preparation of a medicament for treating or ameliorating Huntington's disease (HD) in a subject in need thereof.
11. A compound according to any one of claims 3 or 5, in admixture with one or more pharmaceutically acceptable excipients, for use in the preparation of a pharmaceutical composition for treating or ameliorating Huntington's disease (HD) in a subject in need thereof.
12. A pharmaceutical composition comprising the compound of any one of claims 3 or 5 and at least one pharmaceutically acceptable excipient.
13. A compound according to any one of claims 4 or 6 for use in the preparation of a medicament for treating or ameliorating Huntington's disease (HD) in a subject in need thereof.
14. A compound according to any one of claims 4 or 6, in admixture with one or more pharmaceutically acceptable excipients, for use in the preparation of a pharmaceutical composition for treating or ameliorating Huntington's disease (HD) in a subject in need thereof.
15. A pharmaceutical composition comprising the compound of any one of claims 4 or 6 and at least one pharmaceutically acceptable excipient.
